BMA031 antigen-binding polypeptide

Abstract

The present invention relates to antigen-binding polypeptides which specifically bind to the α / β T cell receptor (TCR) / differentiation cluster 3 (CD3) complex. The present invention further provides a nucleic acid comprising a sequence encoding the antigen-binding polypeptide, or a vector comprising said nucleic acid. The present invention further relates to recombinant host cells comprising the antigen-binding polypeptide, as well as pharmaceutical compositions comprising the antigen-binding polypeptide, nucleic acid, vector and / or host cell. The present invention further relates to antigen-binding polypeptides, nucleic acids, vectors, host cells or pharmaceutical compositions for use in medicine, in particular for use in the diagnosis, prevention and / or treatment of proliferative diseases. The present invention also relates to methods for improving or maintaining binding of the antigen-binding polypeptide and / or for improving the stability of the antigen-binding polypeptide. The present invention also relates to methods for detecting, determining or enriching T cells expressing the α / β TCR / CD3 complex.

Description

[Technical field]

[0001] The present invention relates to antigen-binding polypeptides which specifically bind to the α / β T cell receptor (TCR) / cluster of differentiation 3 (CD3) complex. The present invention further provides a nucleic acid comprising a sequence encoding the antigen-binding polypeptide, or a vector comprising said nucleic acid. The present invention further relates to recombinant host cells comprising the antigen-binding polypeptide, pharmaceutical compositions comprising the antigen-binding polypeptide, nucleic acid, vector and / or host cell. The present invention further relates to antigen-binding polypeptides, nucleic acids, vectors, host cells or pharmaceutical compositions for use in medicine, in particular for use in the diagnosis, prevention and / or treatment of proliferative diseases. The present invention also relates to methods for improving or maintaining binding of the antigen-binding polypeptide and / or for improving the stability of the antigen-binding polypeptide. The present invention also relates to methods for detecting, determining or enriching T cells expressing the α / β TCR / CD3 complex. [Background technology]

[0002] Two types of T lymphocytes can be distinguished based on the expression of two respective TCRs, either α / β TCR or γ / δ TCR. α / β TCR is expressed on the majority of human T lymphocytes (more than about 80%), whereas γ / δ TCR is expressed on less than 20% of human T cells in peripheral lymphoid organs and blood, as well as in most epithelial tissues. α / β TCR recognizes foreign antigens bound to molecules of the major histocompatibility complex (MHC, Borst et al.; Human Immunology, 29, 175-188, 1990). The murine antibody BMA031 is directed against the human α / β TCR / CD3 complex (Borst et al., 1990). Humanized antibodies specific for α / β TCR have been generated based on the murine monoclonal antibody BMA031; Shearman et al., The Journal of Immunology; vol. 147, 4366-4373, no: 12; 1991, or EP 0403156A1). However, humanized versions of BMA031, such as EUCIV3, showed poor binding compared to murine BMA031; Shearman et al., 1991. Furthermore, humanized BMA031 variants have also been disclosed in the prior art and shown to induce cell-mediated cytolysis (Shearman et al.; 1990). Thus, the humanized BMA031 molecule may have considerable medical potential in improving the immunotherapy of diseases and disorders, such as proliferative diseases. However, so far, humanized BMA031 variants have suffered from poor binding and / or poor stability. Summary of the Invention [Problem to be solved by the invention]

[0003] Thus, there is a need in the art for humanized BMA031 variants that bind effectively and have favorable stability. [Means for solving the problem]

[0004] The present invention provides antigen-binding polypeptides that are derived from BMA031 and that specifically bind to the α / β TCR / CD3 complex. The antigen-binding polypeptides include the substitutions provided herein. In particular, the antigen-binding polypeptides include (i) one or more of the following positions in the heavy chain: 30, 31, 53 and 54; and / or (ii) the invention comprises a substitution of a positively charged amino acid at one or more of the following positions of the light chain: 31 and 56, according to the Kabat numbering. Furthermore, the antigen-binding polypeptides provided herein comprise a substitution of a tyrosine (Y) at position 90 according to the Kabat numbering (e.g., of histidine (H) at position 90). The antigen-binding polypeptides of the invention are suitable for use in a variety of different antibody formats, particularly by utilizing antibody engineering methods such as those described in Brinkmann et al.; MABS2017, Vol. 9, No. 2, 182-212. The antigen-binding polypeptides of the invention provide, in particular, the following advantages over the art: (i) increased binding to cells expressing the α / β TCR / CD3 complex, and / or (ii) increased stability, particularly thermostability, compared to antigen-binding polypeptides that do not contain the substitutions provided herein. Furthermore, it has been unexpectedly demonstrated that the combination of substitutions provided herein provides a synergistic effect leading to improved binding to cells expressing the α / β TCR / CD3 complex. Furthermore, the antigen-binding polypeptides of the present invention improve the effector function of the recruited T cells, e.g., improve the medical effect, compared to antigen-binding polypeptides that do not contain the substitutions of the present invention. Antigen-binding polypeptides of the present invention that include an effector molecule can lead to improved efficacy of the effector function of the recruited T cells, e.g., killing of tumor cells, compared to antigen-binding polypeptides that do not contain the substitutions of the present invention, e.g., when the antigen-binding polypeptide is a bispecific molecule and includes a TCR (e.g., a TCER® molecule). Thus, substitutions in the antigen-binding polypeptides provided herein can lead to improved medical properties of the antigen-binding polypeptide.

[0005] A first aspect of the invention provides an antigen-binding polypeptide comprising a heavy chain variable domain (VH) and a light chain variable domain (VL), (1) VH is (a) a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence of SEQ ID NO:52; (b) HCDR2 comprising the amino acid sequence of YINPYNDVTKYX1X2KFX3G (SEQ ID NO: 53), During the ceremony, X1 is A or N; X2 is E or Q, and / or HCDR2, where X3 is Q or K; (c) HCDR3, and (d) Heavy chain framework regions (HFRs) 1 to 4 Including, (2) VL is (a) a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence of SEQ ID NO:54; (b) LCDR2 comprising the amino acid sequence of SEQ ID NO: 55; (c) LCDR3, and (d) Light chain framework regions (LFR) 1-4 Including, (i) at least one amino acid of HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or at least one amino acid of HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, which is not positively charged, is substituted with a positively charged amino acid; and / or (ii) at least one amino acid of LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or at least one amino acid of LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, which is not positively charged, is substituted with a positively charged amino acid; and / or (iii) position 30 in HFR1 according to the Kabat numbering is substituted with a positively charged amino acid; and / or (iv) position 90 in HFR3 according to Kabat numbering is substituted with a tyrosine (Y) residue; The antigen-binding polypeptide specifically binds to the α / β T cell receptor (TCR) / CD3 complex.

[0006] A second aspect of the invention relates to an isolated nucleic acid comprising a sequence encoding an antigen-binding polypeptide of the first aspect of the invention, or a nucleic acid vector comprising said nucleic acid.

[0007] A third aspect of the invention relates to a recombinant host cell comprising an antigen-binding polypeptide of the first aspect of the invention, or a nucleic acid or vector of the second aspect of the invention.

[0008] A fourth aspect of the invention relates to a pharmaceutical composition comprising an antigen-binding polypeptide of the first aspect of the invention, a nucleic acid or vector of the second aspect of the invention, or a host cell of the third aspect of the invention, and a pharma- ceutically acceptable carrier.

[0009] A fifth aspect of the invention relates to an antigen-binding polypeptide of the first aspect of the invention, a nucleic acid or vector of the second aspect of the invention, or a host cell of the third aspect of the invention, or a pharmaceutical composition of the fourth aspect of the invention, for use in medicine.

[0010] A sixth aspect of the invention relates to an antigen-binding polypeptide of the first aspect of the invention, a nucleic acid or vector of the second aspect of the invention, or a host cell of the third aspect of the invention, or a pharmaceutical composition of the fourth aspect of the invention, for use in the diagnosis, prevention and / or treatment of a proliferative disease, preferably cancer.

[0011] A seventh aspect of the invention relates to a method for improving or maintaining binding of an antigen-binding polypeptide of the first aspect of the invention and / or for improving the stability of said antigen-binding polypeptide.

[0012] An eighth aspect of the invention relates to a method for detecting, determining or enriching T cells expressing the α / β TCR / CD3 complex.

[0013] Further aspects relate in particular to methods of producing the antigen-binding polypeptides and / or kits comprising the antigen-binding polypeptides, which are also described below.

[0014] The contents of the figures contained herein are explained below, and in this connection reference is made to the above and / or following detailed description of the invention. [Brief description of the drawings]

[0015] [Figure 1] Binding and specificity screening of selected ScFv clones after phage display selection. Flow cytometry binding analysis was performed with Jurkat, clonal E6-1 cell lines (y-axis) and J.RT3T3.5 cells (x-axis). ScFv BMA031(V36) (open triangles) served as a reference and anti-CD3 antibody (open circles) served as a positive control for target binding. Selected clones with improved staining of target positive cells (filled circles) were taken forward for further analysis. The dotted lines represent background staining of the respective cell lines without ScFv but with detection antibody. [Diagram 2] Binding of selected Fab variants after phage display. Purified Fabs were applied to Jurkat, clonal E6-1 cell lines as a titration series at concentrations ranging from 10 μg / ml to 10 ng / ml, and staining was detected via an anti-His tag antibody. The area under the curve (AUC) of binding was calculated from the median fluorescence intensity (MFI) and the logarithmic concentration. The dashed line represents the binding AUC of the exemplary parent antibody TPP-1374. [Diagram 3] Binding and specificity screening of selected Fab variants after phage display. Purified Fabs were applied to Jurkat, clonal E6-1 cell line and J.RT3T3.5 cells at a concentration of 1 μg / ml and staining was detected via anti-His tag antibody. The dashed line represents the background signal in the absence of Fab. [Figure 4]Binding and specificity screening of designed Fab variants. Purified Fabs were applied to Jurkat, clonal E6-1 cell line and J.RT3T3.5 cells at a concentration of 1 μg / ml and staining was detected via anti-His tag antibody. The dashed line represents the background signal in the absence of Fab. [Diagram 5] Area under the curve and melting temperature of binding of designed Fab variants. Purified Fab was applied to Jurkat, clonal E6-1 cell lines in a titration series of concentrations ranging from 10 μg / ml to 10 ng / ml, and binding AUC was calculated based on the resulting binding curves (left Y-axis). Melting temperatures (Tm) were calculated from nanoDSF measurements (right Y-axis). The top panel represents variants with only mutated CDRs, while the bottom panel further includes variants with the heavy chain framework mutation H90Y. Arrows indicate the relationship between variants with and without the heavy chain framework region 3 (HFR3) mutation H90Y. *: Melting temperature of VH_Y53R_VL_VL_wt (TPP-1378) was not measured. Thick dashed line indicates Tm of VH_wt_VL_wt (TPP-1374, exemplary parent antibody). The dotted line indicates the binding AUC of VH_wt_VL_wt(TPP-1374). [Figure 6] Target cell binding of the designed Fab variants. The purified Fabs were applied to Jurkat, clonal E6-1 cell lines in a titration series of concentrations ranging from 10 μg / ml to 10 ng / ml, and staining was detected via an anti-His tag antibody. [Figure 7]Potency of modified BMA031 molecules in the context of TCER® format. The potency of purified T-cell engaging receptor (TCER®) molecules was evaluated in a lactate dehydrogenase (LDH) release assay. Tumor cell lines (Hs695T, U2OS) presenting different levels of target peptide HLA (pHLA) on the cell surface and a target peptide-human leukocyte antigen (pHLA) negative tumor cell line (T98G) were used as targets for peripheral blood mononuclear cells (PBMCs) from healthy HLA-A*02 positive donor HBC-1005 in the presence of increasing concentrations of TCER® molecules (E:T=10:1). TCER®-induced cell lysis was quantified after 48 hours by measuring released LDH. EC50 values ​​of dose-response curves were calculated using nonlinear 4-point curve fitting. [Figure 8] Potency of modified BMA031 molecules in the context of TCER® format. The potency of purified TCER® molecules was evaluated in an LDH release assay. Tumor cell lines presenting different levels of target pHLA on the cell surface (Hs695T, U2OS) and a target pHLA-negative tumor cell line (T98G) were used as targets for PBMCs from healthy HLA-A*02 positive donor HBC-1039 in the presence of increasing concentrations of TCER® molecules (E:T=10:1). TCER®-induced cell lysis was quantified by measuring released LDH after 48 hours. EC50 values ​​of dose-response curves were calculated using nonlinear 4-point curve fitting. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] Before the present invention is described in detail below, it should be understood that the present invention is not limited to the specific methodology, protocols and reagents described herein, because they may vary.It should also be understood that the terms used herein are for the purpose of describing specific embodiments only, and are not intended to limit the scope of the present invention, which is limited only by the appended claims.Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art.

[0017] Throughout the text of this specification, several documents are cited. Each of the documents cited herein (including all patents, patent applications, scientific publications, manufacturer's specifications, instructions, etc.), whether supra or infra, is hereby incorporated by reference in its entirety. Nothing herein should be construed as an admission that the present invention is not entitled to antedate such disclosure by virtue of prior invention. Some of the documents cited herein are characterized as "incorporated by reference." In the event of a conflict between a definition or teaching of such an incorporated reference and a definition or teaching set forth herein, the text of this specification shall control.

[0018] The elements of the present invention are described below. Although these elements are listed with specific embodiments, it should be understood that they may be combined in any manner and in any number to create additional embodiments. The various described examples and preferred embodiments should not be construed as limiting the invention to only the explicitly described embodiments. This description should be understood to support and encompass embodiments combining the explicitly described embodiments with any number of the disclosed and / or preferred elements. Furthermore, any permutation and combination of all elements described in this application should be considered to be disclosed by the description of this application unless the context indicates otherwise.

[0019] The practice of the present invention employs, unless otherwise indicated, conventional methods of chemistry, biochemistry, and recombinant DNA techniques as described in the art (see, e.g., Molecular Cloning: A Laboratory Manual, 2nd Edition, J. Sambrook et al. eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor 1989).

[0020] Below are provided definitions of some of the terms frequently used herein, which have their respective defined and preferred meanings in the remainder of the specification at each instance of their usage.

[0021] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise.

[0022] The term "antigen-binding polypeptide" in the context of the present invention refers to a polypeptide or binding protein capable of specifically binding to at least one antigen, in particular to an epitope of said antigen. The antigen-binding polypeptide of the present invention comprises complementarity determining regions (CDRs) 1 to 3, which are part of the variable domain.

[0023] Preferably, the antigen-binding polypeptide of the present invention comprises a heavy chain variable domain (VH) and a light chain variable domain (VL), which may be comprised on the same polypeptide chain or on different polypeptide chains. The VH and VL comprise the complementarity determining regions (CDRs) and framework regions (FRs) of an antibody or fragment thereof as defined herein below. Preferably, the antigen-binding polypeptide comprises a VH and a VL as defined herein below, and a specific position in the VH and / or a specific position in the VL has a positively charged amino acid compared to an antigen-binding polypeptide or fragment thereof that does not have a positively charged amino acid at the respective position. In other words, said specific amino acid position is substituted with a positively charged amino acid in the antigen-binding polypeptide of the present invention. Preferably, the antigen-binding polypeptide or functional fragment thereof comprises a CDR in which at least one of the non-positively charged amino acids is substituted with a positively charged amino acid. Position 30 in FR1 of the heavy chain may be substituted with a positively charged amino acid. Additionally, position 90 in FR3 of the heavy chain according to Kabat numbering in the antigen binding polypeptide is substituted with a tyrosine.

[0024] In the context of the present invention, an antigen-binding polypeptide refers to a polypeptide comprising a paratope (alternatively referred to as "antigen-binding site") that specifically binds to an antigen. Examples of antigen-binding polypeptides are, inter alia, antibodies or fragments thereof or single-chain antibodies. The antigen-binding polypeptides of the present invention or functional fragments thereof specifically bind to cells expressing the α / β TCR / CD3 complex or to the α / β TCR / CD3 complex. In certain embodiments, the antigen-binding polypeptides of the present invention or functional fragments thereof do not specifically bind to the cynomolgus α / β TCR / CD3 complex. In further embodiments, the antigen-binding polypeptides of the present invention do not specifically bind to cells expressing the γ / δ T cell receptor (TCR). In further embodiments, the antigen-binding polypeptides of the present invention bind to the extracellular domain of CD3.

[0025] In certain further embodiments, the antigen-binding polypeptides or functional fragments thereof of the invention specifically bind to the human α / β TCR / CD3 complex, in other words, the antigen-binding polypeptides or functional fragments thereof of the invention do not specifically bind to the α / β TCR / CD3 complex of any species other than human.

[0026] The antigen-binding polypeptide comprises a CDR sequence as defined in the appended claims and herein below, wherein at least one non-positively charged amino acid is preferably substituted with a positively charged amino acid as defined herein below. Preferably, in the CDR of the antigen-binding polypeptide, no more than four amino acid positions are substituted with positively charged amino acids. Preferably, the antigen-binding polypeptide of the invention comprises at least a VH and VL variable domain derived from the antibody sequence of BMA031 as defined herein below or the antibody sequence of BMA031(V36), referred to as the reference antibody, parent antigen-binding polypeptide or parent antibody, as further defined herein below. The antigen-binding polypeptide of the invention comprises a VH and VL domain comprising a consensus sequence based on an antibody targeting the α / β TCR / CD3 complex, and includes the substitutions of the invention provided herein. Exemplary sequences of such antibodies are disclosed herein below. As shown in the accompanying examples, the introduction of certain substitutions with positively charged amino acids and / or substitutions at position 90 in HFR3 in the variable domain of a parent antigen-binding polypeptide, e.g., BMA031 (V36), provides the advantageous effects shown herein, e.g., increased binding and / or increased stability, compared to a parent antigen-binding polypeptide that does not contain the substitutions provided herein. In certain further embodiments, the antigen-binding polypeptides of the invention can also have increased stability while essentially maintaining or maintaining binding, compared to an antigen-binding polypeptide that does not contain the substitutions provided herein. In certain further embodiments, the antigen-binding polypeptides provided herein can also have increased binding while essentially maintaining or maintaining the stability of the antigen-binding polypeptide, compared to an antigen-binding polypeptide that does not contain the substitutions provided herein. The term "essentially" in the context of "essentially maintaining binding" means that the binding (e.g., expressed as a "% increase in binding AUC") is substantially unchanged, i.e., not more than a decrease of about 25%, more preferably about 15%, more preferably about 10%, and even more preferably about 5%, compared to the parent antigen-binding polypeptide.The term "essentially" in the context of "essentially maintain stability" means that the stability is substantially unchanged compared to the parent antigen-binding polypeptide, i.e., not more than a decrease of about 25%, more preferably about 15%, more preferably about 10%, and even more preferably about 5%.

[0027] The term "variable domain" in the context of the present invention refers to a region of an immunoglobulin, which is defined based on sequence homology as known to those skilled in the art. Typically, two variable domains form an antigen-binding site. Non-exhaustive examples of such domains include the variable light domain contained in an antibody light chain (VL), the variable heavy domain contained in an antibody heavy chain (VH), the alpha variable domain (Valpha) contained in the alpha chain of a TCR molecule, or the beta variable domain (Vbeta) contained in the beta chain of a TCR.

[0028] The term "complementarity determining region" (CDR) in the context of the present invention refers to non-contiguous antigen-binding sites found within variable domains of immunoglobulins, e.g., in VH, VL, Vα and Vβ. CDRs are identified using the methods described in Lefranc et al. (2003) Developmental and Comparative Immunology 27:55; Kabat et al., J. Biol. Chem. 252:6609-66I6 (1977); Kabat et al., US Dept. of Health and Human Services, "Sequences of proteins of immunological interest", 1991; Chothia et al., J. Mol. Biol. I96:90I-917, 1987; and contact annotations (for contact annotations see MacCallum et al., J. Mol. Biol. 262:732-745 (1996)); for AbM annotations see Abhinandan and Martin, Mol. Immunol. (2008), 45(14):3832-9; IMGT (Lefranc MP. Unique database numbering system for immunogenetic analysis; Immunol. Today (1997) 18:509), and these definitions include overlapping or subsets of amino acid residues when compared to each other. Nevertheless, application of either definition to refer to the CDRs of an antibody or grafted antibody or variants or fragments thereof is intended to be within the scope of the term as defined and used herein. The amino acid residues encompassing the CDRs defined by each of the above cited references are illustratively set forth in Table 1 below for comparison.

[0029] [Table 1]

[0030] The terms "HCDR1", "HCDR2" and "HCDR3" refer in the context of the present invention to the first, second and third CDRs in the heavy chain variable domain of an antigen-binding polypeptide, e.g., an antibody or a functional fragment thereof. As used herein, the terms "LCDR1", "LCDR2" and "LCDR3" refer to the first, second and third CDRs, respectively, of the light chain variable region of an antigen-binding polypeptide, e.g., an antibody or a fragment thereof. As used herein, the terms "CDR1", "CDR2" and "CDR3" refer to the first, second and third CDRs, respectively, of the variable region of either chain of an antigen-binding polypeptide, e.g., an antibody or a functional fragment thereof. The antigen-binding polypeptides of the present invention are substituted with positively charged amino acids, e.g., in the CDRs, compared to a parent antigen-binding polypeptide that does not have a positively charged residue at each position. Amino acid positions within the CDRs, and similarly within VH or VL, are assigned according to the Kabat, Chothia, AbM or contact annotations as described above, in particular according to the Kabat numbering.

[0031] The term "framework region" (FR), in the context of the present invention, refers to all amino acid residues outside the CDR regions within the variable domain of an antigen-binding polypeptide, e.g., an antibody or fragment thereof. A framework region is generally a non-contiguous amino acid sequence of about 100-120 amino acids in length, but is intended to refer only to amino acids outside the CDRs. As used herein, the term "framework region" is intended to mean each domain of the framework separated by the CDRs. FR1-FR4 refers first to framework region 1, which is the first N-terminal amino acid sequence of the variable domain, followed by FR2, FR3 and FR4, which are interposed by CDRs 1, 2 and 3, respectively. In some embodiments, the antigen-binding polypeptides of the present invention comprise substitutions in a framework region, e.g., heavy chain framework region 3 (HFR3).

[0032] The term "polypeptide", in the context of the present invention, refers to a single linear chain of amino acids linked by peptide bonds, which typically comprises at least about 50, at least about 60, at least about 70, at least about 80, at least about 90, or at least about 100 amino acids. It is also contemplated herein that the antigen-binding polypeptides provided herein have lengths shorter than the specified ranges, so long as the antigen-binding polypeptide comprises a substitution of the invention and specifically binds to a cell expressing an α / β TCR / CD3 complex. A polypeptide may be one chain of a protein made up of multiple chains, or it may be the protein itself, where the protein is made up of a single chain.

[0033] The term "protein" refers to a functional unit that may contain one or more polypeptide chains. When a protein contains two or more polypeptide chains, these may be non-covalently and / or covalently bound to each other.

[0034] The term "antigen-binding site" in the context of the present invention refers to at least one binding site responsible for specific and / or selective binding to a target antigen in question, in particular an epitope of the target antigen. The term "antigen-binding site" is used interchangeably with the term "paratope" in the context of the present invention and refers to the portion of an antigen-binding polypeptide that binds to an antigen. Exemplary binding sites include antibody variable domains, e.g., heavy or light chain variable domains, TCR variable domains, e.g., α or β variable domains or γ or δ variable domains. In certain aspects, the antigen-binding polypeptides described herein comprise multiple (e.g., two, three, four, or more) binding sites.

[0035] The term "antigen" or "target antigen", in the context of the present invention, refers to a molecule or part of a molecule or complex that can be bound by at least one antigen-binding site, said one antigen-binding site being comprised, for example, in an antibody, a TCR and / or an antigen-binding polypeptide of the invention.

[0036] The term "epitope" refers in the context of the present invention to the functional epitope of an antigen. A functional epitope comprises residues, typically amino acids or polysaccharides, that contribute to non-covalent interactions between the paratope of an antigen-binding polypeptide and an antigen. Non-covalent interactions include electrostatic forces, van der Waals forces, hydrogen bonds, and hydrophobic interactions, respectively. A functional epitope is a subgroup of residues that constitute the structural epitope of an antigen-binding polypeptide. A structural epitope comprises all residues that are covered by the antigen-binding polypeptide, i.e., the footprint of the antigen-binding polypeptide. Typically, a functional epitope of an antigen bound by an antibody comprises 4-10 amino acids. Similarly, a functional epitope of a peptide presented by MHC typically comprises 4-8 amino acids. Competition between two antibodies occurs when the structural epitopes of the antibodies are identical or overlapping.

[0037] The term "α / β TCR / CD3 complex" in the context of the present invention refers to the T cell receptor complex present on the surface of T cells. Most T cells express α / β TCRs composed of disulfide-linked α and β chains, which typically bind to the composite surface of antigenic peptides presented by MHC. The TCR does not signal by itself, but is constitutively associated with CD3, a protein complex that contains intracellular signaling motifs and is called a T cell coreceptor (Birnbaum et al.; PNAS vol. 11, no. 49; 17576-17581, 2014). The α / β TCR is non-covalently coupled to this conserved multisubunit signaling apparatus that includes CD3εγ, CD3εδ, and CD3ζζ dimers, which collectively form the α / β TCR / CD3 complex. The α / β TCR / CD3 complex contains the epitope that is specifically bound by the antigen-binding polypeptide of the present invention. The specific amino acid sequence of the target epitope of the BMA031 antibody (Shearman et al., 1991) or the antigen-binding polypeptides provided herein is unknown. However, the antigen-binding polypeptides of the present invention bind to the same or similar functional epitope as BMA031 or BMA031(V36), and therefore compete with each other. Thus, the epitope specificity of the antigen-binding polypeptides of the present invention is characterized by their ability to compete with a "reference antibody" for binding to cells expressing an α / β TCR / CD3 complex, preferably T cells, and in particular for binding to the α / β TCR / CD3 complex present on the surface of T cells. Thus, the antigen-binding polypeptides provided herein can compete with a reference antibody, preferably BMA031, or even more preferably BMA031(V36), that specifically binds to the α / β TCR / CD3 complex, for binding to T cells, in particular for binding to T cells expressing an α / β TCR / CD3 complex, and more preferably for binding to the α / β TCR / CD3 complex present on the surface of T cells. The T cells are preferably T lymphocytes, more preferably Jurkat cells, such as clone E6-1 cells.It should be noted that the antigen-binding polypeptides of the present invention were developed based on the sequences of the above-mentioned reference antibodies, i.e., BMA031 or BMA031(V36). Competition between the reference antibody and the antigen-binding polypeptide can be tested by known assay methods. For example, a binding assay as described in the examples attached herein can be used. In particular, competition between the reference antibody and the antigen-binding polypeptide can be tested by a flow cytometry assay, e.g., FACS, as further disclosed herein below, in which the binding of the reference antibody to α / β TCR / CD3 positive cells is measured in the presence of the antigen-binding polypeptide and compared to the binding of the reference antibody alone. An example of an α / β TCR / CD3 positive cell is a T cell, preferably a Jurkat cell. In the competition assay, it is preferable to use an antigen-binding polypeptide of the present invention that comprises an Fc portion, e.g., the antigen-binding polypeptide of the present invention comprises elements of an antibody. For example, the reference antibody can exhibit a constant domain derived from mouse IgG1, while the antigen-binding polypeptide can exhibit a constant domain derived from human IgG1. In such experiments, the reference antibody is used at a concentration approximately equal to the pre-determined EC50 of binding, and is incubated in the presence or absence of equimolar concentrations of the antigen-binding polypeptide on α / β TCR / CD3 positive cells. The binding of the reference antibody can then be determined in a second staining step using a mouse-specific secondary reagent, for example, goat F(ab')2 anti-mouse IgG1(Fc)-RPE (Dianova, SBA-1072-09). Competition between the reference antibody and the antigen-binding polypeptide is indicated by a reduction in the binding of the reference antibody in the presence of the antigen-binding polypeptide compared to the binding of the reference antibody alone. Preferably, the reference antibody reduces the binding of the antigen-binding polypeptide to the α / β TCR / CD3 complex, particularly to α / β TCR / CD3 positive cells, by at least 10%, more preferably at least 20%, more preferably at least 30%.

[0038] As used herein in the context of a competitive assay, a "reference antibody" is defined by its heavy and light chain variable domains, preferably further comprising an IgG1 constant domain and a Cκ light chain. Preferably, the reference antibody comprises a human IgG1 constant domain. More preferably, the reference antibody comprises a hinge-CH2-CH3 region according to SEQ ID NO: 61. Preferably, the reference antibody comprises a VH according to SEQ ID NO: 1 and a VL according to SEQ ID NO: 2, more preferably BMA031(V36) consisting of a heavy chain (HC) according to SEQ ID NO: 60 and a light chain (LC) according to SEQ ID NO: 6. The reference antibody does not comprise a substitution of the invention as defined herein above and below. In particular, the reference antibody does not comprise a substitution of a positively charged amino acid. Preferably, the reference antibody does not comprise a substitution of a positively charged amino acid and / or a substitution with tyrosine at position 90 of the heavy chain.

[0039] A "parent antigen-binding polypeptide" generally refers to an antigen-binding polypeptide that is compared to an antigen-binding polypeptide of the invention when assessing properties such as, for example, % increase in Tm, EC50 or binding AUC. A "parent antigen-binding polypeptide" does not comprise a substitution of the invention as defined herein above and below. In particular, the parent antigen-binding polypeptide does not comprise a substitution of a positively charged amino acid. Preferably, the parent antigen-binding polypeptide does not comprise a substitution with a positively charged amino acid and / or a tyrosine at position 90 of the heavy chain. The effect of a substitution of the invention should preferably be compared between two similar molecules, i.e. molecules that differ only in the substitution of the invention according to the first aspect of the invention. Thus, a "parent antigen-binding polypeptide" may in one particular embodiment refer to a molecule that comprises a VH (BMA031 V36) according to SEQ ID NO: 1 and a VL (VL BMA031 V36) according to SEQ ID NO: 2, but otherwise has the amino acid sequence of an antigen-binding polypeptide. In a preferred embodiment, the parent antigen-binding polypeptide has the amino acid sequence of an antibody, e.g., BMA031(V36), or is a functional fragment thereof, e.g., a Fab, which is referred to in the context of the present invention as a "parent antibody".

[0040] A "parent antibody" does not include substitutions as defined in the context of the present invention. An example of such a "parent antibody" is BMA031 or a further humanized variant of BMA031, such as BMA031(V36) as disclosed herein below, or preferably a fragment thereof. A parent antibody is defined by its heavy and light chain variable domains, preferably the parent antibody comprises a VH (BMA031 V36) according to SEQ ID NO: 1 and a VL (VL BMA031 V36) according to SEQ ID NO: 2. The term parent antibody is also used in the embodiments and examples defined below in the context of a comparison molecule, for example in determining binding (e.g. % increase in EC50 or binding AUC) or in determining melting temperature (Tm).

[0041] In a preferred embodiment, the parent antigen-binding polypeptide comprises or consists of the VH and VL domains of BMA031 (V36) as defined herein.

[0042] In a preferred embodiment, the functional characteristics further described herein below, such as the "% increase in binding AUC", "binding EC50" and / or "Tm", are determined when the antigen-binding polypeptide and the parent antigen-binding polypeptide are both in the same format, e.g., a Fab fragment as described in Example 1, as in the Examples section.

[0043] Comparison of the antigen-binding polypeptides of the invention with the parent antigen-binding polypeptide is performed under similar, preferably identical, experimental conditions, preferably in parallel, more preferably when the antigen-binding polypeptides of the invention and the parent antigen-binding polypeptide are part of the same assay. Most preferably, the functional properties of the antigen-binding polypeptides described herein are compared to the parent antigen-binding polypeptide when both are present as Fab or Fab fragments.

[0044] The term "T cell receptor" (TCR), in the context of the present invention, refers to a heterodimeric cell surface protein of the immunoglobulin superfamily that is associated with an invariant protein of the CD3 complex, which is involved in mediating signal transduction. TCRs exist as α / β and γ / δ types, which are structurally similar but have quite different anatomical locations and possibly different functions. The extracellular portions of the naturally occurring heterodimeric αβ and γδ TCRs each contain two polypeptides, each with a membrane-proximal constant domain and a membrane-distal variable domain. Each of the constant and variable domains contains an intrachain disulfide bond. The variable domains contain highly polymorphic loops similar to the complementarity determining regions (CDRs) of antibodies. In the context of the present invention, the term "TCR" also refers to fragments thereof, as well as single-chain TCRs and fragments thereof, in particular the variable α and β domains of single-domain TCRs, as well as chimeric, humanized, bispecific or multispecific TCRs. The use of TCR gene therapy overcomes several current barriers. This allows the subject's (patient's) own T cells to be endowed with the desired specificity, allowing the generation of sufficient numbers of T cells in a short time and avoiding their exhaustion. TCRs can be transduced into potent T cells (e.g., central memory T cells, or T cells with stem cell characteristics), ensuring better persistence, preservation and function upon transfer. TCR-engineered T cells can be infused into cancer patients who become lymphopenic due to chemotherapy or irradiation, allowing efficient engraftment and simultaneously inhibiting immunosuppression.

[0045] The term "fragment of a TCR" in the context of the present invention refers to a portion of a full-length or wild-type TCR, in particular the antigen-binding site or variable region of such a TCR. Examples of TCR fragments include fragments of the α, β, δ or γ chains, e.g. α -C a Or V β -C β or portions thereof. These fragments also include the corresponding hinge region or single chain variable domains, e.g., V α , V β , V δ, V γ , single chain Vα / Vβ fragments, or bispecific and multispecific TCRs formed from TCR fragments. Fragments of TCRs perform the same function as naturally occurring full-length or wild-type TCRs, i.e., they selectively and / or specifically bind to their target antigens, in particular antigenic peptides or target peptides complexed with major histocompatibility complexes I or II (MHC I or MHC II).

[0046] The term "single chain TCR (scTCR)" in the context of the present invention refers to a single chain TCR comprising a variable domain, e.g. α and V β or V δ and V γ It refers to a protein or antigen-binding polypeptide in which the variable domains are located on one polypeptide chain. Typically, the variable domains are separated by a linker, which typically comprises 10 to 30, e.g., 10 to 25, amino acids.

[0047] The term "wild type α-β heterodimeric TCR" in the context of the present invention refers to a TCR having an α chain and a β chain. Each α chain comprises a variable region, a joining region and a constant region, and the β chain also usually contains a short diversity region between the variable region and the joining region, although this diversity region is often considered as part of the joining region. The constant regions or C regions of the TCR α and β chains are referred to as TRAC and TRBC, respectively (Lefranc, (2001), Curr Protoc Immunol Appendix 1: Appendix 10). Each variable region, referred to herein as the α and β variable domains, comprises three CDRs embedded in a framework sequence, one of which is a hypervariable region designated CDR3. The α variable domain CDRs are referred to herein as CDRa1, CDRa2, CDRa3, and the β variable domain CDRs are referred to herein as CDRb1, CDRb2, CDRb3. There are several types of α chain variable (Vα) regions and several types of β chain variable (Vβ) regions, which are distinguished by their framework, CDR1 and CDR2 sequences, and the partially defined CDR3 sequence. The Vα types are designated by a unique TRAV number in the IMGT nomenclature, and the Vβ types are designated by a unique TRBV number in the IMGT nomenclature (Folch and Lefranc, (2000), Exp Clin Immunogenet 17(1): 42-54; Scaviner and Lefranc, (2000), Exp Clin Immunogenet 17(2): 83-96; LeFranc and LeFranc, (2001), "T cell Receptor Factsbook", Academic Press). For further information regarding immunoglobulin antibodies and TCR genes, see the international ImMunoGeneTics information system®, Lefranc MP et al (Nucleic Acids Res. 2015 Jan; 43 (Database issue):D413-22).Thus, a conventional TCR antigen-binding site typically contains six CDRs, including a set of CDRs from each of the α and β chain variable regions, where the CDR1 and CDR3 sequences are involved in recognizing and binding to a peptide antigen bound to an HLA protein, and the CDR2 sequence is involved in recognizing and binding to the HLA protein.

[0048] The term "antibody", also called "immunoglobulin", in the context of the present invention refers to an antigen-binding polypeptide comprising two heavy chains linked to each other by disulfide bonds, with each heavy chain linked to a light chain by a disulfide bond. There are two types of light chains: lambda (λ) and kappa (κ). There are five major heavy chain classes (or isotypes) that determine the functional activity of the antibody molecule: IgM, IgD, IgG, IgA, and IgE. Each chain contains different sequence domains. The light chain comprises two domains or regions, the variable domain (VL) and the constant domain (CL). The heavy chain comprises four domains, the variable domain (VH) and three constant domains (CH1, CH2, and CH3, collectively CH). The variable regions of both the light chain (VL) and the heavy chain (VH) determine the binding recognition and specificity to the antigen. The constant region domains of the light chain (CL) and heavy chain (CH) confer important biological properties, such as antibody chain association, secretion, transplacental mobility, complement binding, and binding to Fc receptors (FcR). The Fv fragment is the N-terminal portion of the Fab fragment of an immunoglobulin and consists of one variable portion of a light chain and one variable portion of a heavy chain. The specificity of an antibody resides in the structural complementarity between the antibody binding site or paratope and the antigenic determinant. The antibody binding site is composed mainly of residues from the hypervariable regions or complementarity determining regions (CDRs). Sometimes, residues from non-hypervariable regions or FRs affect the overall domain structure and therefore the antigen binding site. CDRs refer to the amino acid sequences that collectively define the binding affinity and specificity of the native Fv region of a natural immunoglobulin binding site. Examples of antibodies or immunoglobulins include IgM, IgD, IgG, IgA, or IgE. The CDR of the antigen-binding polypeptide of the present invention can be grafted to an antibody, a bispecific antibody, or a multispecific antibody.For example, by knowing the amino acid sequence of the CDR of the antibody, TCR, or antigen-binding polypeptide of the present invention, a person skilled in the art can determine the framework region, for example, the antibody framework region or the TCR framework region.However, if the CDR is not shown, a person skilled in the art can first determine the CDR amino acid sequence based on the IMGT definition of antibody, and then determine the amino acid sequence of the framework region.

[0049] The antigen-binding polypeptide may comprise an antibody or a fragment thereof comprising the substitutions provided herein. The term "antibody" in the context of the present invention also refers to antibodies and fragments thereof, as well as single domain antibodies and fragments thereof, as well as multispecific antibodies and fragments thereof, in particular the variable heavy chain of a single domain antibody, a chimeric antibody, a humanized antibody, a bispecific antibody or a multispecific antibody. An "antibody fragment" comprises a portion of an intact antibody, in particular the antigen-binding site or variable region of an antibody. An antibody fragment provided herein comprises a substitution provided herein. Examples of antibody fragments include Fv, Fab, F(ab')2, Fab', dsFv, (dsFv)2, scFv, sc(Fv)2, diabodies, bispecific and multispecific antibodies formed from antibody fragments. An antibody fragment may also be a single domain antibody, for example a heavy chain variable region (VHH). Preferably, an "antibody fragment" comprises a portion of an intact antibody, in particular comprising an antigen-binding site comprising at least the variable domain CDRs comprising a positively charged amino acid at each CDR position, as defined herein below. Fragments of antigen-binding polypeptides or antibodies are essentially the same or perform the same function as the antigen-binding polypeptide or antibody (e.g., a portion of an antigen-binding polypeptide or antibody) from which they are derived, i.e., antibody fragments specifically bind to their target. Fragments of antigen-binding polypeptides provided herein, or fragments of antibodies contained in antigen-binding polypeptides, such as functional variants defined herein below, have improved or increased binding and / or Tm compared to the parent antigen-binding polypeptide or parent antibody. It is particularly preferred that the fragments defined herein lead to at least a 2-fold improved binding or a reduced binding EC50, and / or at least a 1°C improvement in Tm or at least a 1°C ΔTm compared to the parent antibody, as defined herein below.

[0050] The term "human framework region", in the context of the present invention, refers to a framework region that is substantially identical (about 85% or more, particularly 90%, 95%, 97%, 99%) or identical (100%) to the framework region of a naturally occurring antigen-binding polypeptide, e.g., a naturally occurring human antibody or human TCR.

[0051] The term "humanized antibody" in the context of the present invention refers to an antibody that is fully or partially of non-human origin and has been modified to replace certain amino acids, particularly in the framework regions of the heavy and light chains, to avoid or minimize immune responses in humans. The constant domains of a humanized antibody are primarily human heavy and light chain domains. Methods for humanization of antibody sequences are known in the art; (Almagro & Fransson (2008) Front Biosci. 13: 1619-1633). One commonly used method is CDR grafting, or antibody reshaping, which involves grafting the CDR sequences of a donor antibody, typically a murine antibody, onto the framework scaffold of a human antibody with different specificity. Because CDR grafting can reduce the binding specificity and affinity, and thus the biological activity, of the CDR-grafted non-human antibody, back mutations can be introduced at selected positions of the CDR-grafted antibody to retain the binding specificity and affinity of the parent antibody. Amino acid residues that are part of the CDRs are typically not altered, but in certain cases it may be desirable to alter individual CDR amino acid residues, for example to remove glycosylation sites, deamidation sites, isomerization sites, or undesired cysteine ​​residues. N-linked glycosylation occurs by attachment of an oligosaccharide chain to an asparagine residue in the tripeptide sequence Asn-X-Ser or Asn-X-Thr, where X can be any amino acid except Pro. Removal of N-glycosylation sites can be achieved by mutating either the Asn or Ser / Thr residues to a different residue, particularly by conservative substitution. Deamidation of asparagine and glutamine residues can occur depending on factors such as pH and surface exposure. Asparagine residues are particularly susceptible to deamidation when present primarily in Asn-Gly sequences, and to a lesser extent in other dipeptide sequences such as Asn-Ser. Therefore, where such deamidation sites, particularly Asn-Gly, are present in a CDR sequence, it may be desirable to remove the site, typically by a conservative substitution to remove one of the residues involved.Substitutions in the CDR sequences to remove one of the involved residues are also intended to fall within the scope of the invention.

[0052] The term "Fab" in the context of the present invention refers to an antibody fragment having a molecular weight of about 50,000 daltons and antigen-binding activity, in which about the N-terminal half of the heavy chain and the entire light chain are bound together via disulfide bonds, among fragments obtained by treating IgG with a protease, for example, papain.

[0053] The term "bispecific molecule" in the context of the present invention refers to an antigen-binding polypeptide that has at least two valencies and binding specificities for two different antigens, and therefore comprises two antigen-binding sites. The term "valency" refers to the number of binding sites of an antigen-binding polypeptide, for example, a bivalent antigen-binding polypeptide relates to an antigen-binding polypeptide that has two antigen-binding sites. The term valency refers to the number of binding sites that can bind to the same or different targets. A bivalent antigen-binding polypeptide may be monospecific, i.e., bind to one target, or bispecific, i.e., bind to two different targets. The targets may be antigens, target peptides, off-target peptides, e.g., similar peptides, or α / β TCR / CD3 complexes, including their respective epitopes.

[0054] For the term "bispecific" in the context of the present invention, it is preferred that at least one specificity of the antigen-binding site is derived from an antibody, more specifically, at least one antigen-binding site comprises an antibody-derived CDR as disclosed herein. Thus, "bispecific" in the context of the present invention refers to an antigen-binding polypeptide that combines at least one antigen-binding site comprising a CDR as defined in the context of the present invention, preferably an antibody-derived CDR, and at least one further (second) antigen-binding site, where said at least one further antigen-binding site may be derived from an antibody and therefore comprise an antibody CDR, or may be derived from a TCR and therefore comprise a TCR CDR. In a preferred embodiment, said further (second) antigen-binding site is derived from a TCR and therefore comprises a TCR CDR.

[0055] The term "format" in the context of the present invention refers to an antigen-binding polypeptide that comprises a particular number and type of domains present in said antigen-binding polypeptide, as well as its spatial organization. Many different formats, such as bispecific formats, have been described in the art. Such formats include, but are not limited to, diabodies, crossover dual variable domains (CODVs) and / or dual variable domains (DVDs) polypeptides. The antigen-binding polypeptide may be a diabody, crossover dual variable domains (CODVs) and / or dual variable domains (DVDs) polypeptide that comprises the amino acid residues of the present invention at the positions defined in the claims.

[0056] The term "diabody (Db)" in the context of an antibody, and in the context of the present invention, refers to a bivalent molecule typically composed of two chains containing a VH and a VL domain, each of which is derived from the same or different antibodies. The two chains typically have the following configurations: VHA-VLB and VHB-VLA (A and B represent two different specificities) or VLA-VHB and VLB-VHA.

[0057] In the context of the present invention, a "diabody (Db)" or a "diabody format" is used herein to refer to a diabody that is Db1 and L Db2 It refers to a bivalent molecule composed of two polypeptide chains comprising two variable domains linked by a VI (VIII) linker, where two of the domains are the first and second domains (V1 and V2) as defined in the context of the present invention, and the other two domains are TCR-derived or antibody-derived variable domains (VIII). A , V B The V1 and V2 domains can be located on two different polypeptides, and the V A and V B The domains are located on two different polypeptides and dimerize in a head-to-tail orientation. Thus, the orientation is V1-L Db1 -V A and V B -L Db2 -V2, V2-L Db1 -V A and V B -L Db2 -V1, V1-L Db1 -V B and V A -L Db2 -V2 or V2-L Db1 -V B and V A -L Db2 -V1. To allow the domains to dimerize in a head-to-tail orientation, a linker, i.e., L Db1 and L Db1 may be the same or different and are short linkers. Short linkers are typically linkers with a length of 2 to 12 amino acids, 3 to 13 amino acids, for example, 3, 4, 5, 6, 7, 8, 9 amino acids, for example, 4 amino acids, 5 amino acids (Brinkmann U. and Kontermann RE, MAbs. 2017 Feb-Mar; 9(2): 182-212) or 8 amino acids.

[0058] The "dual variable domain immunoglobulin (DVD-Ig™)" format was first described in 2007 by Wu C. et al. (Nat Biotechnol. 2007 Nov; 25(11):1290-7). In this format, the target-binding variable domain of a second monoclonal antibody (B) is typically bound to a target-binding variable domain of a conventional antibody (A) (domain V LA and V HA ) and thus the light chain of the conventional antibody (A) is fused to an additional light chain variable domain (V LB ), and the heavy chain of the conventional antibody (A) contains an additional heavy chain variable domain (V HB Thus, DVD-Ig™ described in the art typically consists of two polypeptide chains, one heavy chain being V HB -LV HA -C H1 -C H2 -C H3 and one light chain is V LB -LV LA -C L Therefore, the domain vs. LA / V HA and V LB / V HB performs pairing in parallel.

[0059] In the context of the present invention, a "dual variable domain Ig format" refers to a polypeptide comprising two polypeptide chains each comprising two variable domains linked by a linker (L1, L3), where two of the domains are the first and second domains (V1 and V2) as defined in the context of the present invention, and the other two domains are the heavy and light chain variable domains (V) derived from an antibody. HA and V HB In the context of the present invention, in the DVD-Ig format, the polypeptide chain is, for example, V1-L1-V HA -L2-C H1 -C H2 -C H3 and V2-L3-V LA -L4-C L or V2-L1-V HA -L2-C H1 -CH2 -C H3 and V1-L3-V LA -L4-C L The linkers L1 and L3 are preferably 5 to 20 amino acid residues in length, for example 5 to 15 amino acid residues in length, and / or the linkers L2 and L4 may or may not be present.

[0060] "Crossover dual variable domain-Ig-like proteins" as known in the art in the context of antibodies are proteins that have two V H and two V's L The domains are (from N-terminus to C-terminus) V HA -V HB and V LB -V LA or V HB -V HA and V LA -V LB Variable V arranged in any order H -V L Formats are described in which the domains are linked in a manner that allows crossover pairing.

[0061] In the context of the present invention, a "crossover dual variable domain-Ig-like protein" comprises two polypeptide chains each comprising two variable domains linked by a linker (L1, L2, L3 and L4), where two of the domains are the first and second domains (V1 and V2) as defined in the context of the present invention, and the other two domains are the heavy and light chain variable domains (V1 and V2) derived from an antibody. HA , V HB In the context of the present invention, in the CDVD-Ig format, the polypeptide chain is, for example, V1-L1-V HA -L2-C H1 -C H2 -C H3 and V LA -L3-V2-L4-C L , V2-L1-V HA -L2-C H1 -C H2 -C H3 and VLA -L3-V1-L4-C L , V HA -L1-V1-L2-C H1 -C H2 -C H3 and V2-L3-V LA -L DVD3 -C L or V HA -L1-V2-L2-C H1 -C H2 -C H3 and V1-L3-V LA -L4-C L In this CDVD format, the linkers (L1-L4) are typically of different lengths. For example, L1 is 3-12 amino acid residues in length, L2 is 3-14 amino acid residues in length, L3 is 1-8 amino acid residues in length, and L4 is 1-3 amino acid residues in length, or L1 is 5-10 amino acid residues in length, L2 is 5-8 amino acid residues in length, L3 is 1-5 amino acid residues in length, and L4 is 1-2 amino acid residues in length, or L1 is 7 amino acid residues in length, L2 is 5 amino acid residues in length, L3 is 1 amino acid residue in length, and L4 is 2 amino acid residues in length.

[0062] The term "covalently bound" or "covalent bond" in the context of the present invention refers to a covalent bond, e.g. via a disulfide bridge or disulfide bond, or a peptide bond, or a linker or linker sequence, e.g. a polypeptide linker.

[0063] The term "linker" or "peptide linker", in the context of the present invention, refers to an amino acid sequence that sterically separates two parts or moieties of a complex, e.g., two peptides, polypeptides or proteins. Typically, such linkers comprise or consist of 1 to 20 amino acids. A peptide linker provides flexibility between the two moieties linked together. Flexibility is generally higher when the amino acids are small. Thus, a flexible peptide linker contains a high content of small amino acids, in particular glycine and / or alanine, and / or hydrophilic amino acids, e.g., serine, threonine, asparagine and glutamine. In the context of the present invention, a peptide linker, e.g., one or more amino acid residues, inserted between two domains provides sufficient flexibility for the domain, e.g., in a single chain construct or between the variable domains of the light and heavy chain variable domains, to allow correct folding to form an antigen binding site. In the case of bispecific antigen-binding polypeptides, the linker allows the antigen-binding polypeptides of the invention to form either a crossover pairing (as in some CODV or diabody formats) or parallel pairing configuration (e.g., in a DVD format) of the antigen-binding site and a further antigen-binding site. Linkers in the context of the present invention are abbreviated as L1, L2, L3, L4, etc.

[0064] The term "dimerization domain" (also abbreviated as D1 or D2, respectively) in the context of the present invention preferably refers to a heterodimerization domain that mediates the heterodimerization of a first polypeptide chain with a second polypeptide chain, but does not mediate the homodimerization of two first polypeptide chains or two second polypeptide chains. In a preferred embodiment, a pair of dimerization domains (e.g., D1 and D2) are selected from immunoglobulin constant domains, e.g., C1 and C2 from an antibody. L and C H1 , or C L -F c and C H1 -F c , or TCR-derived C α and Cβ , or a pair of C H3 Domain or pair of F c domain, where C H3 and F c The domain preferably comprises an introduced mutation that forces heterodimerization, such as a knob-into-hole mutation. In particular, the dimerization domain relates to an Fc domain as defined herein below.

[0065] The term "Fc domain" as used in the context of the present invention encompasses native Fc domains as well as Fc domain variants and sequences as further defined herein below. In the context of Fc variants and native Fc molecules, the term "Fc domain" includes the molecule in monomeric or multimeric form, whether digested from a whole antibody or produced by other means.

[0066] The term "native Fc" as used herein refers to a molecule comprising a sequence of a non-antigen-binding fragment resulting from the digestion of an antibody or generated by other means, whether in monomeric or multimeric form, which may contain a hinge region. The original immunoglobulin source of native Fc is particularly of human origin and may be any of the immunoglobulins, preferably IgG1 or IgG2, most preferably IgG1. Native Fc molecules are composed of monomeric polypeptides that may be linked into dimeric or multimeric forms by covalent bonds (i.e., disulfide bonds) and non-covalent associations. The number of intermolecular disulfide bonds between monomeric subunits of native Fc molecules ranges from 1 to 4, depending on the class (e.g., IgG, IgA, and IgE) or subclass (e.g., IgG1, IgG2, IgG3, IgA1, and IgGA2). One example of a native Fc is a disulfide-linked dimer resulting from papain digestion of IgG. The term "native Fc" is generic for monomeric, dimeric and multimeric forms. The Fc domain preferably comprises or further comprises an "RF" and / or "knob-into-hole" mutation, preferably a "knob-into-hole" mutation. An "RF mutation" typically refers to an amino acid substitution of the amino acid HY in the CH3 domain of the Fc domain to RF, for example, the amino acid substitutions H435R and Y436F in the CH3 domain, as described by Jendeberg, L. et al. (1997, J. Immunological Meth., 201: 25-34), which is described as being advantageous for purification purposes because it abolishes binding to Protein A. When a bispecific antigen-binding polypeptide comprises two Fc domains, the RF mutation may be in one or both, preferably in one of the Fc domains. "Knobs-into-holes", also known as "knobs-into-holes" technology, refers to the amino acid substitutions T366S, L368A and Y407V (holes) and T366W (knobs) at the CH3-CH3 interface to promote heteromultimer formation.These knobs-into-hole mutations can be further stabilized by the introduction of additional cysteine ​​amino acid substitutions Y349C and S354C. The "knobs-into-hole" technology with stabilizing cysteine ​​amino acid substitutions is described in U.S. Patent No. 5,731,168 and U.S. Patent No. 8,216,805, which are incorporated herein by reference.

[0067] The term "amino acid", in the context of the present invention, refers to any monomeric unit that includes a substituted or unsubstituted amino group, a substituted or unsubstituted carboxy group, and one or more side chains or side chain groups, or analogs of any of these groups. Exemplary side chains include, for example, thiol, seleno, sulfonyl, alkyl, aryl, acyl, keto, azido, hydroxyl, hydrazine, cyano, halo, hydrazide, alkenyl, alkynyl, ether, boric acid, boronic acid, phosphate, phosphono, phosphine, heterocycle, enone, imine, aldehyde, ester, thioacid, hydroxylamine, or any combination of these groups. Other representative amino acids include, but are not limited to, amino acids comprising photoactivatable crosslinkers, metal-binding amino acids, spin-labeled amino acids, fluorescent amino acids, metal-containing amino acids, amino acids with novel functional groups, amino acids that covalently or non-covalently interact with other molecules, photocaged and / or photoisomerizable amino acids, radioactive amino acids, amino acids comprising biotin or biotin analogs, glycosylated amino acids, other carbohydrate-modified amino acids, amino acids comprising polyethylene glycol or polyethers, heavy atom substituted amino acids, chemically cleavable and / or photocleavable amino acids, carbon-linked sugar-containing amino acids, redox-active amino acids, aminothioacid-containing amino acids, and amino acids comprising one or more toxic moieties. As used herein, the term "amino acid" includes the twenty naturally occurring or genetically encoded α-amino acids: alanine (Ala or A), arginine (Arg or R), asparagine (Asn or N), aspartic acid (Asp or D), cysteine ​​(Cys or C), glutamine (Gln or Q), glutamic acid (Glu or E), glycine (Gly or G), histidine (His or H), isoleucine (Ile or I), leucine (Leu or L), lysine (Lys or K), methionine (Met or M), phenylalanine (Phe or F), proline (Pro or P), serine (Ser or S), threonine (Thr or T), tryptophan (Trp or W), tyrosine (Tyr or Y), and valine (Val or V).When the "X" residues are not defined, they should be interpreted as "any amino acid." The structures of these 20 naturally occurring amino acids are described, for example, in Stryer et al., Biochemistry, 5. thed., Freeman and Company (2002). Additional amino acids, such as selenocysteine ​​and pyrrolysine, can also be genetically encoded (Stadtman (1996) "Selenocysteine," Annu Rev Biochem. 65:83-100 and Ibba et al. (2002) "Genetic code: introducing pyrrolysine," Curr Biol. 12(13):R464-R466). The term "amino acid" also includes unnatural amino acids, modified amino acids (e.g., having modified side chains and / or backbones), and amino acid analogs (e.g., see Zhang et al. (2004) "Selective incorporation of 5-hydroxytryptophan into proteins in mammalian cells," Proc. Natl. Acad. Sci. USA 101(24):8882-8887; Anderson et al. (2004) "An expanded genetic code with a functional quadruplet codon" Proc. Natl. Acad. Sci. USA 101(20):7566-7571; Ikeda et al. (2003) "Synthesis of a novel histidine analogue and its efficient incorporation into a protein in vivo," Protein Eng. Des. Sel. 16(9):699-706; Chin et al. (2003) "An Expanded Eukaryotic Genetic Code," Science 301(5635):964-967; James et al. (2001) "Kinetic characterization of ribonuclease S mutants containing photoisomerizable phenylazophenylalanine residues," Protein Eng. Des. Sel.14(12):983-991; Kohrer et al. (2001) "Import of amber and ochre suppressor tRNAs into mammalian cells: A general approach to site-specific insertion of amino acid analogues into proteins," Proc. Natl. Acad. Sci. USA 98(25):14310-14315; Bacher et al. (2001) "Selection and Characterization of Escherichia coli Variants Capable of Growth on an Otherwise Toxic Tryptophan Analogue," J. Bacteriol. 183(18):5414-5425, Hamano-Takaku et al. (2000) "A Mutant Escherichia coli Tyrosyl-tRNA Synthetase Utilizes the Unnatural Amino Acid Azatyrosine More Efficiently than Tyrosine," J. Biol. Chem. 275(51):40324-40328, and Budisa et al. (2001) "Proteins with {beta}-(thienopyrrolyl) alanines as alternative chromophores and soluble active amino acids," Protein Sci. 10(7):1281-1292). The amino acids can be fused to peptides, polypeptides, or proteins.

[0068] Amino acids can be further classified into polar and nonpolar amino acids. Polarity is defined as the separation of charges leading to a molecule or its chemical group having an electric dipole moment with a negatively charged end and a positively charged end. Polar molecules interact through dipole-dipole intermolecular forces and hydrogen bonding. Polarity is the basis of several physical properties, including interfacial tension, solubility, and melting and boiling points. Polar amino acids include amino acids with hydrogen donor and / or acceptor atoms, except for tryptophan. In fact, tryptophan is classified in the "nonpolar" class of IMGT despite its hydrogen donor atom, because it participates in the nonpolar core of the structural domain. The group of polar amino acids includes five charged amino acids (R, H, K, D, E) and five uncharged amino acids (N, Q, S, T, Y). The group of nonpolar amino acids includes uncharged amino acids, e.g., (A, C, G, I, L, M, F, P, W, V) amino acids. Polar amino acids are hydrophilic (Q, N) or neutral (S, T, Y) and are usually found on the exterior of proteins, where they are often involved in hydrogen bonds. Nonpolar amino acids tend to cluster their side chains together on the interior of proteins, where they are often involved in van der Waals interactions.

[0069] The term "positively charged amino acid" in the context of the present invention refers to an amino acid whose side chain carries a positive charge. For example, at pH 7, lysine (K), arginine (R) are positively charged. Thus, a positively charged amino acid is preferably R or K. H may be charged at pH 7 under certain conditions. The term "negatively charged" refers to an amino acid whose side chain carries a negative charge. For example, at pH 7, aspartic acid (D) and glutamic acid (E) are negatively charged. It should be noted that the charge may depend on the pH and temperature of the solution containing the amino acid, peptide or protein. In particular, the pH and temperature of the human body are important when the antigen-binding polypeptide of the present invention is applied as a pharmaceutical. Thus, the term "positively charged amino acid" refers to an amino acid that carries a positive charge under the conditions found in the circulation and extracellular space of a subject, in particular in the tumor tissue of a subject to which the antigen-binding polypeptide is administered. Preferably, the subject is a human. In this case, the amino acid carries a positive charge, for example, at the pH and temperature of the human body. In a particular embodiment, the positively charged amino acid is selected from the group consisting of arginine (R), histidine (H) and lysine (K), preferably the positively charged amino acid is R or K. In the context of the present invention, at least one amino acid that is not positively charged at each position in the CDR or VH or VL as defined herein below is substituted with a positively charged amino acid. For example, a position is a position that carries a serine (S) and therefore has a non-positively charged amino acid, which is substituted with a positively charged amino acid, e.g. R. Thus, the residue S constitutes a non-positively charged amino acid. A certain CDR, as defined herein below, or a certain VH or VL residue that has a non-positively charged amino acid can have an uncharged or non-charged amino acid or a negatively charged amino acid residue. In this context, it is preferred that if Q is naturally present at a certain position in HCDR2, it is preferably not substituted with a positively charged amino acid in the context of the present invention.

[0070] The term "substituted" as used throughout this specification refers to the replacement of an amino acid in a parent antigen-binding polypeptide with another amino acid that is different from the amino acid being substituted.

[0071] The term "peptide", in the context of the present invention, refers to a short polymer of amino acids linked by peptide bonds. It has the same chemical (peptide) bonds as proteins, but is generally shorter in length. The shortest peptides are dipeptides, consisting of two amino acids linked by a single peptide bond. There can also be tripeptides, tetrapeptides, pentapeptides, etc. Typically, peptides have a length of up to 8, 10, 12, 15, 18 or 20 amino acids. A peptide has an amino terminus and a carboxyl terminus, unless it is a cyclic peptide or has been chemically modified.

[0072] The term "amino acid sequence identity" in the context of the present invention refers to the percentage of sequence identity, which is determined by comparing two optimally aligned sequences over a comparison window, where the portion of the sequence within the comparison window can contain additions or deletions (i.e., gaps) compared to the reference sequence (which contains no additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions where identical nucleic acid bases or amino acid residues exist in both sequences to obtain the number of matching positions, dividing the number of matching positions by the total number of positions in the comparison window, and multiplying the result by 100 to obtain the percentage of sequence identity.

[0073] The term "identical," in the context of two or more polypeptide or nucleic acid sequences, refers to two or more sequences or subsequences that are the same, i.e., contain the same sequence of amino acids or nucleic acids. Sequences are "substantially identical" to each other if they have a specified percentage of amino acid residues that are the same (e.g., at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity over a specified region) when compared and aligned for maximum correspondence over a comparison window, or designated region, measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. These definitions also refer to the complement of a test sequence. Thus, the term "at least 80% sequence identity" is used throughout the present specification with respect to comparison of polypeptide and polynucleotide sequences.This expression preferably refers to at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with each reference polypeptide or each reference polynucleotide.

[0074] The term "sequence comparison" in the context of the present invention refers to a process in which one sequence acts as a reference sequence to be compared with a test sequence. When using a sequence comparison algorithm, the test sequence and the reference sequence are input into a computer, partial sequence coordinates are designated as necessary, and sequence algorithm program parameters are designated. Default program parameters are generally used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identity or similarity of the test sequence to the reference sequence based on the program parameters. When no reference sequence is designated in the comparison in which two sequences are compared and the percentage of sequence identity is to be calculated, the sequence identity is calculated with reference to the longer of the two sequences to be compared, unless otherwise specifically indicated. When a reference sequence is indicated, the sequence identity is determined based on the full length of the reference sequence indicated by its sequence number, unless otherwise specifically indicated.

[0075] Methods of alignment of sequences for comparison are well known in the art. Optimal alignment of sequences for comparison can be performed, for example, by the local homology algorithm of Smith and Waterman (Adv. Appl. Math. 2:482, 1970), by the homology alignment algorithm of Needleman and Wunsch (J. Mol. Biol. 48:443, 1970), by the similarity search method of Pearson and Lipman (Proc. Natl. Acad. Sci. USA 85:2444, 1988), by computerized implementations of these algorithms (e.g., GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by manual alignment and visual inspection (see, for example, Ausubel et al., Current Protocols in Molecular Biology (1995 supplement)). Suitable algorithms for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (Nuc. Acids Res. 25:3389-402, 1977) and Altschul et al. (J. Mol. Biol. 215:403-10, 1990), respectively. Software for performing BLAST analysis is available from the National Center for Biotechnology Information (http: / / www.ncbi.nlm.nih.gov / ). This algorithm involves first identifying high-scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence that match or meet a certain positive threshold score T when aligned with words of the same length in the database sequence.T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds to initiate searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as long as the cumulative alignment score can be increased. For nucleotide sequences, the parameters M (reward score for a pair of matching residues; always greater than 0) and N (penalty score for mismatching residues; always less than 0) are used to calculate the cumulative score. For amino acid sequences, a scoring matrix is ​​used to calculate the cumulative score. Extension of the word hits in each direction is stopped when: the cumulative alignment score falls by an amount X from its maximum achieved value; when the accumulation of one or more negative-scoring residue alignments causes the cumulative score to fall to 0 or below; or when the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915, 1989) alignment (B) of 50, an expectation (E) of 10, M=5, N=-4, and a comparison of both strands.

[0076] Another measure of similarity provided by the BLAST algorithm is the minimum sum probability (P(N)), which provides an indication of the probability that a match between amino acid sequences would occur by chance. For example, an amino acid is considered similar to a reference sequence if the minimum sum probability in the comparison of the test amino acid with the reference amino acid is less than about 0.2, typically less than about 0.01, and more typically less than about 0.001. Semi-conservative, particularly conservative, amino acid substitutions are preferred, in which an amino acid is replaced with a chemically related amino acid. Typical substitutions are between aliphatic amino acids, between amino acids with aliphatic hydroxyl side chains, between amino acids with acidic residues, between amide derivatives, between amino acids with basic residues, or between amino acids with aromatic residues. Typical semi-conservative and conservative substitutions are shown in Table 2 below.

[0077] [Table 2]

[0078] A change from A, F, H, I, L, M, P, V, W or Y to C is semi-conservative if the new cysteine ​​remains as a free thiol. Furthermore, one of skill in the art will understand that glycines in sterically required positions should not be substituted and that P should not be introduced into portions of proteins that have α-helical or β-sheet structure.

[0079] The term "functional variant" or "variant" as used in the context of the present invention refers to an antigen-binding polypeptide or polypeptide of the invention having substantial or significant sequence identity or similarity to a given antigen-binding polypeptide or polypeptide, wherein said functional variant retains the biological activity of the given antigen-binding polypeptide or polypeptide. In the context of the present invention, an antigen-binding polypeptide comprising a substitution of the invention, in particular each positively charged amino acid at position 90 and / or Y as defined herein above and below, exhibits improved binding (e.g., improved EC binding) compared to a parent or reference antigen-binding polypeptide. 50) and / or improved or increased Tm. Thus, functional variants of the antigen-binding polypeptides of the invention have improved or increased binding (e.g., binding EC 50 ) or Tm are envisaged to be the same or to have an improved and increased / elevated binding (e.g., binding EC50) and / or Tm, respectively. This is further envisaged for portions, regions or fragments of the antigen-binding polypeptides of the invention, e.g., FR or VH or VL. For example, functional variants provided herein of FR, VH, VL or antigen-binding polypeptides defined herein may have an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of a given antigen-binding polypeptide, e.g., antigen-binding polypeptide. In some embodiments, a functional fragment comprises a substitution of the invention. Preferably, a functional fragment has improved or increased binding (e.g., binding EC50) and / or Tm compared to a parent antigen-binding polypeptide or fragment thereof that does not comprise a substitution of the invention.

[0080] A "functional variant" as defined herein may, for example, comprise the amino acid sequence of each antigen-binding polypeptide of the invention having at least one conservative amino acid substitution. Alternatively, or in addition, a functional variant may comprise the amino acid sequence of each antigen-binding polypeptide of the invention having at least one non-conservative amino acid substitution. In this case, it is preferred that the non-conservative amino acid substitution does not interfere with or inhibit the biological activity of the functional variant. Preferably, the non-conservative amino acid substitution enhances the biological activity of the functional variant, such that the biological activity of the functional variant is increased compared to the respective antigen-binding polypeptide or a fragment thereof.

[0081] The term "stability" refers in the context of the present invention to the thermal stability of a protein, polypeptide or antigen-binding polypeptide. A protein or polypeptide is typically characterized by heat resistance or thermal stability, particularly described by the parameter "melting temperature (Tm)". Temperature is a factor for providing a functional correctly folded protein. Thus, the stability of a protein varies under different temperature conditions applied. Above the native temperature of a protein, thermal energy is believed to lead to the unfolding and denaturation of said protein. If a protein is resistant to irreversible changes at high temperatures, it is described as thermostable or thermostable. As mentioned above, thermal stability is defined by the descriptor melting temperature Tm.

[0082] The term "melting temperature (Tm)" in the context of the present invention refers to "thermal stability", i.e., the temperature at which the concentration of the protein in the folded state is equal to the concentration of the unfolded protein (Miotto et al., Insights on protein thermal stability: a graph representation of molecular interactions; bioRxiv preprint doi: https: / / doi.org / 10.1101 / 354266; June 22, 2018). In particular, Tm is the temperature at which 50% of the protein is unfolded, as shown in the examples herein below. When a polypeptide or protein reaches its Tm, the free energy change ΔG is equal to 0. At this point, the polypeptide or protein molecule becomes amorphous and invisible, and the protein chain is no longer able to refold by itself. A general rule of thumb is that an increase in Tm is associated with an increase in the free energy of maximum stability ΔG(T*). Tm can be measured by using circular dichroism (CD), a spectroscopic technique that follows protein unfolding and folding as a function of temperature, or by differential scanning calorimetry (DSC), differential scanning fluorimetry (DSF) or biochemical assays. Generally, a high T mA protein or polypeptide having a higher Tm value is more stable than a protein or polypeptide having a lower Tm value. Increasing thermal stability reduces the denaturation of the antigen-binding polypeptide and therefore improves, for example, the storage conditions of said polypeptide. Nano-differential scanning fluorimetry (nano-DSF) as an exemplary method is disclosed herein below in the accompanying examples for determining Tm using PBS (phosphate buffered saline) buffer at pH 7.4. Preferably, Tm is determined by DSF, more preferably by nanoDSF. In particular, Tm is determined by DSF in PBS at pH 7.4, at a heating ramp rate of 1°C / min, where the antigen-binding polypeptide has a concentration of 50 μg / ml. Absolute melting temperatures can be obtained directly. ΔTm values ​​of various analytes can be calculated. It is preferable that the values ​​to be compared with each other are included in the same experimental run.

[0083] The term "binding" in the context of the present invention refers to "binding affinity" or "area under the curve (AUC) of binding" or "EC50 value of binding" as further defined in detail below. In particular, "binding" refers to the binding of an antigen-binding polypeptide to the α / β TCR / CD3 complex as defined above, or preferably to the binding of an antigen-binding polypeptide to a cell expressing the α / β TCR / CD3 complex, or more preferably to a T cell expressing the α / β TCR / CD3 complex. The binding of an antigen-binding polypeptide can be determined by a flow cytometer assay, e.g., FACS, as further disclosed in the examples below, where the binding of an antigen-binding polypeptide to an α / β TCR / CD3 positive cell is determined, for example, in comparison to a parent antigen-binding polypeptide, in particular an antigen-binding polypeptide not comprising a substitution of the invention, e.g., BMA031(V36). Preferably, the binding of the antigen-binding polypeptide to cells expressing the α / β TCR / CD3 complex is determined by flow cytometry binding analysis using α / β TCR / CD3 positive Jurkat cells (e.g., clone E6-1 cells) and α / β TCR / CD3 negative Jurkat cells. In particular, the binding of the antigen-binding polypeptide is determined by testing various concentrations, for example, from 10 μg / ml to 10 ng / ml, in half-logarithmic steps of the antigen-binding polypeptide. In further particular embodiments, the steps of binding to the cells and washing are carried out in a buffer containing PBS, 2 mM ethylenediaminetetraacetic acid (EDTA), 5% fetal calf serum (FCS). In further particular embodiments, antigen-negative cells (e.g., labeled with CFSE CellTrace) are mixed with antigen-positive cells in a 1:1 ratio. In a further particular embodiment, a fixed concentration of antigen-binding polypeptide (e.g., 100 μl / well) is incubated with the cell mixture (e.g., 100.000 cells / well) for e.g., 15 min on ice in said buffer, and the cells are washed to remove unbound antigen-binding polypeptide. Preferably, live / dead cell sorting / staining is performed.Staining of cells bound to the antigen-binding polypeptides can be measured with a flow cytometer (e.g., Intellicyt iQue Screener (Sartorius AG) or CytoFLEX (Beckmann Coulter, 2089495-01)) and MFI (median fluorescence intensity) values ​​can be compared.

[0084] "Binding affinity" or "affinity" in the context of the present invention refers, for example, to the half-maximal effective concentration (EC 50 ) or the equilibrium dissociation constant (K D ) can be expressed as

[0085] "EC 50 "Half-maximal effective concentration", also abbreviated as "EC50", refers in the context of the present invention to "binding EC50" or "functional EC50", and it will be noted which term is used throughout this application.

[0086] The term "binding EC50" in the context of the present invention can be described as the concentration of a ligand, e.g., an antigen-binding polypeptide or protein, at which half of the target, e.g., the α / β TCR / CD3 complex, is present in a bound state. Binding EC50 is a parameter for measuring the binding of an antigen-binding polypeptide to a target cell, preferably a T cell expressing the α / β TCR / CD3 complex, i.e., the binding of the antigen-binding polypeptides of the present invention to their targets. The binding EC50 value depends on the target concentration. EC50 and affinity are inversely related, which means that the lower the EC50 value, the higher the binding affinity of the molecule. In general, low binding EC50 values ​​are preferred. Binding EC50 values ​​are determined by flow cytometric binding analysis using a flow cytometer (e.g., Intellicyt iQue Screener (Sartorius AG) or CytoFLEX (Beckmann Coulter, 2089495-01)), e.g., as described in the examples herein below. Typically, the measurement is carried out under the following conditions: labeled cells (e.g., cells not expressing the target antigen α / β TCR / CD3 complex, labeled with CFSE CellTrace) are mixed with antigen-positive cells in a 1:1 ratio. In a further particular embodiment, the antigen-binding polypeptide (e.g., at a concentration of 100 μl / well) is incubated with the cell mixture (e.g., 100.000 cells / well), e.g., for 15 minutes on ice in said buffer, and the cells are washed to remove unbound antigen-binding polypeptide. The staining can be determined in a flow cytometer, and the MFI values ​​of the various samples can be compared. Preferably, the EC50 value of the MFI of the antigen-binding polypeptide of the invention is calculated and presented as a 1x reduction in the MFI of the parent antibody BMA031 (V36), also called TPP-1374, which does not contain the amino acid substitutions of the invention. For example, TPP-1389 showed a 31.8-fold reduction in EC50, which means that the EC50 is 31.8-fold reduced compared to the EC50 determined by the same method for the parent antibody TPP-1374.Thus, the binding EC50 value of the antigen-binding polypeptide of the invention is preferably lower than the binding EC50 value of the parent antigen-binding polypeptide, e.g., an antigen-binding polypeptide that does not comprise a substitution of the invention (e.g., does not comprise a substitution with a positively charged amino acid and / or does not comprise a tyrosine at position 90). As used herein below, the x-fold reduction of the antigen-binding polypeptide of the invention is compared to the parent antigen-binding polypeptide that does not comprise a substitution of the invention (e.g., does not comprise a substitution with a positively charged amino acid and / or does not comprise a tyrosine at position 90). Preferably, the x-fold reduction of the antigen-binding polypeptide of the invention is compared to the parent antibody BMA031 (V36), which comprises a VH according to SEQ ID NO: 1 and a VL according to SEQ ID NO: 2.

[0087] The term "functional EC50" in the context of the present invention refers to the half-maximal effective concentration of a substance and is therefore a measure of the concentration of said substance that induces a response halfway between the baseline and the maximum after a specified exposure time. It is commonly used as a measure of drug potency. Thus, the EC50 of a graded dose-response curve represents the concentration of a substance at which 50% of its maximum effect is observed. The EC50 of a mathematical dose-response curve 50 represents the concentration of a compound at which 50% of a population shows a response after a specified exposure period. In one example, a "functional EC50 value" refers to the concentration of an antigen-binding polypeptide of the present invention that induces a response halfway between baseline and maximum after a specified exposure time. EC50 values ​​can be experimentally assessed by a variety of known methods, for example, using an IFN-γ release assay or an LDH release assay, for example, as described in Example 3 herein.

[0088] The term "area under the curve (AUC)" in the context of the present invention refers to "area under the curve of binding (binding AUC)" and is used interchangeably herein.

[0089] As indicated above, binding can also be expressed as AUC or binding AUC, which is calculated based on the logarithmic concentration of the antigen-binding polypeptide and MFI. The calculated EC50, or AUC, indicates the binding strength of the antigen-binding polypeptide, e.g., an antibody, to its target, e.g., an antigen, and vice versa, and thus an increase in the AUC value indicates an increase or improvement in the binding of the antigen-binding polypeptide to its target, e.g., a cell expressing an α / β TCR / CD3 complex, preferably an α / β TCR / CD3 complex, or more preferably a T cell expressing an α / β TCR / CD3 complex, or vice versa. Preferably, the AUC of the antigen-binding polypeptide of the present invention is indicated as a "% increase in binding AUC" or a "% increase in AUC", which means a "% increase in AUC". The terms "% increase in binding AUC" or "% increase in AUC" can be used interchangeably herein. The binding AUC of an antigen-binding polypeptide is compared to the binding AUC of a parent antigen-binding polypeptide, particularly one that does not comprise a substitution of the invention (e.g., does not comprise a substitution with a positively charged amino acid and / or does not comprise a tyrosine at position 90). As used herein, a "% increase in binding AUC" or "% increase in AUC" of an antigen-binding polypeptide of the invention is compared to a parent antigen-binding polypeptide, particularly one that does not comprise a substitution of the invention (e.g., does not comprise a substitution with a positively charged amino acid and / or does not comprise a tyrosine at position 90). Preferably, a "% increase in binding AUC" or "% increase in AUC" of an antigen-binding polypeptide of the invention is compared under identical conditions (and preferably in the same experimental run) to the parent antibody BMA031(V36), also referred to as TPP-1374 in the examples below, which is set to a 0% increase in AUC. For example, the antigen-binding polypeptide TPP-1375 exhibits an 87% increase in AUC (see Table 5 in the Examples section), which represents an 87% increase in binding AUC compared to the parent antibody TPP-1374 used for comparison.

[0090] The term "synergistic or synergistic" in the context of the present invention refers to a synergistic effect caused by two or more different mutations in the CDR or FR of the variable domain of an antigen-binding polypeptide. Synergistic effect is a nonlinear cumulative effect that is greater than the simple sum of the effects caused by each single mutation alone. For example, the % increase in AUC of the antigen-binding polypeptide TPP-1360 carrying R at heavy chain position 31 is 144%, and the % increase in AUC of the antigen-binding polypeptide TPP-1387 carrying Y at position 90 is 14% (see Table 6 in the Examples disclosed herein). Surprisingly, as shown in the Examples, the antigen-binding polypeptides produce a synergistic effect. For example, as shown in TPP-1388, an antigen-binding polypeptide comprising a substitution at position 31 in the heavy chain with R and a substitution at position 90 with Y shows a 273% increase in AUC, which illustrates the synergistic effect in terms of the % increase in AUC; see, for example, Tables 5 or 6.

[0091] In the context of the present invention, the term "dissociation constant (K D The term "dissociation equilibrium constant, k )" (measured in "mol / L" and sometimes abbreviated as "M") refers to the dissociation equilibrium constant, k , of a particular interaction between a binding moiety (e.g., an antigen-binding polypeptide or fragment thereof) and a target molecule (e.g., an antigen or its epitope). off / k on It refers to the ratio of K D and affinity are inversely proportional. D The value is related to the concentration of the antigen-binding polypeptide, K D The lower the value, the higher the affinity of the antigen-binding polypeptide. DK values ​​can be experimentally determined by a variety of known methods, for example, by measuring association and dissociation rates by surface plasmon resonance (SPR)-based assays (e.g., BIAcore assays) or biolayer interferometry (BLI), enzyme-linked immunosorbent assays (ELISAs), and competitive assays (e.g., radioimmunoassays (RIAs)). Low affinity antigen-binding polypeptides generally bind antigens slowly and tend to dissociate easily, whereas high affinity antibodies generally bind antigens quickly and tend to remain bound. K D is typically measured at 30° C. by BLI or SPR.

[0092] Typically, when the antigen-binding polypeptide of the invention comprises a second binding site, the second binding site that specifically binds to a given antigen comprises an affinity matured TCR or a fragment thereof, or when the antigen-binding polypeptide is a soluble molecule or a fragment thereof in a bispecific format, such as a TCER® molecule or a fragment thereof, the TCR or a functional fragment thereof, in particular the K of Vα or Vβ. D is 9 x 10 -8 ~5×10 -13 M, 9×10 -9 ~1×10 -12 M, 8×10 -9 ~5×10 -12 M, 7×10 -9 ~1×10 -11 M, 6×10 -9 ~2×10 -11 M, 5×10 -9 ~5×10 -11 M, 4×10 -9 ~8×10 -11 M, 3×10 -9 ~1×10 -10 M. Molecules in a bispecific format referred to herein as "TCER®" molecules or "TCER®" typically comprise a first antigen-binding site contained in a first polypeptide chain that specifically binds to a surface molecule on a T cell, and a second antigen-binding site contained in a second polypeptide chain that specifically binds to an MHC-peptide complex.

[0093] Typically, when an antigen-binding polypeptide of the invention comprises a second binding site, and the second binding site that specifically binds to a given antigen comprises a TCR or a fragment thereof, the TCR or fragment thereof is at least 3×10 -5 ~1×10 -7 s -1 , 2×10 -5 ~5×10 -7 s -1 , 1×10 -5 ~1×10 -6 s -1 or 5×10 -6 ~1×10 -6 s -1 K in the range D has.

[0094] The term "TCER®", also referred to as "TCER® molecule", in the context of the present invention refers to a bispecific molecule comprising one specificity that specifically binds to a surface molecule on a T cell and one specificity that specifically binds to an MHC-peptide complex. Thus, a "TCER®" is a bispecific TCR that is a soluble antigen-binding polypeptide comprising a first antigen-binding site as defined herein and a second antigen-binding site, where the first antigen-binding site comprises the VH and VL domains of an antigen-binding polypeptide as defined in the context of the present invention that specifically binds to the a / β TCR / CD3 complex, and a further or second antigen-binding site formed by the alpha variable domain (Vα) and the beta variable domain (Vβ) of a TCR that specifically binds to an MHC-peptide complex, e.g., a tumor-associated peptide-MHC complex.

[0095] The term "specifically bind" in the context of the present invention refers to the binding of an antigen-binding polypeptide or a fragment thereof, such as an antibody or a fragment thereof, or a TCR or a fragment thereof, to a specific binding site of a target, when the target contains specific and non-specific binding sites. However, sometimes the binding of a polypeptide to closely related proteins may be unavoidable, in which case the antigen-binding polypeptide is considered to be non-specific with respect to the intended target binding, although the actual binding to the target may be specific. An antigen-binding polypeptide of the present invention is considered to specifically bind if it binds more strongly or enhanced to its target than one or more similar antigens. When the antigen-binding polypeptide is an antibody, it is preferred that the antibody specifically binds to its target.

[0096] The term "cell surface protein" in the context of the present invention refers to proteins embedded in or spanning the layers of the cell membrane of more complex organisms. These proteins are essential to how cells interact with their surrounding environment, including other cells. Examples of cell surface proteins include antigen receptors, such as antibodies or TCRs or TCR chains; antigen-presenting molecules, such as MHC molecules or β-microglobulin; co-receptor molecules, such as CD4, CD8 or CD19, antigen receptor accessory molecules, such as CD3-γ, -δ and -ε chains, CD79a and CD79b; costimulatory or inhibitory molecules, such as CD28, CD80 or CD86; receptors on natural killer cells; receptors on leukocytes, immunoglobulin-like cell adhesion molecules, such as ICAM; NCAM, CD2; cytokine receptors, such as IL-1 receptor or colony-stimulating factor 1 receptor; growth factor receptors; receptor tyrosine kinases or phosphatases, Ig-binding receptors, such as polymeric immunoglobulin receptor (PIGR) or Fc receptors. Further examples are surface marker molecules selected from the group consisting of CD3, CD4, CD25, CTLA4, GITR, NK1.1, SLAMF1, SLAMF6, TGFβ, Vα24, Jα18, IL-12R, IFNγR, CXCR3, IL-4R, IL33R, CCR4, IL-17RB, CRTH2; IL-23R, CCR6, IL-1R, CD161; CCR7 hi, CD44, CD62Lhi, TCR, CD3, IL-7R (CD127), IL-15R.

[0097] The term "MHC" in the context of the present invention refers to an abbreviation of the term "major histocompatibility complex". MHC is a set of cell surface proteins, i.e. cell surface receptors, that play an essential role in establishing adaptive immunity to altered native or foreign proteins in vertebrates, thus determining tissue compatibility within tissues. The main function of MHC molecules is to bind antigens derived from altered proteins or pathogens and present them on the cell surface for recognition by appropriate T cells. Human MHC is also called HLA (human leukocyte antigen) complex or HLA. The MHC gene family is divided into three subgroups: class I, class II, and class III. Complexes of peptides and MHC class I are recognized by CD8 positive T cells with the appropriate TCR, while complexes of peptides and MHC class II molecules are recognized by CD4 positive helper T cells with the appropriate TCR. Since both types of responses, CD8- and CD4-dependent, cooperate and synergistically contribute to antitumor effects, the identification and characterization of tumor-associated antigens and corresponding TCRs are important in the development of cancer immunotherapy, e.g., vaccines and cell therapies.

[0098] The term "MHC-I" refers in the context of the present invention to MHC class I molecules or MHC-I. MHC I molecules consist of an α chain, also called MHC I heavy chain, and a β chain that constitutes the β2 microglobulin molecule. The α chain contains three α domains, namely the α1 domain, the α2 domain and the α3 domain. The α1 and α2 domains mainly contribute to the formation of the peptide pocket to generate the peptide-ligand MHC (pMHC) complex. MHC-I typically binds peptides derived from cytosolic antigenic proteins that are degraded by the proteasome after ubiquitination and subsequently transported from the cytosol to the endoplasmic reticulum (ER) via specific transporters associated with antigen processing (TAP). MCH I typically binds peptides that are 8-12 amino acids in length.

[0099] The term "MHC-II" refers in the context of the present invention to MHC class II molecules or MHC-II. MHC-II molecules consist of an α chain and a β chain, where the α chain contains two α domains, α1 domain, α2 domain, and the β chain contains two β domains, β domain 1 and β domain 2. MHC II typically folds in the ER to form a complex with a protein called the invariant chain, and is subsequently transported to late endosomal compartments, where the invariant chain is cleaved by cathepsin proteases and a short fragment remains bound to the peptide-binding groove of MHC II, called class II-associated invariant chain peptide (CLIP). This placeholder peptide is then exchanged for a higher affinity peptide, usually derived from proteolytically degraded proteins available in the endocytic compartment. MHC-II typically binds to peptides of 10-30 amino acids in length or peptides of 13-25 amino acids in length.

[0100] The term "HLA" in the context of the present invention refers to human MHC molecules which differ in amino acid sequence among different humans.

[0101] The term "nucleic acid", in the context of the present invention, refers to single- or double-stranded oligo- or polymers of deoxyribonucleotide or ribonucleotide bases or both. A nucleotide monomer is composed of a nucleobase, a five-carbon sugar (e.g., but not limited to, ribose or 2'-deoxyribose), and one to three phosphate groups. Typically, nucleic acids are formed via phosphodiester bonds between individual nucleotide monomers. In the context of the present invention, the term nucleic acid includes, but is not limited to, ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) molecules, as well as synthetic forms of nucleic acids containing other bonds (e.g., peptide nucleic acids as described in Nielsen et al. (Science 254:1497-1500, 1991)). Typically, nucleic acids are single- or double-stranded molecules and are composed of naturally occurring nucleotides. The depiction of a single strand of a nucleic acid also defines (at least in part) the sequence of the complementary strand. Nucleic acids may be single- or double-stranded, or may contain portions of both double-stranded and single-stranded sequences. Exemplary double-stranded nucleic acid molecules may have 3' or 5' overhangs, and thus are not required or expected to be completely double-stranded over their entire length. Nucleic acids can be obtained by any method known in the art, including but not limited to biological, biochemical or chemical synthesis methods, or RNA amplification and reverse transcription methods. The term nucleic acid includes chromosomes or chromosomal segments, vectors (e.g., expression vectors), expression cassettes, naked DNA or RNA polymers, primers, probes, cDNA, genomic DNA, recombinant DNA, cRNA, mRNA, tRNA, microRNA (miRNA) or small interfering RNA (siRNA). Nucleic acids can be, for example, single-stranded, double-stranded, or triple-stranded, and are not particularly limited in length. Unless otherwise indicated, a particular nucleic acid sequence includes or codes for complementary sequences in addition to any sequence explicitly indicated.

[0102] The term "vector" in the context of the present invention refers to a polynucleotide encoding a protein of interest, or a mixture comprising a polypeptide and a polynucleotide encoding a protein of interest, which is introduced into a cell or the protein and / or nucleic acid contained therein can be introduced into a cell. Examples of vectors include, but are not limited to, plasmids, cosmids, phages, viruses, or artificial chromosomes. A vector is used to introduce a gene product of interest, e.g., foreign or heterologous DNA, into a host cell. A vector may contain a "replicon" polynucleotide sequence that facilitates autonomous replication of the vector in a host cell. Foreign DNA is defined as heterologous DNA, which is DNA that does not naturally occur in the host cell, e.g., to replicate the vector, to encode a selectable or screenable marker, or to encode a transgene. Once inside the host cell, a vector can replicate independently of or simultaneously with the host chromosomal DNA, generating several copies of the vector and its inserted DNA. In addition, a vector may also contain elements necessary to allow transcription of the inserted DNA into mRNA or otherwise cause replication of multiple copies of the inserted DNA into RNA. A vector can further include an "expression control sequence" that regulates the expression of a gene of interest. Typically, an expression control sequence is a polypeptide or polynucleotide, such as a promoter, enhancer, silencer, insulator, or repressor. In a vector that contains two or more polynucleotides encoding one or more gene products of interest, the expression can be controlled together or separately by one or more expression control sequences. More specifically, each polynucleotide contained in a vector can be controlled by a separate expression control sequence, or all polynucleotides contained in a vector can be controlled by a single expression control sequence. Polynucleotides contained in a single vector controlled by a single expression control sequence can form an open reading frame.Some expression vectors further contain sequence elements adjacent to the inserted DNA, which extend the half-life of the expressed mRNA and / or allow the translation of the mRNA into a protein molecule. Thus, multiple molecules of the mRNA and polypeptide encoded by the inserted DNA can be rapidly synthesized. Such vectors may contain regulatory elements, such as promoters, enhancers, terminators, to cause or direct the expression of the polypeptide upon administration to a subject. Examples of promoters and enhancers used in expression vectors for animal cells include the SV40 early promoter and enhancer (Mizukami T. et al. 1987), the Moloney murine leukemia virus LTR promoter and enhancer (Kuwana Y et al. 1987), the immunoglobulin H chain promoter (Mason JO et al. 1985) and enhancer (Gillies SD et al. 1983), and the like. Any expression vector for animal cells can be used as long as a gene encoding a human antibody C region can be inserted and expressed. Examples of suitable vectors include pAGE107 (Miyaji H et al. 1990), pAGE103 (Mizukami T et al. 1987), pHSG274 (Brady G et al. 1984), pKCR (O'Hare K et al. 1981), pSG1 βd2-4- (Miyaji H et al. 1990), etc. Other examples of plasmids include replicative plasmids containing an origin of replication, or integrative plasmids, such as pUC, pcDNA, pBR.

[0103] The term "transformation", in the context of the present invention, refers to the naturally occurring process of gene transfer into a host cell, which involves the absorption of genetic material, e.g., nucleic acid (DNA or RNA), by the cell through the cell membrane, so that the host cell expresses the introduced gene or sequence to produce a desired gene product, typically a protein or enzyme, encoded by the gene or sequence introduced into the host cell. There are two types of transformation, known as natural transformation, and artificial or induced transformation. Artificial or induced transformation is typically referred to as "transfection".

[0104] The term "transfection", in the context of the present invention, refers to a mode of gene transfer that involves the creation of pores on the cell membrane of a host cell, allowing the host cell to receive foreign genetic material. Transfection refers to the transformation of eukaryotic cells, such as insect or mammalian cells. Chemically mediated transfection involves, for example, the use of calcium phosphate or cationic polymers or liposomes. Non-chemically mediated transfection methods are typically electroporation, sonoporation, imperfection, optical transfection or hydrodynamic delivery methods. Particle-based transfection uses a gene gun approach that uses nanoparticles to introduce nucleic acid into the host cell, or another method called magnetofection. Nucleofection and the use of heat shock are other evolved methods for successful transfection. A host cell that receives foreign nucleic acid via a transfection method is "transfected".

[0105] The term "transduction", in the context of the present invention, refers to the transfer of foreign nucleic acid, such as DNA or RNA, into a cell by a virus or viral vector. A host cell that receives and expresses foreign nucleic acid (DNA or RNA) by a virus or viral vector is "transduced".

[0106] The term "pharmaceutical composition" or "therapeutic composition", in the context of the present invention, refers to a compound or composition capable of inducing a desired therapeutic effect when properly administered to a subject.

[0107] The terms "pharmacologically" or "pharmacologically acceptable" in the context of the present invention refer to molecular entities and compositions that do not produce adverse, allergic, or other undesirable reactions when properly administered to a mammal, particularly a human. A pharmaceutically acceptable carrier or excipient refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material, or formulation auxiliary of any type.

[0108] The term "pharmaceutically acceptable carrier" in the context of the present invention is also referred to as a "pharmaceutically acceptable diluent" or "pharmaceutically acceptable vehicle" and may include physiologically compatible solvents, fillers, stabilizers, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like.

[0109] The term "therapeutic agent", in the context of the present invention, refers to an agent that has a therapeutic effect.

[0110] In the following, the various aspects of the invention are defined in more detail. Each aspect so defined may be combined with any other aspect, unless expressly stated to the contrary. In particular, any feature indicated as being preferred or advantageous may be combined with any other feature or features indicated as being preferred or advantageous.

[0111] As described above, the positions of the CDRs and FRs in the VH and VL can be determined by any of the annotations defined above, such as Chothia, Kabat, AbM or contact.

[0112] A first aspect of the invention provides an antigen-binding polypeptide comprising a heavy chain variable domain (VH) and a light chain variable domain (VL), the CDRs and FRs being designated according to Chothia, (1) VH is (a) a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence of SEQ ID NO: 62; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 63; (c) HCDR3, and (d) Heavy chain framework regions (HFRs) 1 to 4 Including, (2) VL is (a) a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence of SEQ ID NO:54; (b) LCDR2 comprising the amino acid sequence of SEQ ID NO: 55; (c) LCDR3, and (d) Light chain framework regions (LFR) 1-4 Including, (i) at least one amino acid of HCDR1 comprising the amino acid sequence of SEQ ID NO: 62 and / or at least one amino acid of HCDR2 comprising the amino acid sequence of SEQ ID NO: 63, which is not positively charged, is substituted with a positively charged amino acid; and / or (ii) at least one amino acid of LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or at least one amino acid of LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, which is not positively charged, is substituted with a positively charged amino acid; and / or (iii) position 90 in HFR3 according to Chothia numbering is substituted with a tyrosine (Y) residue; The antigen-binding polypeptide specifically binds to the α / β T cell receptor (TCR) / CD3 complex.

[0113] In a further particular embodiment of this aspect, the antigen-binding polypeptide comprises: (i) at one or more of the following positions in the heavy chain: 30, 31, 53, and 54; and / or (ii) at one or more of the following positions in the light chain: 31 and 56; It contains positively charged amino acids, the positions of which are according to the Chothia numbering system.

[0114] In a further particular embodiment of this aspect, the antigen-binding polypeptide comprises: (a)(i) at position 30, R, K or H; (ii) at position 31, R, K or H; (iii) at position 53, R, K or H; and / or (iv) at position 54, R or K; positively charged amino acids in the heavy chain, and / or (b)(i) at position 31, which is R or K; and / or (ii) at position 56, which is R or K; Positively charged amino acids in the light chain These positions are according to the numbering system of Chothia.

[0115] Alternatively, the first aspect can be specified based on the Kabat annotation, as follows: An antigen-binding polypeptide comprising a heavy chain variable domain (VH) and a light chain variable domain (VL), (1) VH is (a) a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence of SEQ ID NO:52; (b) HCDR2 comprising the amino acid sequence of YINPYNDVTKYX1X2KFX3G (SEQ ID NO: 53), During the ceremony, X1 is A or N; X2 is E or Q, and / or X3 is Q or K; HCDR2; (c) HCDR3, and (d) Heavy chain framework regions (HFRs) 1 to 4 Including, (2) VL is (a) light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence of SEQ ID NO: 54 (b) LCDR2 comprising the amino acid sequence of SEQ ID NO: 55; (c) LCDR3, and (d) Light chain framework regions (LFR) 1-4 Including, (i) at least one amino acid of HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or at least one amino acid of HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, which is not positively charged, is substituted with a positively charged amino acid; and / or (ii) at least one amino acid of LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or at least one amino acid of LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, which is not positively charged, is substituted with a positively charged amino acid; and / or (iii) position 30 in HFR1 according to the Kabat numbering is substituted with a positively charged amino acid; and / or (iv) position 90 in HFR3 according to Kabat numbering is substituted with a tyrosine (Y) residue; An antigen-binding polypeptide, wherein the antigen-binding polypeptide specifically binds to an α / β T cell receptor (TCR) / CD3 complex.

[0116] In particular, when describing the following embodiments of the invention, amino acid positions within the variable light and heavy chains are indicated according to Kabat numbering, unless otherwise indicated.

[0117] In the context of the present invention, it has been observed that mutation of position 90 in HFR3 to Y results in increased binding to the α / β TCR / CD3 complex and / or increased thermal stability (e.g., Tm °C or ΔTm °C) of the antigen-binding polypeptide compared to a parent antigen-binding polypeptide not comprising any of the substitutions specified in (i) to (iv), and that these positive effects are more pronounced when combined with one, two or all of the substitutions specified in (i) to (iii) above. Increased binding is described herein as, for example, a decrease in binding EC50, referred to as a "x-fold" decrease. Alternatively, increased binding is also described herein as a "% increase in binding AUC". The difference in Tm is described herein as "ΔTm °C" as defined above.

[0118] Thus, in one embodiment of the antigen binding polypeptide, position 90 in HFR3 is substituted with Y and, furthermore, at least one amino acid in HCDR1 comprising the amino acid sequence of SEQ ID NO: 52, which is not positively charged, and / or at least one amino acid in HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, which is not positively charged, is substituted with a positively charged amino acid.

[0119] In one embodiment of the antigen-binding polypeptide of the first aspect of the invention, position 30 in HFR1 is substituted with a positively charged amino acid. In one embodiment, position 90 in HFR3 is substituted with Y.

[0120] In one embodiment, position 30 in HFR1 is substituted with a positively charged amino acid and position 90 in HFR3 is substituted with Y.

[0121] In one embodiment of the antigen binding polypeptide, position 90 in HFR3 is substituted with Y, position 30 in HFR1 is substituted with a positively charged amino acid, and further at least one amino acid in HCDR1 which is not positively charged and comprises the amino acid sequence of SEQ ID NO: 52, and / or at least one amino acid in HCDR2 which is not positively charged and comprises the amino acid sequence of SEQ ID NO: 53, is substituted with a positively charged amino acid.

[0122] In one embodiment of the antigen-binding polypeptide, position 30 in HFR1 is substituted with a positively charged amino acid, and furthermore at least one amino acid in HCDR1, which is not positively charged and comprises the amino acid sequence of SEQ ID NO: 52, and / or at least one amino acid in HCDR2, which is not positively charged and comprises the amino acid sequence of SEQ ID NO: 53, is substituted with a positively charged amino acid.

[0123] In one embodiment, the antigen-binding polypeptide comprises an LCDR1 according to SEQ ID NO: 54, in which at least one non-positively charged amino acid has been replaced with a positively charged amino acid, and / or an LCDR2 according to SEQ ID NO: 55, in which at least one non-positively charged amino acid has been replaced with a positively charged amino acid.

[0124] In one embodiment of the antigen-binding polypeptide, position 30 in HFR1 is substituted with a positively charged amino acid, and furthermore at least one amino acid in LCDR1, which is not positively charged and comprises the amino acid sequence of SEQ ID NO: 54, and / or at least one amino acid in LCDR2, which is not positively charged and comprises the amino acid sequence of SEQ ID NO: 55, is substituted with a positively charged amino acid.

[0125] In one embodiment of the antigen-binding polypeptide, position 90 in HFR3 is substituted with Y, and further, at least one amino acid of LCDR1, which is not positively charged and comprises the amino acid sequence of SEQ ID NO: 54, and / or at least one amino acid of LCDR2, which is not positively charged and comprises the amino acid sequence of SEQ ID NO: 55, is substituted with a positively charged amino acid.

[0126] In one embodiment of the antigen-binding polypeptide, position 30 in HFR1 is substituted with a positively charged amino acid, position 90 in HFR3 is substituted with Y, and further, at least one amino acid in LCDR1 that is not positively charged and comprises the amino acid sequence of SEQ ID NO: 54, and / or at least one amino acid in LCDR2 that is not positively charged and comprises the amino acid sequence of SEQ ID NO: 55, is substituted with a positively charged amino acid.

[0127] In one embodiment of the antigen-binding polypeptide, (iv) position 90 in HFR3 is substituted with Y, (i) at least one amino acid of HCDR1 that is not positively charged and comprises the amino acid sequence of SEQ ID NO: 52, and / or at least one amino acid of HCDR2 that is not positively charged and comprises the amino acid sequence of SEQ ID NO: 53, is substituted with a positively charged amino acid, and (ii) at least one amino acid of LCDR1 that is not positively charged and comprises the amino acid sequence of SEQ ID NO: 54, and / or at least one amino acid of LCDR2 that is not positively charged and comprises the amino acid sequence of SEQ ID NO: 55, is substituted with a positively charged amino acid.

[0128] In one embodiment of the antigen-binding polypeptide, (iv) position 90 in HFR3 is substituted with Y, (iii) position 30 in HFR1 is substituted with a positively charged amino acid, (i) at least one amino acid in HCDR1 that is not positively charged and comprises the amino acid sequence of SEQ ID NO: 52, and / or at least one amino acid in HCDR2 that is not positively charged and comprises the amino acid sequence of SEQ ID NO: 53, is substituted with a positively charged amino acid, and (ii) at least one amino acid in LCDR1 that is not positively charged and comprises the amino acid sequence of SEQ ID NO: 54, and / or at least one amino acid in LCDR2 that is not positively charged and comprises the amino acid sequence of SEQ ID NO: 55, is substituted with a positively charged amino acid.

[0129] In one embodiment, at least one amino acid of the antigen-binding polypeptide is substituted with a positively charged amino acid at position HCDR1 and / or HCDR2 and / or LCDR1 and / or LCDR as defined herein above and below, and no more than four positions in the CDRs are substituted with a positively charged amino acid, preferably no more than three positions in the CDRs are substituted with a positively charged amino acid.

[0130] In one embodiment, at least one amino acid of the antigen-binding polypeptide which is substituted with a positively charged amino acid in HCDR1 and / or HCDR2 and / or LCDR1 and / or LCDR2 is no more than 2, no more than 3, no more than 4 amino acids. In the following embodiments, if a positively charged amino acid is present at a particular position in HCDR1 of SEQ ID NO: 52, HCDR2 of SEQ ID NO: 53, LCDR1 of SEQ ID NO: 54, LCDR2 of SEQ ID NO: 55, HCDR3 of SEQ ID NO: 56 or LCDR3 of SEQ ID NO: 57, it is preferred that said amino acid is not substituted with a different positively charged amino acid in the context of the present invention.

[0131] In one embodiment of the first aspect of the invention, the antigen-binding polypeptide comprises an HCDR1 according to SEQ ID NO: 52, in which at least one non-positively charged amino acid has been replaced with a positively charged amino acid. In particular, in one embodiment, in SEQ ID NO: 52, which comprises the amino acid sequence SYVMH, S is replaced with either H, K or R. In one embodiment, in SEQ ID NO: 52, which comprises the amino acid sequence SYVMH, Y is replaced with either H, K or R. In one embodiment, in SEQ ID NO: 52, which comprises the amino acid sequence SYVMH, V is replaced with either H, K or R. In one embodiment, in SEQ ID NO: 52, which comprises the amino acid sequence SYVMH, M is replaced with either H, K or R.

[0132] In one embodiment of the first aspect of the invention, the antigen-binding polypeptide comprises an HCDR2 according to SEQ ID NO: 53, in which at least one non-positively charged amino acid has been replaced with a positively charged amino acid. In particular, in one embodiment, HCDR2 comprises SEQ ID NO: 53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is E and X3 is Q, which means that the N-terminal Y is replaced with either H, K or R. In particular, in one embodiment, HCDR2 comprises SEQ ID NO: 53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is E and X3 is Q, which means that the penultimate Y from the N-terminus is replaced with either H, K or R. In particular, in one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is E and X3 is Q, which means that the third Y from the N-terminus is substituted with either H, K or R.

[0133] In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is E, and X3 is Q, which means that I is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is E, and X3 is Q, which means that the N-terminal N is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is E, and X3 is Q, which means that the penultimate N from the N-terminus is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is E, and X3 is Q, which means that both Ns are replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is E, and X3 is Q, which means that P is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is E, and X3 is Q, which means that V is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is E, and X3 is Q, which means that F is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is E, and X3 is Q, which means that G is replaced with either H, K, or R.

[0134] In one embodiment of the first aspect of the invention, the antigen-binding polypeptide comprises an HCDR2 according to SEQ ID NO: 53, in which at least one non-positively charged amino acid has been replaced with a positively charged amino acid. In particular, in one embodiment, HCDR2 comprises SEQ ID NO: 53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is E and X3 is K, which means that the N-terminal Y is replaced with either H, K or R. In one embodiment, HCDR2 comprises SEQ ID NO: 53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is E and X3 is K, which means that the penultimate N-terminal Y is replaced with either H, K or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is E, and X3 is K, which means that the third Y from the N-terminus is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is E, and X3 is K, which means that all three Y's are replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is E, and X3 is K, which means that I is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is E, and X3 is K, which means that the N-terminal N is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is E, and X3 is K, which means that the penultimate N from the N-terminus is replaced with either H, K, or R.In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is E, and X3 is K, which means that both Ns are replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is E, and X3 is K, which means that P is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is E, and X3 is K, which means that V is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is E, and X3 is K, which means that T is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is E, and X3 is K, which means that F is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is E, and X3 is K, which means that G is replaced with either H, K, or R.

[0135] In one embodiment of the first aspect of the invention, the antigen-binding polypeptide comprises an HCDR2 according to SEQ ID NO: 53, in which at least one non-positively charged amino acid has been replaced with a positively charged amino acid. In particular, in one embodiment, HCDR2 comprises SEQ ID NO: 53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is Q and X3 is Q, which means that the N-terminal Y is replaced with either H, K or R. In particular, in one embodiment, HCDR2 comprises SEQ ID NO: 53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is Q and X3 is Q, which means that the penultimate Y from the N-terminus is replaced with either H, K or R. In particular, in one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is Q, and X3 is Q, which means that the third Y from the N-terminus is replaced with either H, K, or R. In particular, in one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is Q, and X3 is Q, which means that all three Y's are replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is Q, and X3 is Q, which means that I is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is Q, and X3 is Q, which means that the N-terminal N is substituted with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is Q, and X3 is Q, which means that the second N from the N-terminus is substituted with either H, K, or R.In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is Q, and X3 is Q, which means that both Ns are replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is Q, and X3 is Q, which means that P is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is Q, and X3 is Q, which means that V is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is Q, and X3 is Q, which means that T is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is Q, and X3 is Q, which means that F is replaced with either H, K, or R. HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is Q, and X3 is Q, which means that G is replaced with either H, K, or R.

[0136] In one embodiment of the first aspect of the invention, the antigen-binding polypeptide comprises an HCDR2 according to SEQ ID NO: 53, in which at least one non-positively charged amino acid has been replaced with a positively charged amino acid. In particular, in one embodiment, HCDR2 comprises SEQ ID NO: 53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is Q and X3 is K, which means that the N-terminal Y is replaced with either H, K or R. In particular, in one embodiment, HCDR2 comprises SEQ ID NO: 53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is Q and X3 is K, which means that the penultimate N-terminal Y is replaced with either H, K or R. In particular, in one embodiment, HCDR2 comprises SEQ ID NO: 53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is Q, and X3 is K, which means that the third Y from the N-terminus is replaced with either H, K, or R. In particular, in one embodiment, HCDR2 comprises SEQ ID NO: 53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is Q, and X3 is K, which means that all three Ys are replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO: 53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is Q, and X3 is K, which means that I is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is Q, and X3 is K, which means that the N-terminal N is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is Q, and X3 is K, which means that the penultimate N from the N-terminus is replaced with either H, K, or R.In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is Q, and X3 is K, which means that both Ns are substituted with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is Q, and X3 is K, which means that P is substituted with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is Q, and X3 is K, which means that V is substituted with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is Q, and X3 is K, which means that T is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is Q, and X3 is K, which means that F is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is A, X2 is Q, and X3 is K, which means that G is replaced with either H, K, or R.

[0137] In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is E, and X3 is Q, which means that the N-terminal Y is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is E, and X3 is Q, which means that the second Y from the N-terminus is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is E, and X3 is Q, which means that the third Y from the N-terminus is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is E, and X3 is Q, which means that all three Y's are replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is E, and X3 is Q, which means that I is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is E, and X3 is Q, which means that the N at the N-terminus is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is E, and X3 is Q, which means that the penultimate N is substituted with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYR. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is E, and X3 is Q, which means that both Ns are substituted with either H, K, or R.In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is E, and X3 is Q, which means that P is substituted with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is E, and X3 is Q, which means that V is substituted with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is E, and X3 is Q, which means that T is substituted with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is E, and X3 is Q, which means that F is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is E, and X3 is Q, which means that G is replaced with either H, K, or R.

[0138] In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is Q, and X3 is Q, which means that the N-terminal Y is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is Q, and X3 is Q, which means that the second Y from the N-terminus is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is Q, and X3 is Q, which means that the third Y from the N-terminus is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is Q, and X3 is Q, which means that all three Y's are replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is Q, and X3 is Q, which means that I is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is Q, and X3 is Q, which means that the N at the N-terminus is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is Q, and X3 is Q, which means that the second N from the N-terminus is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2HCDR2, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is Q, and X3 is Q, which means that both Ns are replaced with either H, K, or R.In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is Q, and X3 is Q, which means that P is substituted with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is Q, and X3 is Q, which means that V is substituted with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is Q, and X3 is Q, which means that T is substituted with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is Q, and X3 is Q, which means that F is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is Q, and X3 is Q, which means that G is replaced with either H, K, or R.

[0139] In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is Q, and X3 is K, which means that the N-terminal Y is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is Q, and X3 is K, which means that the second Y from the N-terminus is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is Q, and X3 is K, which means that the third Y from the N-terminus is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is Q, and X3 is K, which means that all three Y's are replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is Q, and X3 is K, which means that I is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is Q, and X3 is K, which means that the N at the N-terminus is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is Q, and X3 is K, which means that the penultimate N is substituted with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is Q, and X3 is K, which means that both Ns are substituted with either H, K, or R.In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is Q, and X3 is K, which means that P is substituted with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is Q, and X3 is K, which means that V is substituted with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is Q, and X3 is K, which means that T is substituted with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is Q, and X3 is Q, which means that F is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is Q, and X3 is Q, which means that G is replaced with either H, K, or R.

[0140] In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is E, and X3 is K, which means that the N-terminal Y is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is E, and X3 is K, which means that the second Y from the N-terminus is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is E, and X3 is K, which means that the third Y from the N-terminus is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is E, and X3 is K, which means that all three Y's are replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is E, and X3 is K, which means that I is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is E, and X3 is K, which means that the N at the N-terminus is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is E, and X3 is K, which means that the penultimate N is substituted with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is E, and X3 is K, which means that both Ns are substituted with either H, K, or R.In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is E, and X3 is K, which means that P is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is E, and X3 is K, which means that V is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is E, and X3 is K, which means that T is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is E, and X3 is Q, which means that F is replaced with either H, K, or R. In one embodiment, HCDR2 comprises SEQ ID NO:53, which comprises the amino acid sequence YINPYNDVTKYX1X2KFX3G, where X1 is N, X2 is E, and X3 is K, which means that G is replaced with either H, K, or R.

[0141] In one embodiment, the antigen binding polypeptide comprises an HCDR1 according to SEQ ID NO:52, in which at least one non-positively charged amino acid has been replaced with a positively charged amino acid, and an HCDR2 as described above, and further comprises heavy chain framework regions (HFRs) 1-4, in which position 30 in the HFR has been replaced with a positively charged amino acid.

[0142] In one embodiment, the antigen-binding polypeptide comprises an HCDR1 according to SEQ ID NO:52, in which at least one non-positively charged amino acid has been replaced with a positively charged amino acid, and an HCDR2 as described above, and further comprises an HCDR3 and HFRs 1-4.

[0143] In one embodiment, the antigen binding polypeptide comprises an HCDR1 according to SEQ ID NO:52, in which at least one non-positively charged amino acid has been substituted with a positively charged amino acid, and an HCDR2 as described above, and further comprises an HCDR3 and HFR1-4, in which preferably position 90 is substituted with a Y.

[0144] In one embodiment, the antigen-binding polypeptide comprises an HCDR1 according to SEQ ID NO:52, in which at least one non-positively charged amino acid has been substituted with a positively charged amino acid, and an HCDR2 as described above, and further comprises an HCDR3 and HFR1-4, in which position 30 of HFR1 has been substituted with a Y.

[0145] In one embodiment, the antigen-binding polypeptide comprises an HCDR1 according to SEQ ID NO: 52, in which at least one non-positively charged amino acid has been replaced with a positively charged amino acid, and an HCDR2 as described above, further comprising an HCDR3 and HFR1-4, in which position 30 in HFR1 has been replaced with Y, and position 90 in HFR3 has been replaced with Y. Said HFR1-4 sequences may also comprise one or more further modifications, e.g. substitutions, deletions or insertions, compared to a FR sequence not comprising any of said modifications. However, it is preferred that the FR1-4 sequences are not modified at certain positions, e.g. those at the Vernier zone, the VH / VL interchain interface, or positions that determine the CDR canonical class. Preferably, HFR3 comprises a Y residue at position 90. Hereinafter, further positions in the FRs, which should preferably not be modified in the context of the present invention, are provided. It is also preferred that certain positions are included in the FRs and not in the CDRs, regardless of the annotation used.

[0146] In one embodiment, the antigen-binding polypeptide comprises a variable light chain (VL) comprising a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence of SEQ ID NO: 54 (SATSSVSYMH), in which at least one amino acid of SEQ ID NO: 54 that is not positively charged has been replaced with a positively charged amino acid. In particular, in one embodiment, for SEQ ID NO: 54 comprising the amino acid sequence SATSSVSYMH, the N-terminal S is replaced with either H, K or R. In particular, in one embodiment, for SEQ ID NO: 54 comprising the amino acid sequence SATSSVSYMH, the second S from the N-terminus is replaced with either H, K or R. In particular, in one embodiment, for SEQ ID NO: 54 comprising the amino acid sequence SATSSVSYMH, the third S from the N-terminus is replaced with either H, K or R. In particular, in one embodiment, for SEQ ID NO: 54 comprising the amino acid sequence SATSSVSYMH, the fourth S from the N-terminus is replaced with either H, K or R. In particular, in one embodiment, for SEQ ID NO: 54 comprising the amino acid sequence SATSSVSYMH, all four S's are replaced with either H, K or R. In particular, in one embodiment, for SEQ ID NO: 54 comprising the amino acid sequence SATSSVSYMH, A is replaced with either H, K or R. In one embodiment, for SEQ ID NO: 54 comprising the amino acid sequence SATSSVSYMH, T is replaced with either H, K or R. In one embodiment, for SEQ ID NO: 54 comprising the amino acid sequence SATSSVSYMH, V can be replaced with either H, K or R. In one embodiment, for SEQ ID NO: 54 comprising the amino acid sequence SATSSVSYMH, Y is replaced with either H, K or R. In one embodiment, for SEQ ID NO: 54 comprising the amino acid sequence SATSSVSYMH, M is replaced with either H, K or R.

[0147] In one embodiment, the antigen-binding polypeptide comprises a variable light chain (VL) comprising a light chain complementarity determining region 2 (LCDR2) comprising the amino acid sequence of SEQ ID NO: 55 (DTSKLAS), in which at least one amino acid of SEQ ID NO: 55 that is not positively charged is replaced with a positively charged amino acid. In particular, in one embodiment, for SEQ ID NO: 55 comprising the amino acid sequence DTSKLAS, T is replaced with either H, K or R. In one embodiment, for SEQ ID NO: 55 comprising the amino acid sequence DTSKLAS, S is replaced with either H, K or R. In one embodiment, for SEQ ID NO: 55 comprising the amino acid sequence DTSKLAS, L is replaced with either H, K or R. In one embodiment, for SEQ ID NO: 55 comprising the amino acid sequence DTSKLAS, A is replaced with either H, K or R.

[0148] In one embodiment, the antigen-binding polypeptide comprises an LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 (SATSSVSYMH), in which at least one amino acid of SEQ ID NO: 54 that is not positively charged has been replaced with a positively charged amino acid, and an LCDR2 comprising the amino acid sequence of SEQ ID NO: 55 (DTSKLAS), in which at least one amino acid of SEQ ID NO: 55 that is not positively charged has been replaced with a positively charged amino acid.

[0149] In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the N-terminal S is replaced with R, K or H, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L is replaced with R. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the second S from the N-terminus is replaced with R, K or H, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L is replaced with R. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the third S from the N-terminus is replaced with R, K or H, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L is replaced with R. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the fourth S from the N-terminus is replaced with R, K or H, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L is replaced with R. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, all four S's are replaced with R, K or H, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L is replaced with R. In particular, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the N-terminal S is replaced with K, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L is replaced with R. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the second S from the N-terminus is replaced with K, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L is replaced with R, K or H. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the third S from the N-terminus is replaced with K, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L is replaced with R, K or H. In particular, in one embodiment, in the case of SEQ ID NO: 54, which contains the amino acid sequence SATSSVSYMH, the fourth S from the N-terminus is replaced with K, and in the case of SEQ ID NO: 55, which contains the amino acid sequence DTSKLAS, L can be replaced with R, K or H.In particular, in one embodiment, in the case of SEQ ID NO: 54, which contains the amino acid sequence SATSSVSYMH, all four S's are replaced with K, and in the case of SEQ ID NO: 55, which contains the amino acid sequence DTSKLAS, L can be replaced with R, K or H.

[0150] In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the N-terminal S is replaced with H, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L can be replaced with R. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the second S from the N-terminus is replaced with H, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L can be replaced with R. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the third S from the N-terminus is replaced with H, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L can be replaced with R. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the fourth S from the N-terminus is replaced with H, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L can be replaced with R. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, all four S's are replaced with H, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L can be replaced with R.

[0151] In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the N-terminal S is replaced with R, K or H, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L is replaced with K. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the second S from the N-terminus is replaced with R, K or H, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L is replaced with K. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the third S from the N-terminus is replaced with R, K or H, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L is replaced with K. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the fourth S from the N-terminus is replaced with R, K or H, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L is replaced with K. In particular, in one embodiment, in the case of SEQ ID NO: 54, which comprises the amino acid sequence SATSSVSYMH, all four S's are replaced with R, K or H, and in the case of SEQ ID NO: 55, which comprises the amino acid sequence DTSKLAS, L is replaced with K.

[0152] In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the S at the N-terminus is replaced with K, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L is replaced with K. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the second S from the N-terminus is replaced with K, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L is replaced with K. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the third S from the N-terminus is replaced with K, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L is replaced with K. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the fourth S from the N-terminus is replaced with K, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L is replaced with K. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, all four S's are replaced with K, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L is replaced with K.

[0153] In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the N-terminal S is replaced with H, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L can be replaced with K. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the second S from the N-terminus is replaced with H, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L can be replaced with K. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the third S from the N-terminus is replaced with H, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L can be replaced with K. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the fourth S from the N-terminus is replaced with H, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L can be replaced with K. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, all four S's are replaced with H, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L can be replaced with K.

[0154] In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the N-terminal S is replaced with R, K or H, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L is replaced with H. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the second S from the N-terminus is replaced with R, K or H, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L is replaced with H. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the third S from the N-terminus is replaced with R, K or H, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L is replaced with H. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the fourth S from the N-terminus is replaced with R, K or H, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L is replaced with H. In particular, in one embodiment, in the case of SEQ ID NO:54, which comprises the amino acid sequence SATSSVSYMH, all four S's are replaced with R, K or H, and in the case of SEQ ID NO:55, which comprises the amino acid sequence DTSKLAS, L is replaced with H.

[0155] In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the N-terminal S is replaced with K, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L can be replaced with H. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the second S from the N-terminus is replaced with K, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L can be replaced with H. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the third S from the N-terminus is replaced with K, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L can be replaced with H. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the fourth S from the N-terminus is replaced with K, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L can be replaced with H. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, all four S's are replaced with K, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L can be replaced with H.

[0156] In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the S at the N-terminus is replaced with H, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L is replaced with H. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the second S from the N-terminus is replaced with H, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L is replaced with H. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the third S from the N-terminus is replaced with H, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L is replaced with H. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, the fourth S from the N-terminus is replaced with H, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L is replaced with H. In particular, in one embodiment, in the case of SEQ ID NO: 54 containing the amino acid sequence SATSSVSYMH, all four S's are replaced with H, and in the case of SEQ ID NO: 55 containing the amino acid sequence DTSKLAS, L is replaced with H.

[0157] In one embodiment, the antigen-binding polypeptide comprises an LCDR1 comprising the amino acid sequence of SEQ ID NO:54 (SATSSVSYMH), in which at least one amino acid of SEQ ID NO:54 that is not positively charged has been replaced with a positively charged amino acid, and / or an LCDR2 comprising the amino acid sequence of SEQ ID NO:55 (DTSKLAS), in which at least one amino acid of SEQ ID NO:55 that is not positively charged has been replaced with a positively charged amino acid as described above, and further comprising a positively charged amino acid at position 30 of HFR1. Preferably, the antigen-binding polypeptide further comprises an HFR3. It is particularly preferred that HFR3 comprises a Y at position 90.

[0158] In another embodiment, the antigen-binding polypeptide comprises a VH and a VL comprising an HCDR1, and / or an HCDR2 as defined above, and / or an LCDR2 as defined above, wherein at least one amino acid of HCDR1 comprising the amino acid sequence of SEQ ID NO: 52, which is not positively charged, and / or at least one amino acid of HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, which is not positively charged, is substituted with a positively charged amino acid, and at least one amino acid of LCDR1 comprising the amino acid sequence of SEQ ID NO: 54, which is not positively charged, and / or at least one amino acid of LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, which is not positively charged, is substituted with a positively charged amino acid. Preferably, the antigen-binding polypeptide further comprises an HFR3. It is particularly preferred that HFR3 comprises a Y at position 90. It is also preferred that the antigen-binding polypeptide further comprises an HFR1, in which position 30 in HFR1 is substituted with a positively charged amino acid.

[0159] In one embodiment, the antigen-binding polypeptide comprises an LCDR1 according to SEQ ID NO: 54, in which at least one non-positively charged amino acid has been replaced with a positively charged amino acid, and an LCDR2 as described above, further comprising a light chain CDR 3 (LCDR3) and light chain framework regions (LFR) 1-4. In one embodiment, the antigen-binding polypeptide comprises an LCDR1 according to SEQ ID NO: 54, in which at least one non-positively charged amino acid has been replaced with a positively charged amino acid, and an LCDR2 as described above, further comprising a heavy chain CDR 3 (LCDR3) and heavy chain framework regions (LFR) 1-4. The LFR1-4 sequence may also comprise one or more further modifications, e.g., substitutions, deletions or insertions, compared to a FR sequence that does not comprise any of the modifications. However, in some embodiments, in the case of the further modifications, the modified FR sequence still comprises a substitution of the invention, e.g., a tyrosine at position 90 of FR3 in VH, and / or a positively charged amino acid at position 30 in VH. Furthermore, it is preferred that the FR1-4 sequences are not modified at certain positions, such as those at the Vernier zone, the VH / VL interchain interface, or those that determine the CDR canonical class. Hereinafter, further positions in the FRs that should preferably not be modified in the context of the present invention are provided. It is also preferred that certain positions are included in the FRs and not in the CDRs, regardless of the annotation used.

[0160] Preferably, the antigen-binding polypeptide specifically binds to the α / β TCR / CD3 complex, which is preferably present on T cells, more preferably on T lymphocytes. The antigen-binding polypeptide of the present invention competes with a reference antibody for binding to T cells expressing the α / β TCR / CD3 complex. In certain embodiments, the antigen-binding polypeptide binds to the same epitope as a reference antibody comprising a VH amino acid sequence according to SEQ ID NO: 1 and a VL amino acid sequence according to SEQ ID NO: 2. In certain embodiments, the antigen-binding polypeptide competes with a reference antibody comprising a VH according to SEQ ID NO: 1 and a VL according to SEQ ID NO: 2 for binding to T cells expressing the α / β TCR / CD3 complex. In a preferred embodiment, the reference antibody comprises a constant domain, preferably a human IgG1 constant domain, and a human kappa light chain region. In certain embodiments, the antigen-binding polypeptide competes with a reference antibody comprising a heavy chain (HC) amino acid sequence according to SEQ ID NO: 60 and a light chain (LC) amino acid sequence according to SEQ ID NO: 6 for binding to T cells expressing the α / β TCR / CD3 complex. Preferably, the antigen-binding polypeptide competes with a reference antibody, which is an antibody comprising a heavy chain (HC) amino acid sequence according to SEQ ID NO: 60 and a light chain (LC) amino acid sequence according to SEQ ID NO: 6, for binding to T cells expressing the α / β TCR / CD3 complex.

[0161] In one embodiment of the first aspect of the invention, the positively charged amino acids comprised in the HCDR and / or the LCDR of the antigen-binding polypeptide are at positions 31, 53 and / or 54 of the heavy chain and / or at positions 31 and / or 56 of the light chain.

[0162] In one embodiment, the positively charged amino acids in the HCDR of the antigen binding polypeptide are at position 31 in the heavy chain. In one embodiment, the positively charged amino acids in the HCDR of the antigen binding polypeptide are at positions 31 and 53 in the heavy chain. In one embodiment, the positively charged amino acids in the HCDR of the antigen binding polypeptide are at positions 31 and 54 in the heavy chain. In one embodiment, the positively charged amino acids in the HCDR of the antigen binding polypeptide are at positions 31, 53 and 54 in the heavy chain. Additionally, the antigen binding polypeptide of any of these embodiments may further comprise a Y at position 90 in HFR3.

[0163] In one embodiment, the positively charged amino acid in the LCDR of the antigen binding polypeptide is at position 31 in the light chain. In one embodiment, the positively charged amino acid in the LCDR of the antigen binding polypeptide is at position 56 in the light chain. In one embodiment, the positively charged amino acids in the LCDR of the antigen binding polypeptide are at positions 31 and 56 in the light chain. Additionally, the antigen binding polypeptide of any of these embodiments may further comprise a Y at position 90 in HFR3.

[0164] In one embodiment, the antigen-binding polypeptide comprises a positively charged amino acid at position 31 of the heavy chain and at position 31 and / or position 56 of the light chain. In one embodiment, the antigen-binding polypeptide comprises a positively charged amino acid at position 53 of the heavy chain and at position 31 and / or position 56 of the light chain. In one embodiment, the antigen-binding polypeptide comprises a positively charged amino acid at position 54 of the heavy chain and at position 31 and / or position 56 of the light chain. In one embodiment, the antigen-binding polypeptide comprises a positively charged amino acid at position 31 and position 53 of the heavy chain and at position 31 and / or position 56 of the light chain. In one embodiment, the antigen-binding polypeptide comprises a positively charged amino acid at position 31 and position 54 of the heavy chain and at position 31 and / or position 56 of the light chain. In one embodiment, the antigen-binding polypeptide comprises a positively charged amino acid at position 53 and position 54 of the heavy chain and at position 31 and / or position 56 of the light chain. In one embodiment, the antigen-binding polypeptide comprises positively charged amino acids at positions 53 and 54 of the heavy chain and at positions 31 and / or 56 of the light chain. The antigen-binding polypeptide of any of these embodiments may further comprise a Y at position 90 of FR3 in the VH and / or a positively charged amino acid at position 30 in the VH.

[0165] In one embodiment, the positively charged amino acid in the heavy chain of the antigen binding polypeptide at position 30 is R, K or H. Preferably, the positively charged amino acid in the heavy chain of the antigen binding polypeptide at position 30 is R or K. Even more preferably, the positively charged amino acid in the heavy chain of the antigen binding polypeptide at position 30 is R. In one embodiment, the positively charged amino acid in the heavy chain of the antigen binding polypeptide at position 30 in HFR1 is R or K and at position 90 in HFR3 is Y.

[0166] In one embodiment of the first aspect of the invention, the positively charged amino acid in the heavy chain of the antigen binding polypeptide at position 31 is R, K or H, more preferably the positively charged amino acid in the heavy chain of the antigen binding polypeptide at position 31 is R or K. Even more preferably, the positively charged amino acid in the heavy chain of the antigen binding polypeptide at position 31 is R. Even more preferably, the positively charged amino acid in the heavy chain of the antigen binding polypeptide at position 31 is R or K and the one at position 90 is Y, or the positively charged amino acid in the heavy chain of the antigen binding polypeptide at position 31 is R and the one at position 90 in the HFR is Y.

[0167] In one embodiment, the positively charged amino acid in the heavy chain of the antigen-binding polypeptide at position 53 is R, K or H. Preferably, the positively charged amino acid in the heavy chain of the antigen-binding polypeptide at position 53 is K, R or H and that at position 90 is Y. Preferably, the positively charged amino acid in the heavy chain of the antigen-binding polypeptide at position 53 is R or K. More preferably, the positively charged amino acid in the heavy chain of the antigen-binding polypeptide at position 53 is R. It is particularly preferred that the positively charged amino acid in the heavy chain of the antigen-binding polypeptide at position 53 is R and that at position 90 in HFR3 is Y. It is even more preferred that the positively charged amino acid in the heavy chain of the antigen-binding polypeptide at position 53 is R or K and that a serine is at position 30 of the heavy chain of the antigen-binding polypeptide. It is particularly preferred that the positively charged amino acid in the heavy chain of the antigen-binding polypeptide at position 53 is R and that a serine is at position 30 of the heavy chain of the antigen-binding polypeptide.

[0168] In one embodiment, the positively charged amino acid in the heavy chain of the antigen binding polypeptide at position 54 is R or K. Preferably, the positively charged amino acid in the heavy chain of the antigen binding polypeptide at position 54 is K. It is particularly preferred that the positively charged amino acid in the heavy chain of the antigen binding polypeptide at position 54 is K and that at position 90 is Y, or that the positively charged amino acid in the heavy chain of the antigen binding polypeptide at position 54 is R and that at position 90 in HFR3 is Y.

[0169] In one embodiment, the positively charged amino acid in the light chain of the antigen binding polypeptide at position 31 is R or K. Preferably, the positively charged amino acid in the heavy chain of the antigen binding polypeptide at position 31 is R. It is particularly preferred that the positively charged amino acid in the light chain of the antigen binding polypeptide at position 31 is R and that at position 90 in HFR3 is Y, or that the positively charged amino acid in the light chain of the antigen binding polypeptide at position 31 is K and that at position 90 in HFR3 is Y.

[0170] In one embodiment, the positively charged amino acid in the light chain of the antigen binding polypeptide at position 56 is R or K. Preferably, the positively charged amino acid in the light chain of the antigen binding polypeptide at position 56 is R. It is particularly preferred that the positively charged amino acid in the light chain of the antigen binding polypeptide at position 56 is R and that at position 90 is Y, or that the positively charged amino acid in the light chain of the antigen binding polypeptide at position 56 is K and that at position 90 in HFR3 is Y.

[0171] The following combinations of positively charged amino acids are preferred in the heavy chain: R31 and R53; R31 and K53; R31 and H53; R31 and R54; R31 and K54; K31 and R53; K31 and K53; K31 and H53; K31 and R54; K31 and K54; H31 and R53; H31 and K51; H31 and H51; H31 and R54; H31 and K54; R31, R53 and R54; R31, R53 and K54; R31, K53 and R54; R31, K53 and K54; R31, H53 and R5 4;R31, H53 and K54;K31, R53 and R54;K31, R53 and K54;K31, K53 and R54;K31, K53 and K54;K31, H53 and R54;K31, H53 and K54;H31, R53 and R54;H31, R53 and K54;H31, K53 and R54;H31, K53 and K54;H31, H53 and R54;H31, H53 and K54;R53 and R54;R53 and K54;K53 and R54;K53 and K54;H53 and R54;and H53 and K54. The antigen binding polypeptide of any of these embodiments may further comprise a Y at position 90 in FR3 in VH, and / or a positively charged amino acid at position 30 in VH. It is even more preferred that the positively charged amino acid in the heavy chain of the antigen binding polypeptide at position 53 is R and the antigen binding polypeptide comprises a Y at position 90 in FR3 in VH.

[0172] The following combinations of positively charged amino acids are preferred in the light chain: R31 and R56; R31 and K56; K31 and R56; and K31 and K56.

[0173] The following combination of positively charged amino acids is particularly preferred in the light chain, together with a substitution at position 90 in HFR3: R31 and R56; and position 90 is Y; R31 and K56; and position 90 is Y; K31 and R56; and position 90 is Y; K31 and K56, and position 90 are Y.

[0174] The following combinations of positively charged amino acids are particularly preferred in the heavy and light chains: heavy chain 31R and light chain 56R; heavy chain 54K and light chain 56R; heavy chain 54K and light chain 31R; heavy chain 53R and light chain 56R; heavy chain 53R and light chain 31R and 56R; and heavy chain 31R, light chain 31R and light chain 56R.

[0175] The following combinations of positively charged amino acids are particularly preferred in the heavy and light chains; with or without a substitution at position 90 in the heavy chain: heavy chain 31R and light chain 56R, and heavy chain position 90 is Y; heavy chain 54K and light chain 56R, and heavy chain position 90Y; heavy chain 54K and light chain 31R and 56R, and heavy chain position 90Y; heavy chain 53R and light chain 56R; heavy chain 53R and light chain 56R, and heavy chain position 90Y.

[0176] In the context of the present invention, it has been observed that substitutions with positively charged amino acids in an antigen-binding polypeptide (e.g., at the respective positions in HCDR1 and / or HCDR2 and / or LCDR1 and / or LCDR2 as defined above and / or at position 30 in HFR1) result in increased binding to the α / β TCR / CD3 complex. Thus, a reduced binding EC50 is provided compared to a parent antigen-binding polypeptide that does not contain any of the substitutions of the present invention. The reduced binding EC50 is described as a "x-fold" decrease in binding EC50 or a "% increase in binding AUC".

[0177] In the context of the present invention, an antigen-binding polypeptide specifically binds to the α / β T cell receptor (TCR) / CD3 complex and has increased binding compared to a parent antigen-binding polypeptide, the antigen-binding polypeptide has a 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 20-fold, 22-fold, 24-fold, 26-fold, 28-fold, 30-fold or less decrease in binding EC50 compared to the parent antigen-binding polypeptide.

[0178] In one embodiment, the antigen-binding polypeptide has a 2-fold decrease in binding EC50 compared to the parent antigen-binding polypeptide.

[0179] In one embodiment, the antigen-binding polypeptide comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or an HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, in which at least one amino acid of the HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or at least one amino acid of the HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, which is not positively charged, has been substituted with a positively charged amino acid, and the antigen-binding polypeptide exhibits at least a 2-fold decrease in binding EC50 compared to a parent antigen-binding polypeptide.

[0180] In one embodiment, the antigen-binding polypeptide comprises an LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or an LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, in which at least one amino acid of the LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or at least one amino acid of the LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, which is not positively charged, has been substituted with a positively charged amino acid, and the antigen-binding polypeptide exhibits a 2-fold or greater decrease in binding EC50 compared to the parent antigen-binding polypeptide.

[0181] In one embodiment, the antigen-binding polypeptide comprises an HFR3 comprising a Y residue at position 90 and exhibits a two-fold or greater decrease in EC50 compared to a parent antigen-binding polypeptide.

[0182] In one embodiment, the antigen binding polypeptide comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or an HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, in which at least one amino acid of HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or at least one amino acid of HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, which is not positively charged, has been replaced with a positively charged amino acid, and comprises an HFR3 comprising a Y at position 90, wherein the antigen binding polypeptide exhibits at least a two-fold decrease in binding EC50 compared to a parent antigen binding polypeptide.

[0183] In one embodiment, the antigen-binding polypeptide comprises an LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or an LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, in which at least one amino acid of the LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or at least one amino acid of the LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, which is not positively charged, has been replaced with a positively charged amino acid, and comprises an HFR3 comprising a Y at position 90, and the antigen-binding polypeptide exhibits a 2-fold or greater decrease in binding EC50 compared to the parent antigen-binding polypeptide.

[0184] In one embodiment of the antigen-binding polypeptide, the antigen-binding polypeptide comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or an HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, in which at least one amino acid of the HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or at least one amino acid of the HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, which is not positively charged, is substituted with a positively charged amino acid, and an LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or an LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, in which at least one amino acid of the LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or at least one amino acid of the LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, which is not positively charged, is substituted with a positively charged amino acid, and the antigen-binding polypeptide exhibits at least a two-fold decrease in binding EC50 compared to the parent antigen-binding polypeptide.

[0185] In one embodiment of the antigen-binding polypeptide, the antigen-binding polypeptide comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or an HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, in which at least one amino acid of the HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or at least one amino acid of the HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, which is not positively charged, is replaced with a positively charged amino acid, and an LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or an LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, in which at least one amino acid of the LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or at least one amino acid of the LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, which is not positively charged, is replaced with a positively charged amino acid, and comprises an HFR3 comprising a Y at position 90, wherein the antigen-binding polypeptide exhibits at least a two-fold decrease in binding EC50 compared to a parent antigen-binding polypeptide.

[0186] In one embodiment, the antigen binding polypeptide comprises a positively charged amino acid at position 30 in the heavy chain and exhibits a 2-fold reduction in EC50 compared to a parent antigen binding polypeptide. Preferably, the positively charged amino acid at position 30 in the heavy chain of the antigen binding polypeptide is R, K or H and the antigen binding polypeptide exhibits at least a 2-fold reduction in EC50 compared to a parent antigen binding polypeptide, preferably a parent antibody. Even more preferably, the positively charged amino acid at position 30 in the heavy chain of the antigen binding polypeptide is R or K and the antigen binding polypeptide exhibits at least a 2-fold reduction in EC50 compared to a parent antigen binding polypeptide.

[0187] In one embodiment, the antigen-binding polypeptide of the first aspect of the invention preferably comprises one of the following mutations in the heavy chain: position 30R, position 30K, position 31R, position 31K, position 53R, position 54R and position 54K, and exhibits at least a 2-fold reduction in binding EC50 compared to the parent antigen-binding polypeptide. In one embodiment, the antigen-binding polypeptide of the first aspect of the invention preferably comprises one of the following mutations in the heavy chain: position 31R, position 31K, position 53R and position 54K, and exhibits at least a 4-fold reduction in binding EC50 compared to the parent antigen-binding polypeptide.

[0188] In one embodiment, the antigen-binding polypeptide of the first aspect of the invention preferably comprises one of the following mutations in the heavy chain: position 31R, position 53R, position 54K and exhibits at least a 5-fold decrease in binding EC50 compared to the parent antigen-binding polypeptide. More preferably, the antigen-binding polypeptide comprises a mutation in the heavy chain at position 54K and exhibits at least an 8-fold decrease in binding EC50 compared to the parent antigen-binding polypeptide.

[0189] In one embodiment, the antigen-binding polypeptide preferably comprises a mutation at position 56R or at position 56K in the light chain and exhibits at least a 4-fold decrease in binding EC50 compared to the parent antigen-binding polypeptide. More preferably, the antigen-binding polypeptide preferably comprises a mutation at position 56R in the light chain and exhibits at least an 8-fold decrease in binding EC50 compared to the parent antigen-binding polypeptide.

[0190] In one embodiment, the antigen-binding polypeptide preferably comprises a mutation at position 90Y in the heavy chain and exhibits at least a 3-fold decrease in binding EC50 compared to the parent antigen-binding polypeptide. In one embodiment, the antigen-binding polypeptide preferably comprises one of the following preferred amino acid combinations in the heavy chain: position 31R and position 90Y; position 53R and position 90Y; and position 54K and position 90Y; and position 54R and position 90Y and exhibits at least a 4-fold decrease in binding EC50 compared to the parent antigen-binding polypeptide.

[0191] In one embodiment, the antigen-binding polypeptide preferably comprises one of the following preferred amino acid combinations in the heavy chain: position 31R and position 90Y; position 53R and position 90Y; and position 54K and position 90Y, and exhibits at least a 5-fold reduction in binding EC50 compared to the parent antigen-binding polypeptide.

[0192] In one embodiment, the antigen-binding polypeptide preferably comprises one of the following preferred amino acid combinations in the heavy chain: position 31R and position 90Y; position 53R and position 90Y; and position 54K and position 90Y, and exhibits a 7-fold or greater decrease in binding EC50 compared to the parent antigen-binding polypeptide.

[0193] In one embodiment, the antigen-binding polypeptide preferably comprises mutations at position 31R and position 90Y in the heavy chain, and the parent antigen-binding polypeptide preferably exhibits an 8-fold or greater decrease in binding EC50 compared to the parent antibody.

[0194] In one embodiment, the antigen-binding polypeptide preferably comprises a mutation at position 56R in the light chain and further comprises a mutation at position 90Y, and exhibits a 13-fold or greater decrease in binding EC50 compared to the parent antigen-binding polypeptide.

[0195] In one embodiment, the antigen-binding polypeptide comprises the following preferred amino acid combinations in the heavy and light chains: position 31R, position 90Y and position 56R in the light chain; position 53R, position 90Y and position 56R in the heavy chain; and position 53R, position 90Y and position 56R in the heavy chain and light chain, and exhibits at least a 15-fold reduction in binding EC50 compared to the parent antigen-binding polypeptide. Preferably, the antigen-binding polypeptide comprises the following amino acid combinations in the heavy and light chains: position 31R, position 90Y and position 56R in the heavy chain; and position 54K, position 90Y and position 56R in the heavy chain and light chain, and exhibits at least a 20-fold reduction in binding EC50 compared to the parent antigen-binding polypeptide. Even more preferably, the antigen-binding polypeptide comprises the following preferred amino acid combinations in the heavy and light chains: position 31R, position 90Y in the heavy chain and position 56R in the light chain, and exhibits at least a 30-fold reduction in binding EC50 compared to the parent antigen-binding polypeptide.

[0196] The inventors have surprisingly demonstrated in the accompanying examples that the binding AUC of the antigen-binding polypeptides of the invention is increased compared to the binding AUC of the parent antigen-binding polypeptide, preferably the binding AUC of the parent antibody, described as a % increase in binding AUC. Thus, the antigen-binding polypeptides provided herein have an increase in binding AUC compared to the parent antigen-binding polypeptide, preferably the antigen-binding polypeptide has at least about a 10% increase in binding AUC, has at least about a 15% increase in binding AUC, has at least about a 50% increase in binding AUC, at least about a 140% increase in binding AUC, at least about a 200% increase in binding AUC, at least about a 250% increase in binding AUC, at least about a 400% increase in binding AUC, at least about a 500% increase in binding AUC, at least about a 600% increase in binding AUC, at least about a 700% increase in binding AUC, or at least about a 800% increase in binding AUC.

[0197] In one embodiment, an antigen-binding polypeptide of the invention has at least about a 10% increase in binding AUC compared to the parent antigen-binding polypeptide.

[0198] In one embodiment, the antigen-binding polypeptide of the first aspect of the invention has at least about a 10% increase in binding AUC, i.e. increased binding to cells expressing the α / β TCR / CD3 complex, compared to a parent antigen-binding polypeptide. In one embodiment, the antigen-binding polypeptide comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or an HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, in which at least one amino acid of HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or at least one amino acid of HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, which is not positively charged, has been replaced with a positively charged amino acid, and the antigen-binding polypeptide has at least about a 15% increase in binding AUC compared to a parent antigen-binding polypeptide.

[0199] In one embodiment, the antigen-binding polypeptide comprises an LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or an LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, in which at least one amino acid of the LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or at least one amino acid of the LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, which is not positively charged, has been replaced with a positively charged amino acid, and the antigen-binding polypeptide has at least about a 10% increase in binding AUC compared to the parent antigen-binding polypeptide.

[0200] In one embodiment, the antigen-binding polypeptide comprises a Y at position 90 in HFR3 and has at least about a 10% increase in binding AUC compared to the parent antigen-binding polypeptide.

[0201] In one embodiment, the antigen binding polypeptide comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or an HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, in which at least one amino acid of HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or at least one amino acid of HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, which is not positively charged, has been replaced with a positively charged amino acid, and comprises a Y at position 90 in HFR3, and the antigen binding polypeptide has at least about a 10% increase in binding AUC compared to a parent antigen binding polypeptide.

[0202] In one embodiment, the antigen-binding polypeptide comprises an LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or an LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, in which at least one amino acid of LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or at least one amino acid of LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, which is not positively charged, has been replaced with a positively charged amino acid, and comprises a Y at position 90 in HFR3, and the antigen-binding polypeptide has at least about a 10% increase in binding AUC compared to the parent antigen-binding polypeptide.

[0203] In one embodiment of the antigen-binding polypeptide, the antigen-binding polypeptide comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or an HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, in which at least one amino acid of the HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or at least one amino acid of the HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, which is not positively charged, is substituted with a positively charged amino acid, and an LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or an LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, in which at least one amino acid of the LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or at least one amino acid of the LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, which is not positively charged, is substituted with a positively charged amino acid, and the antigen-binding polypeptide has at least about a 10% increase in binding AUC compared to a parent antigen-binding polypeptide.

[0204] In one embodiment of the antigen binding polypeptide, the antigen binding polypeptide comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or an HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, in which at least one amino acid of the HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or at least one amino acid of the HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, which is not positively charged, is substituted with a positively charged amino acid, and an LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or an LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, in which at least one amino acid of the LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or the LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, which is not positively charged, is substituted with a positively charged amino acid, and comprises a Y at position 90 in HFR3, wherein the antigen binding polypeptide has at least about a 10% increase in binding AUC compared to a parent antigen binding polypeptide.

[0205] In one embodiment, the antigen-binding polypeptide of the first aspect of the invention preferably comprises one of the following substitutions in the heavy chain: position 30R, position 30K; position 31R, position 31K; position 53R, position 54R; position 54K and has an increase in binding AUC of at least about 15% compared to the parent antigen-binding polypeptide.

[0206] In one embodiment, the antigen-binding polypeptide of the first aspect of the invention preferably comprises one of the following mutations in the heavy chain: position 30R, position 30K; position 31R, position 31K; position 53R, position 54K and has at least about a 50% increase in binding AUC compared to the parent antigen-binding polypeptide.

[0207] In one embodiment, the antigen binding polypeptide further comprises a positively charged amino acid at position 30 in HFR1 in the heavy chain and exhibits at least an 80% increase in AUC. Preferably, the positively charged amino acid at position 30 in HFR1 of the antigen binding polypeptide is R, K or H, and the antigen binding polypeptide exhibits at least an 80% increase in AUC compared to the parent antigen binding polypeptide. Even more preferably, the positively charged amino acid at position 30 in HFR1 of the antigen binding polypeptide is R or K, and the antigen binding polypeptide exhibits at least an 80% increase in binding AUC compared to the parent antigen binding polypeptide.

[0208] In one embodiment, the antigen-binding polypeptide of the first aspect of the invention preferably comprises one of the following mutations in the heavy chain: position 30R, position 30K; position 31R, position 31K; position 53R, position 54K and has at least a 100% increase in binding AUC compared to the parent antigen-binding polypeptide. Particularly preferred, the antigen-binding polypeptide has a substitution at position 31R in the heavy chain and has about a 140% increase in binding AUC compared to the parent antigen-binding polypeptide.

[0209] In one embodiment, the antigen-binding polypeptide preferably comprises a mutation at position 56R in the light chain and has at least about a 15% or greater increase in binding AUC, at least about a 20% increase in binding AUC, at least about a 50% increase in binding AUC, at least about a 100% increase in binding AUC, or at least about a 200% increase in binding AUC compared to the parent antigen-binding polypeptide. More preferably, the antigen-binding polypeptide preferably comprises a mutation at position 56R in the light chain and has at least about a 200% increase in binding AUC compared to the parent antigen-binding polypeptide.

[0210] In one embodiment, the antigen-binding polypeptide preferably comprises a mutation at position 90Y in the heavy chain and has at least about a 10% increase in binding AUC compared to the parent antigen-binding polypeptide. In one embodiment, the antigen-binding polypeptide preferably comprises one of the following preferred amino acid combinations in the heavy chain: position 31R and position 90Y; position 53R and position 90Y; and position 54K and position 90Y and has at least about a 200% increase in binding AUC compared to the parent antigen-binding polypeptide.

[0211] In one embodiment, the antigen-binding polypeptide preferably comprises one of the following preferred amino acid combinations in the heavy chain: position 31R and position 90Y; position 53R and position 90Y; and position 54K and position 90Y, and has at least about a 250% increase in binding AUC compared to the parent antigen-binding polypeptide.

[0212] In one embodiment, the antigen-binding polypeptide preferably comprises one of the following preferred amino acid combinations in the heavy chain: position 54K and position 90Y, position 53R and position 90Y; and position 54K and position 90Y, and has at least about a 300% increase in binding AUC compared to the parent antigen-binding polypeptide.

[0213] In one embodiment, the antigen-binding polypeptide preferably comprises a mutation at position 56R in the light chain and further comprises a mutation at position 90Y in the heavy chain and has at least about a 10% increase in binding AUC, at least about a 50% increase in binding AUC, about a 100% increase in binding AUC, or about a 200% increase in binding AUC compared to a parent antigen-binding polypeptide.

[0214] In one embodiment, the antigen-binding polypeptide comprises the following preferred amino acid combinations in the heavy chain and light chain: position 31R, position 90Y and position 56R in the light chain; position 53R, position 90Y and position 56R in the heavy chain; and position 54K, position 90Y and position 56R in the light chain, and has at least about a 200% increase in binding AUC compared to a parent antigen-binding polypeptide.

[0215] In one embodiment, the antigen-binding polypeptide comprises the following preferred amino acid combinations in the heavy chain and light chain: position 31R, position 90Y and position 56R in the light chain, or position 53R, position 90Y and position 56R in the heavy chain and has at least about a 250% increase in binding AUC compared to a parent antigen-binding polypeptide.

[0216] In one embodiment, the antigen-binding polypeptide comprises the following preferred amino acid combinations in the heavy chain and light chain: position 31R, position 90Y and position 56R in the light chain, or position 53R, position 90Y and position 56R in the heavy chain and has at least about a 300% increase in binding AUC compared to a parent antigen-binding polypeptide.

[0217] In one embodiment, the antigen-binding polypeptide comprises the following preferred amino acid combinations in the heavy and light chains: position 31R, position 90Y in the heavy chain and position 56R in the light chain, or position 53R, position 90Y in the heavy chain and position 56R in the light chain, and has at least about a 400% increase in binding AUC compared to a parent antigen-binding polypeptide.

[0218] In one embodiment, the antigen-binding polypeptide comprises the following preferred amino acid combinations in the heavy and light chains: position 53R, position 90Y and position 56R in the light chain compared to the parent antigen-binding polypeptide, and has at least about a 500% increase in binding AUC; at least about a 600% increase in binding AUC; at least about a 700% increase in binding AUC; or at least about an 800% increase in binding AUC compared to the parent antigen-binding polypeptide. It is particularly preferred that the antigen-binding polypeptide comprises the following preferred amino acid combinations in the heavy and light chains: position 53R, position 90Y and position 56R in the heavy chain, and has at least about a 500% increase in binding AUC compared to the parent antigen-binding polypeptide.

[0219] The inventors have surprisingly demonstrated in the accompanying examples that the Tm of antigen binding polypeptides of the invention is increased compared to the Tm of a parent antigen binding polypeptide, described as ΔTm in °C or absolute temperature value in °C. Thus, the antigen binding polypeptides provided herein have an increased Tm compared to the parent antigen binding polypeptide. Preferably, the antigen binding polypeptide has a ΔTm of at least 1°C, a ΔTm of at least 2°C, a ΔTm of at least 3°C, a ΔTm of at least 3.5°C, or a ΔTm of at least 4°C compared to the parent antigen binding polypeptide.

[0220] The antigen-binding polypeptides provided herein have an increased Tm compared to a parent antigen-binding polypeptide, preferably compared to a parent antibody, and have a Tm of at least 72.5° C., have a Tm of at least 72.8° C., have a Tm of at least 73.8° C., have a Tm of at least 74.8° C., or have a Tm of at least 75.3° C. More preferably, the antigen-binding polypeptide has a Tm of at least 73.0° C., even more preferably has a Tm of at least 73.5° C., has a Tm of at least 74° C., has a Tm of at least 75° C., or has a Tm of at least 76° C.

[0221] In one embodiment, an antigen-binding polypeptide of the invention has a ΔTm of at least 1° C. compared to a parent antigen-binding polypeptide, for example a parent antigen-binding polypeptide comprising the VH and VL amino acid sequences as described herein in relation to parent antibody BMA031 (V36).

[0222] In one embodiment, the antigen-binding polypeptides provided herein have a ΔTm of at least 1° C., or a Tm of at least 72.8° C., compared to an antigen-binding polypeptide that does not contain a substitution of the invention.

[0223] In one embodiment, the antigen binding polypeptide comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or an HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, in which at least one amino acid of HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or at least one amino acid of HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, which is not positively charged, has been replaced with a positively charged amino acid, and the antigen binding polypeptide has a ΔTm of at least 1°C or has a Tm of at least 72.8°C compared to a parent antigen binding polypeptide.

[0224] In one embodiment, the antigen-binding polypeptide comprises an LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or an LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, in which at least one amino acid of LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or at least one amino acid of LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, which is not positively charged, has been replaced with a positively charged amino acid, and the antigen-binding polypeptide has a ΔTm of at least 1°C or has a Tm of at least 72.8°C compared to a parent antigen-binding polypeptide.

[0225] In one embodiment, the antigen binding polypeptide comprises an HFR3 comprising a Y residue at position 90 and has a ΔTm of at least 2° C., preferably at least 2.5° C., more preferably at least 3° C. compared to a parent antigen binding polypeptide.

[0226] In one embodiment of the antigen binding polypeptide, it comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or an HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, in which at least one amino acid of HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or at least one amino acid of HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, which is not positively charged, has been replaced with a positively charged amino acid, and it comprises an HFR3 comprising a Y at position 90, wherein the antigen binding polypeptide has a ΔTm of at least 1°C or has a Tm of at least 72.8°C compared to a parent antigen binding polypeptide.

[0227] In one embodiment, the antigen binding polypeptide comprises an LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or an LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, in which at least one amino acid of LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or at least one amino acid of LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, which is not positively charged, has been replaced with a positively charged amino acid, and comprises an HFR3 comprising a Y at position 90, and the antigen binding polypeptide has a ΔTm of at least 1°C or has a Tm of at least 72.8°C compared to a parent antigen binding polypeptide.

[0228] In one embodiment of the antigen-binding polypeptide, the antigen-binding polypeptide comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or an HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, in which at least one amino acid of the HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or at least one amino acid of the HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, which is not positively charged, is substituted with a positively charged amino acid, and an LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or an LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, in which at least one amino acid of the LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or at least one amino acid of the LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, which is not positively charged, is substituted with a positively charged amino acid, and the antigen-binding polypeptide has a ΔTm of at least 1°C or has a Tm of at least 72.8°C compared to a parent antigen-binding polypeptide.

[0229] In one embodiment of the antigen binding polypeptide, the antigen binding polypeptide comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or an HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, in which at least one amino acid of the HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or at least one amino acid of the HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, which is not positively charged, is replaced with a positively charged amino acid, and an LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or an LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, in which at least one amino acid of the LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or at least one amino acid of the LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, which is not positively charged, is replaced with a positively charged amino acid, and comprises an HFR3 comprising a Y at position 90, wherein the antigen binding polypeptide has a ΔTm of at least 1° C. or has a Tm of at least 72.8° C. compared to a parent antigen binding polypeptide.

[0230] In one embodiment, the antigen binding polypeptide preferably comprises a mutation at position 90Y in the heavy chain and has a ΔTm of at least 1.0° C. compared to the parent antigen binding polypeptide. In one embodiment, the antigen binding polypeptide preferably comprises one of the following amino acid combinations in the heavy chain: position 31R and position 90Y; position 53R and position 90Y; and position 54K and position 90Y; and position 54R and position 90Y and has a ΔTm of at least 1.0° C. compared to the parent antigen binding polypeptide. Preferably, the antigen binding polypeptide comprises one of the following amino acid combinations in the heavy chain: position 31R and position 90Y; position 53R and position 90Y; and position 54K and position 90Y; and position 54R and position 90Y and has a ΔTm of at least 2.0° C. compared to the parent antigen binding polypeptide. Even more preferably, the antigen-binding polypeptide preferably comprises one of the following amino acid combinations in the heavy chain: position 31R and position 90Y; position 53R and position 90Y; and position 54K and position 90Y; and position 54R and position 90Y, and has a ΔTm of at least 3.0°C compared to a parent antigen-binding polypeptide.

[0231] In one embodiment, the antigen-binding polypeptide preferably comprises one of the following amino acid combinations in the heavy chain: position 31R and position 90Y; and position 53R and position 90Y, and has a ΔTm of at least 3.5° C. compared to a parent antigen-binding polypeptide.

[0232] In one embodiment, the antigen-binding polypeptide preferably comprises one of the following amino acid combinations in the heavy chain: position 53R and position 90Y; and position 53R and position 90Y, and has a ΔTm of at least 4.0°C compared to a parent antigen-binding polypeptide.

[0233] In one embodiment, the antigen-binding polypeptide preferably comprises a mutation at position 56R in the light chain and further comprises a mutation at position 90Y and has a ΔTm of at least 3.0° C. compared to the parent antigen-binding polypeptide.

[0234] In one embodiment, the antigen binding polypeptide comprises the following preferred amino acid combinations in the heavy chain and light chain: position 31R, position 90Y and position 56R in the light chain; position 53R in the heavy chain, position 90Y and position 56R in the light chain; and position 54K in the heavy chain, position 90Y and position 56R in the light chain, and has a ΔTm of at least 2.0° C. compared to a parent antigen binding polypeptide.

[0235] Preferably, the antigen-binding polypeptide comprises the following amino acid combinations in the heavy chain and light chain: position 31R, position 90Y and position 56R in the light chain, and position 53R, position 90Y and position 56R in the heavy chain and has a ΔTm of at least 3.5°C compared to a parent antigen-binding polypeptide.

[0236] In one embodiment, the antigen-binding polypeptide preferably comprises a mutation at position 90Y in the heavy chain and has a Tm of at least 73.0°C, has a Tm of at least 74°C, has a Tm of at least 75°C, or has a Tm of at least 76°C.

[0237] In one embodiment, the antigen-binding polypeptide preferably comprises one of the following amino acid combinations in the heavy chain: position 31R and position 90Y; position 53R and position 90Y; and position 54K and position 90Y; and position 54R and position 90Y, and has a Tm of at least 73.46°C. In one embodiment, the antigen-binding polypeptide preferably comprises one of the following amino acid combinations in the heavy chain: position 31R and position 90Y; position 53R and position 90Y; and position 54K and position 90Y; and position 54R and position 90Y, and has a Tm of at least 74.46°C. In one embodiment, the antigen-binding polypeptide preferably comprises one of the following amino acid combinations in the heavy chain: position 31R and position 90Y; position 53R and position 90Y; and position 54K and position 90Y; and position 54R and position 90Y, and has a Tm of at least 75.46°C.

[0238] In one embodiment, the antigen-binding polypeptide comprises one of the following amino acid combinations in the heavy chain: position 31R and position 90Y, position 53R and position 90Y, position 54K and position 90Y, position 54R and position 90Y, and has a Tm of at least 75.5° C. Even more preferably, the antigen-binding polypeptide comprises one of the following amino acid combinations in the heavy chain: position 31R and position 90Y; position 53R and position 90Y; position 54K and position 90Y; position 54R and position 90Y, and has a Tm of at least 75.9° C.

[0239] In one embodiment, the antigen-binding polypeptide preferably comprises one of the following amino acid combinations in the heavy chain: position 31R and position 90Y; and position 53R and position 90Y, and has a Tm of at least 76.0°C.

[0240] In one embodiment, the antigen-binding polypeptide preferably comprises mutations at position 53R and position 90Y in the heavy chain and has a Tm of at least 76.5°C.

[0241] In one embodiment, the antigen-binding polypeptide preferably comprises a mutation at position 56R in the light chain and further comprises a mutation at position 90Y in the heavy chain and has a Tm of at least 72.0° C., a Tm of at least 73.0° C., a Tm of at least 74.0° C., a Tm of at least 75.0° C., or a Tm of at least 76.0° C. Preferably, the antigen-binding polypeptide has a Tm of at least 75.0° C. Even more preferably, the antigen-binding polypeptide has a Tm of at least 75.5° C.

[0242] In one embodiment, the antigen-binding polypeptide comprises the following preferred amino acid combinations in the heavy and light chains: position 31R, position 90Y and position 56R; position 53R, position 90Y and position 56R; and position 54K, position 90Y and position 56R, and has a Tm of at least 74.0° C. Preferably, the antigen-binding polypeptide comprises the following preferred amino acid combinations in the heavy and light chains: position 31R, position 90Y and position 56R; position 53R, position 90Y and position 56R; and position 54K, position 90Y and position 56R, and has a Tm of at least 75.0° C.

[0243] In one embodiment, the antigen-binding polypeptide comprises the following amino acid combinations in the heavy chain and light chain: position 31R, position 90Y and position 56R in the light chain; and position 53R, position 90Y and position 56R in the heavy chain and has a Tm of at least 76.0°C.

[0244] In one embodiment, an antigen-binding polypeptide of the invention has a 10% increase in binding AUC and a ΔTm of at least 1° C. compared to a parent antigen-binding polypeptide.

[0245] In one embodiment, an antigen-binding polypeptide of the invention has at least about a 10% increase in binding AUC and has a ΔTm of at least 1° C. compared to a parent antigen-binding polypeptide.

[0246] In one embodiment, the antigen binding polypeptide comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or an HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, in which at least one amino acid of HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or at least one amino acid of HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, which is not positively charged, has been replaced with a positively charged amino acid, and the antigen binding polypeptide has at least about a 10% increase in binding AUC compared to a parent antigen binding polypeptide and has a ΔTm of at least 1°C.

[0247] In one embodiment, the antigen-binding polypeptide comprises an LCDR1 comprising the amino acid sequence of SEQ ID NO: 54, and / or an LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, in which at least one amino acid of the LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or at least one amino acid of the LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, which is not positively charged, has been replaced with a positively charged amino acid, and the antigen-binding polypeptide has at least about a 10% increase in binding AUC compared to the parent antigen-binding polypeptide and has a ΔTm of at least 1°C.

[0248] In one embodiment, the antigen-binding polypeptide comprises a Y at position 90 in HFR3 and has at least about a 10% increase in binding AUC compared to the parent antigen-binding polypeptide.

[0249] In one embodiment, the antigen binding polypeptide comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or an HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, in which at least one amino acid of HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or at least one amino acid of HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, which is not positively charged, has been replaced with a positively charged amino acid, and comprises a Y at position 90 in HFR3, and the antigen binding polypeptide has at least about a 10% increase in binding AUC compared to a parent antigen binding polypeptide and has a ΔTm of at least 1°C.

[0250] In one embodiment, the antigen binding polypeptide comprises an LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or an LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, in which at least one amino acid of LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or at least one amino acid of LCDR2 comprising the amino acid sequence of SEQ ID NO: 62, which is not positively charged, has been replaced with a positively charged amino acid, and comprises a Y at position 90 in HFR3, and the antigen binding polypeptide has at least about a 10% increase in binding AUC compared to the parent antigen binding polypeptide and has a ΔTm of at least 1°C.

[0251] In one embodiment of the antigen-binding polypeptide, the antigen-binding polypeptide comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or an HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, in which at least one amino acid of the HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or at least one amino acid of the HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, which is not positively charged, is substituted with a positively charged amino acid, and an LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or an LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, in which at least one amino acid of the LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or the LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, which is not positively charged, is substituted with a positively charged amino acid, and the antigen-binding polypeptide has at least about a 10% increase in binding AUC and has a ΔTm of at least 1° C. compared to a parent antigen-binding polypeptide.

[0252] In one embodiment of the antigen binding polypeptide, the antigen binding polypeptide comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or an HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, in which at least one amino acid of HCDR1 comprising the amino acid sequence of SEQ ID NO: 52 and / or at least one amino acid of HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, which is not positively charged, is replaced with a positively charged amino acid, and an LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or an LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, in which at least one amino acid of LCDR1 comprising the amino acid sequence of SEQ ID NO: 54 and / or LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, which is not positively charged, is replaced with a positively charged amino acid, and comprises a Y at position 90 in HFR3, wherein the antigen binding polypeptide has at least about a 10% increase in binding AUC compared to a parent antigen binding polypeptide and has a ΔTm of at least 1° C.

[0253] In one embodiment, the antigen-binding polypeptide preferably comprises a mutation at position 90Y in the heavy chain and has at least about a 10% increase in binding AUC and a ΔTm of at least 1° C. compared to the parent antigen-binding polypeptide.

[0254] In one embodiment, the antigen-binding polypeptide preferably comprises one of the following preferred amino acid combinations in the heavy chain: position 31R and position 90Y; position 53R and position 90Y; and position 54K and position 90Y; and position 54R and position 90Y, and has a ΔTm of at least 1.0°C and at least about a 200% increase in binding AUC compared to the parent antigen-binding polypeptide.

[0255] Preferably, the antigen-binding polypeptide comprises one of the following amino acid combinations in the heavy chain: position 31R and position 90Y; position 53R and position 90Y; and position 54K and position 90Y; and position 54R and position 90Y, and has a ΔTm of at least 2.0°C and at least about a 200% increase in binding AUC compared to the parent antigen-binding polypeptide.

[0256] In one embodiment, the antigen-binding polypeptide comprises one of the following preferred amino acid combinations in the heavy chain: position 31R and position 90Y; position 53R and position 90Y; and position 54K and position 90Y, and has a ΔTm of at least 3.0°C and at least about a 240% increase in binding AUC compared to the parent antigen-binding polypeptide.

[0257] In one embodiment, the antigen-binding polypeptide preferably comprises mutations at position 54K and position 90Y in the heavy chain, has a ΔTm of at least 3.0°C, and has at least about a 300% increase in binding AUC compared to the parent antigen-binding polypeptide.

[0258] In one embodiment, the antigen-binding polypeptide preferably comprises one of the following amino acid combinations in the heavy chain: position 31R and position 90Y; and position 53R and position 90Y, and has a ΔTm of at least 3.5° C. and at least about a 200% increase in binding AUC compared to the parent antigen-binding polypeptide.

[0259] In one embodiment, the antigen-binding polypeptide preferably comprises one of the following amino acid combinations in the heavy chain: position 31R and position 90Y; and position 53R and position 90Y, and has a ΔTm of at least 3.5° C. and at least about a 250% increase in binding AUC compared to the parent antigen-binding polypeptide.

[0260] In one embodiment, the antigen-binding polypeptide preferably comprises mutations at position 53R and position 90Y in the heavy chain and has a ΔTm of at least 4.0° C. and at least about a 200% increase in binding AUC compared to the parent antigen-binding polypeptide.

[0261] In one embodiment, the antigen-binding polypeptide preferably comprises mutations at position 53R and position 90Y in the heavy chain and has a ΔTm of at least 4.0° C. and at least about a 250% increase in binding AUC compared to the parent antigen-binding polypeptide.

[0262] In one embodiment, the antigen-binding polypeptide preferably comprises a mutation at position 56R in the light chain and further comprises a mutation at position 90Y, and has a ΔTm of at least 3.0° C. and an increase in binding AUC of at least about 150% compared to the parent antigen-binding polypeptide.

[0263] In one embodiment, the antigen-binding polypeptide preferably comprises a mutation at position 56R in the light chain and further comprises a mutation at position 90Y, has a ΔTm of at least 3.0° C. and has an increase in binding AUC of at least about 200%.

[0264] In one embodiment, the antigen-binding polypeptide comprises the following preferred amino acid combinations in the heavy and light chains: position 31R, position 90Y and position 56R in the light chain; position 53R, position 90Y and position 56R in the heavy chain; and position 54K and position 90Y in the light chain and position 56R in the heavy chain, and has a ΔTm of at least 2.0° C. and at least about a 200% increase in binding AUC compared to a parent antigen-binding polypeptide.

[0265] In one embodiment, the antigen-binding polypeptide comprises the following preferred amino acid combinations in the heavy chain and light chain: position 31R, position 90Y, and position 56R in the light chain; position 53R, position 90Y, and position 56R in the heavy chain; and position 54K and position 90Y in the heavy chain and position 56R in the light chain, and has a ΔTm of at least 2.0° C. and at least about a 300% increase in binding AUC compared to a parent antigen-binding polypeptide.

[0266] In one embodiment, the antigen-binding polypeptide comprises the following preferred amino acid combinations in the heavy chain and light chain: position 31R, position 90Y and position 56R in the light chain; position 53R, position 90Y and position 56R in the heavy chain; and position 54K and position 90Y in the heavy chain and position 56R in the light chain, and has a ΔTm of at least 2.0° C. and at least about a 400% increase in binding AUC compared to a parent antigen-binding polypeptide.

[0267] In one embodiment, the antigen binding polypeptide comprises the following preferred amino acid combinations in the heavy chain and light chain: position 31R, position 90Y and position 56R in the light chain; position 53R, position 90Y and position 56R in the heavy chain; and position 54K and position 90Y in the heavy chain and position 56R in the light chain, and has a ΔTm of at least 2.0° C. and at least about a 500% increase in binding AUC compared to a parent antigen binding polypeptide.

[0268] In one embodiment, the antigen-binding polypeptide comprises the following preferred amino acid combinations in the heavy chain and light chain: position 31R, position 90Y and position 56R in the light chain; position 53R, position 90Y and position 56R in the heavy chain; and position 54K and position 90Y in the heavy chain and position 56R in the light chain, and has a ΔTm of at least 2.0° C. and at least about a 600% increase in binding AUC compared to a parent antigen-binding polypeptide.

[0269] In one embodiment, the antigen-binding polypeptide comprises the following preferred amino acid combinations in the heavy chain and light chain: position 31R, position 90Y and position 56R in the light chain; position 53R, position 90Y and position 56R in the heavy chain; and position 54K and position 90Y in the heavy chain and position 56R in the light chain, and has a ΔTm of at least 2.0° C. and at least about a 700% increase in binding AUC compared to a parent antigen-binding polypeptide.

[0270] In one embodiment, the antigen binding polypeptide comprises the following preferred amino acid combinations in the heavy chain and light chain: position 31R, position 90Y and position 56R in the light chain; position 53R, position 90Y and position 56R in the heavy chain; and position 54K and position 90Y in the heavy chain and position 56R in the light chain, and has a ΔTm of at least 2.0° C. and at least about an 800% increase in binding AUC compared to a parent antigen binding polypeptide.

[0271] In one embodiment, the antigen-binding polypeptide comprises the following preferred amino acid combinations in the heavy and light chains: position 31R, position 90Y and position 56R in the light chain; position 53R, position 90Y and position 56R in the heavy chain, and has a ΔTm of at least 3.0° C. and at least about a 200% increase in binding AUC compared to a parent antigen-binding polypeptide.

[0272] In one embodiment, the antigen binding polypeptide comprises the following preferred amino acid combinations in the heavy and light chains: position 31R, position 90Y and position 56R in the light chain; position 53R, position 90Y and position 56R in the heavy chain, and has a ΔTm of at least 3.0° C. and at least about a 300% increase in binding AUC compared to the parent antigen binding polypeptide.

[0273] In one embodiment, the antigen-binding polypeptide comprises the following preferred amino acid combinations in the heavy and light chains: position 31R, position 90Y and position 56R in the light chain; position 53R, position 90Y and position 56R in the heavy chain, and has a ΔTm of at least 3.0° C. and at least about a 400% increase in binding AUC compared to a parent antigen-binding polypeptide.

[0274] In one embodiment, the antigen-binding polypeptide comprises the following preferred amino acid combinations in the heavy and light chains: position 31R, position 90Y and position 56R in the light chain; position 53R, position 90Y and position 56R in the heavy chain, and has a ΔTm of at least 3.0° C. and at least about a 500% increase in binding AUC compared to a parent antigen-binding polypeptide.

[0275] In one embodiment, the antigen-binding polypeptide comprises the following preferred amino acid combinations in the heavy and light chains: position 31R, position 90Y and position 56R in the light chain; position 53R, position 90Y and position 56R in the heavy chain, and has a ΔTm of at least 3.0° C. and at least about a 600% increase in binding AUC compared to a parent antigen-binding polypeptide.

[0276] In one embodiment, the antigen-binding polypeptide comprises the following preferred amino acid combinations in the heavy and light chains: position 31R, position 90Y and position 56R in the light chain; position 53R, position 90Y and position 56R in the heavy chain, and has a ΔTm of at least 3.0° C. and at least about a 700% increase in binding AUC compared to a parent antigen-binding polypeptide.

[0277] In one embodiment, the antigen-binding polypeptide comprises the following preferred amino acid combinations in the heavy and light chains: position 31R, position 90Y and position 56R in the light chain; position 53R, position 90Y and position 56R in the heavy chain, and has a ΔTm of at least 3.0° C. and at least about an 800% increase in binding AUC compared to the parent antigen-binding polypeptide.

[0278] Surprisingly, it could be shown that certain substitutions of positions carrying a non-positively charged amino acid with a positively charged amino acid lead to an improvement in binding (e.g. binding AUC (Figure 5, top panel)). Surprisingly, it was found that position 90 Y leads to a significant increase in Tm (Figure 5, bottom panel). The amino acid Y at position 90 can be considered as a component of the Tm improvement, since substitution of position 90 with Y leads to an increase in Tm for all molecules tested (see Figure 5, bottom panel). Furthermore, the inventors surprisingly found that molecules carrying a Y at position 90, when accompanied by substitutions with positively charged amino acids at one or more positions, lead to a significant increase / improvement in binding (e.g. binding AUC), in addition to an increase in Tm, i.e. these substitutions lead to a synergistic effect.

[0279] In one embodiment, the antigen binding polypeptide comprises the following preferred amino acid combinations in the heavy chain: position 31R and position 90Y; position 53R and position 90Y; position 54R and position 90Y; and position 54K and position 90Y, preferably said antigen binding polypeptide has a ΔTm of at least 3°C ​​and has at least about a 200% increase in binding AUC compared to the parent antigen binding polypeptide. Preferably, the antigen binding polypeptide comprises the following amino acid combinations in the heavy chain: position 31R and position 90Y; position 53R and position 90Y, preferably said antigen binding polypeptide has a ΔTm of at least 3°C ​​and has at least about a 270% increase in binding AUC compared to the parent antigen binding polypeptide. Even more preferably, the antigen binding polypeptide comprises the following amino acid combinations in the heavy chain: position 54K and position 90Y, preferably said antigen binding polypeptide has a ΔTm of at least 3°C ​​and has at least about a 240% increase in binding AUC compared to the parent antigen binding polypeptide.

[0280] In one embodiment, the antigen-binding polypeptide comprises the following preferred amino acid combinations in the heavy and light chains: position 31R in VH, position 90Y and position 56R in VL; position 53R in VH, position 90Y and position 56R in VL; and position 54K in VH, position 90Y and position 56R in VL, and has a ΔTm of at least 2.50° C. and has an increase in binding AUC of at least about 245% compared to the parent antigen-binding polypeptide. More preferably, the antigen-binding polypeptide comprises the following preferred amino acid combinations in the heavy and light chains: position 31R in VH, position 90Y and position 56R in VL; position 53R in VH, position 90Y and position 56R in VL, and has a ΔTm of at least 3.50° C. and has an increase in binding AUC of at least about 400% compared to the parent antigen-binding polypeptide. It is particularly preferred that the antigen-binding polypeptide comprises the following preferred amino acid combinations in the heavy and light chains: position 53R in VH, position 90Y and position 56R in VL; position 53R in VH, position 90Y and position 56R in VL, and has a ΔTm of at least 3.50°C and at least about an 800% increase in binding AUC compared to the parent antigen-binding polypeptide.

[0281] In one embodiment, the antigen-binding polypeptide comprises the following preferred amino acid combinations in the heavy chain: position 31R and position 90Y; position 53R and position 90Y; position 54R and position 90Y; and position 54K and position 90Y, and preferably has a Tm of at least 75°C and at least about a 200% increase in binding AUC compared to the parent antigen-binding polypeptide. Preferably, the antigen-binding polypeptide comprises the following amino acid combinations in the heavy chain: position 31R and position 90Y; position 53R and position 90Y, and preferably has a Tm of at least 76°C and at least about a 270% increase in binding AUC compared to the parent antigen-binding polypeptide. Even more preferably, the antigen-binding polypeptide comprises the following amino acid combinations in the heavy chain: position 54K and position 90Y, and preferably has a Tm of at least 75°C and at least about a 240% increase in binding AUC compared to the parent antigen-binding polypeptide.

[0282] In one embodiment, the antigen-binding polypeptide comprises the following preferred amino acid combinations in the heavy and light chains: position 31R in the heavy chain, position 90Y in the VH and position 56R in the light chain; position 53R in the heavy chain, position 90Y and position 56R in the light chain; and position 54K in the heavy chain, position 90Y and position 56R in the light chain, and has a Tm of at least 75° C. and at least about a 245% increase in binding AUC compared to the parent antigen-binding polypeptide. More preferably, the antigen-binding polypeptide comprises the following preferred amino acid combinations in the heavy and light chains: position 31R in the heavy chain, position 90Y and position 56R in the light chain; position 53R in the heavy chain, position 90Y and position 56R in the light chain, and has a Tm of at least 76° C. and at least about a 400% increase in binding AUC compared to the parent antigen-binding polypeptide. It is particularly preferred that the antigen-binding polypeptide comprises the following preferred amino acid combinations in the heavy and light chains: position 53R in the heavy chain, position 90Y and position 56R in the heavy chain, and has a Tm of at least 76°C and at least about an 800% increase in binding AUC compared to the parent antigen-binding polypeptide.

[0283] In one embodiment of the first aspect of the present invention, the antigen-binding polypeptide is an antibody or a fragment thereof.Preferably, the antigen-binding polypeptide is a bispecific antibody or a fragment thereof.More preferably, the antigen-binding polypeptide is a bispecific antibody or a fragment thereof further comprising a TCR.

[0284] In one embodiment of the first aspect of the invention, the antigen-binding polypeptide comprises a VH and a VL forming a first binding site as described above, and further comprises a second binding site. Preferably, said second binding site specifically binds to a cell surface protein. Preferred cell surface proteins are selected from the group consisting of glycoproteins, MHC class I proteins, MHC class II proteins; β-microglobulins, immunoglobulins such as IgA, IgD, IgE, IgG, IgM, TCR, co-receptor molecules such as CD4 or CD8. In a preferred embodiment, the cell surface protein is a surface protein of a cancer cell. Preferably, the second binding site of the antigen-binding polypeptide specifically binds to an MHC-peptide complex. More preferably, the MHC molecule is an MHC I molecule complexed with a peptide, preferably the MHC I molecule is a human leukocyte antigen (HLA) molecule complexed with a peptide. Even more preferably, the second binding site of the antigen-binding polypeptide specifically binds to an HLA-peptide complex of a cancer cell, preferably the HLA is HLA-A*02.

[0285] In one embodiment, the second antigen-binding site of the antigen-binding polypeptide of the first aspect of the invention is comprised in or formed by, for example, an antibody, a TCR, a scaffold protein, or an antibody mimetic, such as a designed ankyrin repeat protein (DARPin), a knottin, an anticalin, a finomer or an affibody. Preferably, the second antigen-binding site is comprised in a TCR or a fragment thereof.

[0286] In one embodiment, the second antigen-binding site of the antigen-binding polypeptide comprises at least one α(V α ) and / or β(Vβ ) chain variable region; or the γ (V γ ) and / or δ(V δ ) chain, or the VL and / or VH of a further antibody. Preferably, the second binding site of the antigen-binding polypeptide comprises at least the V α and / or V β , or V γ and / or V δ The V of the second antigen-binding site α and V β , or V γ and V δ The V of the second antigen-binding site can be present on two separate polypeptide chains. α and V β , or V γ and V δ can be present on the same polypeptide chain. Preferably, the V of the second antigen-binding site α and V β , or V γ and V δ are present on two separate polypeptide chains. Preferably, the antigen-binding polypeptide further comprises a constant domain.

[0287] In the context of the present invention, V α and V β , or (V γ Or V δ ) preferably binds to a tumor-associated antigen (TAA) / MHC complex. V that may be included in the antigen-binding polypeptide of the present invention α and V β , or V γ Or V δare described in detail in, for example, WO2018172533, WO2018033291, WO2017158103, WO2018104438, WO2018104478, WO2019002444, WO2017158116, U.S. Patent No. 10800845, U.S. Patent No. 10537624, U.S. Patent No. 10538573, U.S. Patent No. 10537624, U.S. Patent No. 10590194, U.S. Patent No. 10800832, and U.S. Patent No. 10527623, the contents of each of which are incorporated herein by reference in their entireties.

[0288] Thus, in one embodiment, V α and V β , or V γ and V δ The present invention relates to a method for the preparation of a medicament ... α and V β or V γ and V δ binds to TAA peptides disclosed in the same patent applications cited above, the contents of each of which are incorporated herein by reference in their entirety.

[0289] In one aspect, tumor associated antigen (TAA) peptides that can be used with the methods and embodiments described herein include, for example, those described in U.S. Patent Application No. 20160187351, U.S. Patent Application No. 20170165335, U.S. Patent Application No. 20170035807, U.S. Patent Application No. 20160280759, U.S. Patent Application No. 20160287687, U.S. Patent Application No. 20160346371, U.S. Patent Application No. 20160368965, U.S. Patent Application No. 201700 22251, U.S. Patent Application No. 20170002055, U.S. Patent Application No. 20170029486, U.S. Patent Application No. 20170037089, U.S. Patent Application No. 20170136108, U.S. Patent Application No. 20170101473, U.S. Patent Application No. 20170096461, U.S. Patent Application No. 20170165337, U.S. Patent Application No. 20170189505, U.S. Patent Application No. 20170173132, U.S. Patent Application No. 20170296640, U.S. Patent Application No. 20170253633, U.S. Patent Application No. 20170260249, U.S. Patent Application No. 20180051080, U.S. Patent Application No. 20180164315, U.S. Patent Application No. 20180291082, U.S. Patent Application No. 20180291083, U.S. Patent Application No. 20190255110, U.S. Patent No. 9,717,774, U.S. Patent No. 9,895,415, U.S. Patent Application No. 20190247433, U.S. Patent Application No. 20190292520, U.S. Patent Application No. No. 20200085930, U.S. Pat. No. 10,336,809, U.S. Pat. No. 10,131,703, U.S. Pat. No. 10,081,664, U.S. Pat. No. 10,081,664, U.S. Pat. No. 10,093,715, U.S. Pat. No. 10,583,573, and U.S. Patent Application No. 20200085930, the contents of each of these publications, the sequences set forth therein, and the sequence listing are incorporated herein by reference in their entireties.

[0290] In the context of the present invention, the VL and / or VH of the further antibody preferably binds to a protein present on the surface of a tumor.

[0291] In one embodiment, the VH and VL of the antigen-binding polypeptide are those of an antibody.In one embodiment, the first antigen-binding site comprises VH and VL on two separate polypeptide chains.In one embodiment, the first antigen-binding site comprises VH and VL on the same polypeptide chain.Preferably, the VH and VL comprised in the first antigen-binding site are on two separate polypeptide chains, unless the antigen-binding polypeptide is a single-chain polypeptide.

[0292] In one embodiment, at least one amino acid of the antigen-binding polypeptide that is substituted with a positively charged amino acid is in SEQ ID NO:52 (HCDR1). In one embodiment, at least one amino acid of the antigen-binding polypeptide that is substituted with a positively charged amino acid is in SEQ ID NO:52 (HCDR1) and SEQ ID NO:53 (HCDR1 and HCDR2). In one embodiment, at least one amino acid of the antigen-binding polypeptide that is substituted with a positively charged amino acid is in SEQ ID NO:52 and SEQ ID NO:3 (HCDR1 and LCDR1). In one embodiment, at least one amino acid of the antigen-binding polypeptide that is substituted with a positively charged amino acid is in SEQ ID NO:52 and SEQ ID NO:55 (HCDR1 and LCDR2). In one embodiment, at least one amino acid of the antigen-binding polypeptide that is substituted with a positively charged amino acid is in SEQ ID NO:52 and SEQ ID NO:3 and SEQ ID NO:55 (HCDR1, LCDR1 and LCDR2). In one embodiment, at least one amino acid of the antigen-binding polypeptide that is substituted with a positively charged amino acid is in SEQ ID NO:52 and SEQ ID NO:53 and SEQ ID NO:54 (HCDR1, HCDR2 and LCDR1). In one embodiment, at least one amino acid of the antigen-binding polypeptide that is substituted with a positively charged amino acid is in SEQ ID NO:52 and SEQ ID NO:53 and SEQ ID NO:54 and SEQ ID NO:55 (HCDR1, HCDR2, LCDR1 and LCDR2). In one embodiment, at least one amino acid of the antigen-binding polypeptide that is substituted with a positively charged amino acid is in SEQ ID NO:53 and SEQ ID NO:54 (HCDR2 and LCDR1). In one embodiment, at least one amino acid of the antigen-binding polypeptide that is substituted with a positively charged amino acid is in SEQ ID NO:53 and SEQ ID NO:55 (HCDR2 and LCDR2). In one embodiment, at least one amino acid of the antigen-binding polypeptide that is substituted with a positively charged amino acid is in SEQ ID NO:53 and SEQ ID NO:54 and SEQ ID NO:55 (HCDR2 and LCDR1 and LCDR2). In one embodiment, at least one amino acid substituted with a positively charged amino acid of the antigen-binding polypeptide is in SEQ ID NO:54.In one embodiment, the at least one amino acid substituted with a positively charged amino acid in the antigen-binding polypeptide is in SEQ ID NO:54 and SEQ ID NO:53 (LCDR1 and HCDR2). In one embodiment, the at least one amino acid substituted with a positively charged amino acid in the antigen-binding polypeptide is in SEQ ID NO:54 and SEQ ID NO:55 (LCDR1 and LCDR2). In one embodiment, the at least one amino acid substituted with a positively charged amino acid in the antigen-binding polypeptide is in SEQ ID NO:55 (LCDR2). Preferably, the at least one amino acid substituted with a positively charged amino acid in the antigen-binding polypeptide is in SEQ ID NO:55 (LCDR2), SEQ ID NO:53 (HCDR2) or SEQ ID NO:52 (HCDR1). More preferably, the at least one amino acid substituted with a positively charged amino acid in the antigen-binding polypeptide is in SEQ ID NO:52 (HCDR1) and SEQ ID NO:55 (LCDR2). It is particularly preferred that the at least one amino acid substituted with a positively charged amino acid of the antigen-binding polypeptide is in SEQ ID NO: 53 (HCDR2) and SEQ ID NO: 55 (LCDR2).

[0293] In one embodiment, the antigen binding polypeptide comprises a serine (S) or an asparagine (N) at position 30 in HFR1 of the antigen binding polypeptide. It is even more preferred that the positively charged amino acid at position 53 in the heavy chain of the antigen binding polypeptide is R or K and a serine is at position 30 in HFR1 of the antigen binding polypeptide. It is also even more preferred that the positively charged amino acid at position 53 in the heavy chain of the antigen binding polypeptide is R and a serine is at position 30 in HFR1 of the antigen binding polypeptide.

[0294] In one embodiment, the antigen-binding polypeptide comprises a serine (S) or asparagine (N) at position 30 in HFR1 of the antigen-binding polypeptide.

[0295] In one embodiment, the threonine (T) at position 30 in HFR1 of the antigen binding polypeptide is substituted with asparagine (N) or serine (S). In one embodiment, the S at position 31 in HFR1 of the antigen binding polypeptide is substituted with asparagine (N). In one embodiment, the valine (V) at position 56 in the heavy chain of the antigen binding polypeptide is substituted with isoleucine (I). In one embodiment, the glutamic acid (E) at position 100a in the heavy chain of the antigen binding polypeptide is substituted with aspartic acid (D).

[0296] In one embodiment, the threonine (T) at position 30 in the heavy chain of the antigen binding polypeptide is substituted with asparagine (N) or serine (S). In one embodiment, the S at position 31 in the heavy chain of the antigen binding polypeptide is substituted with asparagine (N). In one embodiment, the valine (V) at position 56 in the heavy chain of the antigen binding polypeptide is substituted with isoleucine (I). In one embodiment, the glutamic acid (E) at position 100a in the heavy chain of the antigen binding polypeptide is substituted with aspartic acid (D). In one embodiment, the S at position 31 in the light chain of the antigen binding polypeptide is substituted with N. In one embodiment, the S at position 93 in the light chain is substituted with N. In one embodiment, the S at positions 31 and 93 in the light chain are both substituted with N. In one embodiment, the T at position 30 in the heavy chain of the antigen binding polypeptide is substituted with N or S, the S at position 31 in the heavy chain of the antigen binding polypeptide is substituted with N, the V at position 56 in the heavy chain of the antigen binding polypeptide is substituted with I, the E at position 100a in the heavy chain of the antigen binding polypeptide is substituted with D, and the S at position 93 in the light chain of the antigen binding polypeptide is substituted with N. In one embodiment, the T at position 30 in the heavy chain of the antigen binding polypeptide is substituted with N or S, the S at position 31 in the heavy chain of the antigen binding polypeptide is substituted with N, the V at position 56 in the heavy chain of the antigen binding polypeptide is substituted with I, the E at position 100a in the heavy chain of the antigen binding polypeptide is substituted with D, and the S at position 93 in the light chain of the antigen binding polypeptide is substituted with N.In one embodiment, the T at position 30 in the heavy chain of the antigen binding polypeptide is substituted with N or S, the S at position 31 in the heavy chain of the antigen binding polypeptide is substituted with N, the V at position 56 in the heavy chain of the antigen binding polypeptide is substituted with N, the V at position 56 in the heavy chain of the antigen binding polypeptide is substituted with I, the E at position 100a in the heavy chain of the antigen binding polypeptide is substituted with D, and the S at position 31 in the heavy chain of the antigen binding polypeptide is substituted with N.

[0297] In one embodiment, the antigen-binding polypeptide comprises a further modification in the heavy chain CDR3 (HCDR3). In one embodiment, said modification is a substitution with a negatively charged amino acid, for example E or D. Preferably, the amino acid at position 100a of HCDR3 is substituted. Particularly preferably, position 100a is substituted with E or D. In one embodiment, the antigen-binding polypeptide comprises a further modification in the light chain CDR3 (LCDR3). In one embodiment, said modification is a substitution with a polar amino acid selected from the group consisting of R, H, K, D, E, N, Q, S, T, Y. Preferably, the amino acid at position 93 of LCDR3 is substituted. Particularly preferably, position 93 is N or S. In one embodiment, the antigen-binding polypeptide comprises a further modification in the heavy chain HCDR3 and in LCDR3. In one embodiment, the antigen-binding polypeptide comprises a substitution with a negatively charged amino acid in HCDR3 and a substitution with a polar amino acid in LCDR3. Preferably, position 100a in HCDR3 is substituted with a negatively charged amino acid and position 93 in LCDR3 is substituted with a polar amino acid. Even more preferably, position 100a in HCDR3 is substituted with E and position 93 in LCDR3 is substituted with a polar amino acid S; position 100a in HCDR3 is substituted with E and position 93 in LCDR3 is substituted with a polar amino acid N; position 100a in HCDR3 is substituted with D and position 93 in LCDR3 is substituted with a polar amino acid S; position 100a in HCDR3 is substituted with D and position 93 in LCDR3 is substituted with a polar amino acid N.

[0298] In one embodiment, the HCDR3 of the antigen-binding polypeptide has the sequence GSYYDYX1GFVY (SEQ ID NO:56), where X1 is D or E. Preferably, X1 is E (GSYYDYEGFVY, SEQ ID NO:64). In one embodiment, the LCDR3 of the antigen-binding polypeptide has the sequence QQWSX1X2X3LT (SEQ ID NO:57), where X1 is S or N, X2 is an amino acid selected from the group consisting of Q, D, H, S, Y, A and N, and X3 is P or A. Preferably, the LCDR3 of the antigen-binding polypeptide has the sequence QQWSSX2X3LT (SEQ ID NO:65). Preferably, the LCDR3 of the antigen-binding polypeptide has the sequence QQWSX1NX3LT (SEQ ID NO:66), where X2 is N. Preferably, the LCDR3 of the antigen-binding polypeptide has the sequence QQWSX1X2PLT (SEQ ID NO:67). In one embodiment, the LCDR3 of the antigen binding polypeptide has the sequence QQWSSQPLT (SEQ ID NO: 68). In one embodiment, the LCDR3 of the antigen binding polypeptide has the sequence QQWSSDPLT (SEQ ID NO: 69). In one embodiment, the LCDR3 of the antigen binding polypeptide has the sequence QQWSSHPLT (SEQ ID NO: 70). In one embodiment, the LCDR3 of the antigen binding polypeptide has the sequence QQWSSSPLT (SEQ ID NO: 71). In one embodiment, the LCDR3 of the antigen binding polypeptide has the sequence QQWSSYPLT (SEQ ID NO: 72). In one embodiment, the LCDR3 of the antigen binding polypeptide has the sequence QQWSSAPLT (SEQ ID NO: 73). In a particularly preferred embodiment, the LCDR3 of the antigen binding polypeptide has the sequence QQWSSNPLT (SEQ ID NO: 74).

[0299] In one embodiment, the LCDR3 of the antigen binding polypeptide has the sequence QQWSSQALT (SEQ ID NO: 75). In one embodiment, the LCDR3 of the antigen binding polypeptide has the sequence QQWSSDALT (SEQ ID NO: 76). In one embodiment, the LCDR3 of the antigen binding polypeptide has the sequence QQWSSHALT (SEQ ID NO: 77). In one embodiment, the LCDR3 of the antigen binding polypeptide has the sequence QQWSSSALT (SEQ ID NO: 78). In one embodiment, the LCDR3 of the antigen binding polypeptide has the sequence QQWSSYALT (SEQ ID NO: 79). In one embodiment, the LCDR3 of the antigen binding polypeptide has the sequence QQWSSAALT (SEQ ID NO: 80). In one embodiment, the LCDR3 of the antigen binding polypeptide has the sequence QQWSSNALT (SEQ ID NO: 81).

[0300] In one embodiment, the LCDR3 of the antigen binding polypeptide has the sequence QQWSNQPLT (SEQ ID NO: 82). In one embodiment, the LCDR3 of the antigen binding polypeptide has the sequence QQWNSDPLT (SEQ ID NO: 83). In one embodiment, the LCDR3 of the antigen binding polypeptide has the sequence QQWNSHPLT (SEQ ID NO: 84). In one embodiment, the LCDR3 of the antigen binding polypeptide has the sequence QQWNSSPLT (SEQ ID NO: 85). In one embodiment, the LCDR3 of the antigen binding polypeptide has the sequence QQWNSYPLT (SEQ ID NO: 86). In one embodiment, the LCDR3 of the antigen binding polypeptide has the sequence QQWNSAPLT (SEQ ID NO: 87). In one embodiment, the LCDR3 of the antigen binding polypeptide has the sequence QQWNSNPLT (SEQ ID NO: 88).

[0301] In one embodiment, the LCDR3 of the antigen binding polypeptide has the sequence QQWSNQALT (SEQ ID NO: 89). In one embodiment, the LCDR3 of the antigen binding polypeptide has the sequence QQWNSDALT (SEQ ID NO: 90). In one embodiment, the LCDR3 of the antigen binding polypeptide has the sequence QQWNSHALT (SEQ ID NO: 91). In one embodiment, the LCDR3 of the antigen binding polypeptide has the sequence QQWNSSALT (SEQ ID NO: 92). In one embodiment, the LCDR3 of the antigen binding polypeptide has the sequence QQWNSYALT (SEQ ID NO: 93). In one embodiment, the LCDR3 of the antigen binding polypeptide has the sequence QQWNSAALT (SEQ ID NO: 94). In one embodiment, the LCDR3 of the antigen binding polypeptide has the sequence QQWNSNALT (SEQ ID NO: 95). Preferably, the LCDR3 of the antigen binding polypeptide has the sequence QQWSX1NPLT (SEQ ID NO: 96), wherein X1 is S or N. Even more preferably, X1 is S.

[0302] In one embodiment, the antigen binding polypeptide comprises or consists of HFR1, HFR2 and HFR3 comprised in the VH set forth in SEQ ID NO: 1 (BMA031 V36_VH), SEQ ID NO: 97 (GL1_BM_VH28_HV), SEQ ID NO: 98 (GL1_BM_VH31_HV), SEQ ID NO: 99 (HEBE1_H10_HV), SEQ ID NO: 100 (HEBE1_H66_HV), and SEQ ID NO: 101 (HEBE1_H71_HV). Preferably, HFR1, HFR2 and HFR3 are comprised in the VH set forth in SEQ ID NO: 1 (BMA031 V36_VH). In a preferred embodiment of an antigen binding polypeptide of the invention in which position 30 in HFR1 and / or position 90 in HFR3 are substituted, this substitution is maintained notwithstanding that the remaining amino acids of the framework regions comprise or consist of HFR1, HFR2 and HFR2 as described above.

[0303] In one embodiment, the antigen-binding polypeptide comprises or consists of LFR1, LFR2 and LFR3 contained in the VL set forth in SEQ ID NO: 2 (BMA031 V36_VL) or SEQ ID NO: 102 (GL1BMVK43_VL). Preferably, LFR1, LFR2, LFR3 and LFR4 are contained in the VL set forth in SEQ ID NO: 2 (BMA031 V36_VL).

[0304] In one embodiment, the antigen-binding polypeptide comprises or consists of HFR1, HFR2 and HFR3 contained in the VH set forth in SEQ ID NO:1 (BMA031 V36_VH), SEQ ID NO:97 (GL1_BM_VH28_HV), SEQ ID NO:98 (GL1_BM_VH31_HV), SEQ ID NO:99 (HEBE1_H10_HV), SEQ ID NO:100 (HEBE1_H66_HV), and SEQ ID NO:101 (HEBE1_H71_HV), and comprises or consists of LFR1, LFR2 and LFR3 contained in the VL set forth in SEQ ID NO:2 (BMA031 V36_VL). In one embodiment, the antigen-binding polypeptide comprises or consists of HFR1, HFR2 and HFR3 contained in the VH set forth in SEQ ID NO:1 (BMA031 V36_VH), SEQ ID NO:97 (GL1_BM_VH28_HV), SEQ ID NO:98 (GL1_BM_VH31_HV), SEQ ID NO:99 (HEBE1_H10_HV), SEQ ID NO:100 (HEBE1_H66_HV), and SEQ ID NO:101 (HEBE1_H71_HV), and comprises or consists of LFR1, LFR2 and LFR3 contained in the VL set forth in SEQ ID NO:102 (GL1BMVK43_VL). Preferably, the antigen binding polypeptide comprises HFR1, HFR2 and HFR3 contained in the VH set forth in SEQ ID NO: 1 (BMA031 V36_VH), and comprises or consists of LFR1, LFR2 and LFR3 contained in the VL set forth in SEQ ID NO: 2 (BMA031 V36_VL). In preferred embodiments of antigen binding polypeptides of the invention in which position 30 and / or position 90 in HFR1 is substituted, this substitution is maintained notwithstanding that the remaining amino acids of the framework regions comprise or consist of HFR1, HFR2 and HFR2 as described above.

[0305] In one embodiment, the antigen-binding polypeptide further comprises or consists of an HFR4 contained in the VH set forth in SEQ ID NO: 1 (BMA031 V36_VH); or an LFR4 contained in the VL set forth in SEQ ID NO: 2 (BMA031 V36_VL). In a preferred embodiment, the antigen-binding polypeptide comprises or consists of HFR1, HFR2, HFR3 and HFR4 contained in the VH set forth in SEQ ID NO: 1 (BMA031 V36_VH) and LFR1, LFR2, LFR3 and LFR4 contained in the VL set forth in SEQ ID NO: 2 (BMA031 V36_VL). In a preferred embodiment of an antigen-binding polypeptide of the invention in which position 30 and / or position 90 in HFR1 is substituted, this substitution is maintained notwithstanding that the remaining amino acids of the framework regions comprise or consist of HFR1, HFR2 and HFR2 as described above.

[0306] In further embodiments, described in more detail below, the antigen-binding polypeptides of the invention comprise a heavy chain framework region (HFR) and / or a light chain framework region (LFR), or a functional variant thereof, as defined herein above. Antigen-binding polypeptides comprising HFR or LFR sequences with a degree of sequence identity, as defined above, also have similar or even higher functional properties, e.g., binding EC 50or may exert an increase / elevation or improvement in Tm. In particular, antigen-binding polypeptides comprising functional variants of HFR or LFR have at least a 2-fold improvement or increase in binding EC50 and / or have at least a 1°C improvement or increase in Tm or have a ΔTm of at least 1°C as defined herein above. In one embodiment, the antigen-binding polypeptide comprises HFR1 as set forth in SEQ ID NO: 103, or a human HFR1 sequence having at least about 75% sequence identity to HFR1 as set forth in SEQ ID NO: 103, HFR2 as set forth in SEQ ID NO: 104, or a human HFR2 sequence having at least about 75% sequence identity to SEQ ID NO: 104, HFR3 as set forth in SEQ ID NO: 105, or a human HFR3 sequence having at least about 55% sequence identity to SEQ ID NO: 105, and HFR4 sequence as set forth in SEQ ID NO: 106, or a human HFR4 sequence having at least 90% sequence identity to SEQ ID NO: 106. In each of these cases, the preferred amino acid substitutions in HFR as outlined above are maintained, particularly at positions 30 and / or 90. For example, HFR1 of SEQ ID NO: 1 (BMA031 V36_VH) has 63.33% sequence identity to HFR1 of SEQ ID NO: 100 (HEBE1_H66_HV), or HFR2 of SEQ ID NO: 1 (BMA031 V36_VH) has 78.6% sequence identity to HFR2 of SEQ ID NO: 99 (HEBE1_H10_HV). Accordingly, the framework regions provided herein above and below are envisaged as being included in the antigen-binding polypeptides provided herein.

[0307] In a preferred embodiment, the antigen-binding polypeptide comprises HFR1, HFR2, HFR3, and HFR4 according to SEQ ID NO: 103 to SEQ ID NO: 106, or human HFR1, HFR2, HFR3, and HFR4 sequences having at least 90% sequence identity in each case, respectively, to SEQ ID NO: 103 to SEQ ID NO: 106. In embodiments in which the antigen-binding polypeptide comprises 90Y in the heavy chain, the framework regions of the antigen-binding polypeptide as provided herein above and below comprise HFRs of defined sequence identity and further comprise 90Y in the heavy chain.

[0308] In one embodiment, the antigen-binding polypeptide comprises an LFR1 set forth in SEQ ID NO: 107, or a human LFR1 sequence having at least about 50% sequence identity to SEQ ID NO: 107, an LFR2 set forth in SEQ ID NO: 108, or a human LFR2 sequence having at least about 80% sequence identity to SEQ ID NO: 108, an LFR3 sequence set forth in SEQ ID NO: 109, or a human LFR3 sequence having at least about 80% sequence identity to SEQ ID NO: 109, and an LFR4 sequence set forth in SEQ ID NO: 110, or a human LFR4 sequence having at least about 80% sequence identity to SEQ ID NO: 110. In a preferred embodiment, the antigen-binding polypeptide comprises LFR1, LFR2, LFR3, and LFR4 set forth in SEQ ID NO: 107 to SEQ ID NO: 110, or human LFR1, LFR2, LFR3, and LFR4 sequences having at least at least 90% sequence identity in each case to SEQ ID NO: 107 to SEQ ID NO: 110, respectively.

[0309] HFR1-4 and LFR1-4 sequences having at least 50, 60, 70, 80, 90 or 95% sequence identity to the amino acid sequences depicted by SEQ ID NOs: 103-110, respectively, are preferably not modified at specific positions, e.g., positions of the Vernier zone, positions contributing to the VH / VL interchain interface, or positions determining the CDR canonical class. In embodiments where the antigen-binding polypeptide comprises Y90 in the heavy chain, the antigen-binding polypeptide comprising the framework regions provided herein above and below comprises 90Y in the heavy chain. In embodiments where the antigen-binding polypeptide comprises a positively charged amino acid at position 30 in the heavy chain, the antigen-binding polypeptide comprising the framework regions provided herein above and below comprises a positively charged amino acid at position 30 in the heavy chain. In all the following embodiments, the sequence of the HCDR according to (i) and the sequence of the LCDR according to (ii) of the first aspect of the invention are maintained.

[0310] In certain embodiments, the positions that are not modified in the VL are position 6, position 23, position 38, position 44, position 59, position 61, position 62, position 64, position 66, position 82, position 86, position 87, position 88, position 98, position 99, and / or position 101.

[0311] In particular aspects, the positions that are not modified in VH are position 6, position 14, position 22, position 36, position 37, position 39, position 45, position 46, position 69, position 71, position 78, position 86, position 91, position 92, position 103, position 104, and position 106.

[0312] In one embodiment the antigen-binding polypeptide comprises a VH domain with at least 80% sequence identity to SEQ ID NO:1, wherein the VH domain with at least 80% sequence identity comprises amino acids 14P, 46E, 86D, 104G and 106G and comprises a substitution of the invention, in particular HCDR1 and / or HCDR2 as defined in (i) and / or (iii) and / or (iv) of the first aspect of the invention.

[0313] In one embodiment, preferably the antigen-binding polypeptide comprises a VL domain having at least 80% sequence identity to SEQ ID NO:2, wherein the VL domain having at least 80% sequence identity to SEQ ID NO:2 comprises the amino acids 59P, 61R, 62F, 82D, 99G and 101G and comprises the substitutions of the invention, in particular the LCDR1 and / or LCDR2 as defined in (ii) of the first aspect of the invention.

[0314] In one embodiment the antigen binding polypeptide comprises a VH domain with at least 80% sequence identity to SEQ ID NO: 1 and comprising amino acids 14P, 46E, 86D, 104G and 106G and comprising substitutions of the invention, in particular HCDR1 and / or HCDR2 as defined in (i) of the first aspect of the invention, and / or a substitution as defined in (iii) and / or (iv); and a VL domain according to SEQ ID NO: 2 or a sequence with at least about 80% sequence identity to SEQ ID NO: 2 and comprising amino acids 59P, 61R, 62F, 82D, 899G and 101G and comprising substitutions of the invention, in particular LCDR1 and / or LCDR2 as defined in (ii) of the first aspect of the invention.

[0315] In one embodiment, preferably the antigen-binding polypeptide comprises a VH domain having at least 80% sequence identity to SEQ ID NO:1, wherein the VH domain having at least 80% sequence identity comprises the amino acids: 6Q and 36W and comprises a substitution of the invention, in particular HCDR1 and / or HCDR2 as defined in (i) and / or (iii) and / or (iv) of the first aspect of the invention.

[0316] In one embodiment, preferably the antigen-binding polypeptide comprises a VL domain having at least 80% sequence identity to SEQ ID NO:2, wherein the VL domain having at least 80% sequence identity comprises amino acids 6Q and 86Y, and the antigen-binding polypeptide comprises a substitution according to the invention, in particular an LCDR1 and / or LCDR2 as defined in (ii) of the first invention.

[0317] In one embodiment, preferably the antigen binding polypeptide comprises a VH domain having at least 80% sequence identity to SEQ ID NO: 1, wherein the VH domain comprises amino acids 6Q and 36W, and wherein the antigen binding polypeptide comprises a substitution according to the invention, in particular an HCDR1 and / or HCDR2 as defined in (i) of the first aspect of the invention, and / or a substitution as defined in (iii) and / or (iv), and a VL domain having at least 80% sequence identity to SEQ ID NO: 2, wherein the VL domain comprises amino acids 6Q and 86Y, and wherein the antigen binding polypeptide comprises a substitution according to the invention, in particular an LCDR1 and / or LCDR2 as defined in (ii) of the first aspect of the invention.

[0318] In one embodiment, preferably the antigen binding polypeptide comprises a VH domain with at least 80% sequence identity to SEQ ID NO:1, wherein the VH domain with at least 80% sequence identity comprises the amino acids: 22C, 37V, 39Q, 45L, 69L, 71S, 78A, 91Y, 92C and 103W, and wherein the antigen binding polypeptide comprises a substitution of the invention, in particular HCDR1 and / or HCDR2 as defined in (i) and / or (iii) and / or (iv) of the first aspect of the invention.

[0319] In one embodiment, preferably the antigen binding polypeptide comprises a VL domain which has at least 80% sequence identity to SEQ ID NO:2, wherein the VL domain which has at least 80% sequence identity comprises the amino acids: C23, 38Q, 44P, 64G, 66G, 87Y, 88C and 98F, and wherein the antigen binding polypeptide comprises a substitution of the invention, in particular an LCDR1 and / or LCDR2 as defined in (ii) of the first aspect of the invention.

[0320] In one embodiment, preferably the antigen binding polypeptide comprises a VH domain with at least 80% sequence identity to SEQ ID NO: 1 and comprises the amino acids: 22C, 37V, 39Q, 45L, 69L, 71S, 78A, 91Y, 92C and 103W, wherein the antigen binding polypeptide comprises a substitution according to the invention, in particular an HCDR1 and / or HCDR2 as defined in (i) of the first aspect of the invention, and / or a substitution as defined in (iii) and / or (iv), and a VL domain with at least 80% sequence identity to SEQ ID NO: 2 and comprises the amino acids: 23C, 38Q, 44P, 64G, 66G, 87Y, 88C and 98F, wherein the antigen binding polypeptide comprises a substitution according to the invention, in particular an LCDR1 and / or LCDR2 as defined in (ii) of the first aspect of the invention.

[0321] In one embodiment, preferably the antigen binding polypeptide comprises a VH domain with at least 80% sequence identity to SEQ ID NO:1, wherein the VH domain with at least 80% sequence identity comprises the amino acids: 6Q, 14P, 22C, 36W, 37V, 39Q, 45L, 46E, 69L, 71S, 78A, 86D, 91Y, 92C, 103W, 104G and 106G, and wherein the antigen binding polypeptide comprises a substitution of the invention, in particular HCDR1 and / or HCDR2 as defined in (i) and / or (iii) and / or (iv) of the first aspect of the invention.

[0322] In one embodiment, preferably the antigen binding polypeptide comprises a VL domain having at least 80% sequence identity to SEQ ID NO:2, wherein the VL domain having at least 80% sequence identity comprises the amino acids: 6Q, 23C, 38Q, 44P, 59P, 61R, 62F, 64G, 66G, 82D, 86Y, 88C, 98F, 99G, and 101G, and wherein the antigen binding polypeptide comprises the substitutions of the invention, in particular the LCDR1 and / or LCDR2 as defined in (ii) of the first invention.

[0323] In one embodiment, preferably the antigen binding polypeptide is a VH domain having at least 80% sequence identity to SEQ ID NO:1 and comprises the amino acids: 6Q, 14P, 22C, 36W, 37V, 39Q, 45L, 46E, 69L, 71S, 78A, 86D, 91Y, 92C, 103W, 104G and 106G, and wherein the antigen binding polypeptide comprises a VH domain having the substitutions of the invention, in particular HCDR1 and / or HCDR2 as defined in (i) and / or (iii) and / or (iv) of the first aspect of the invention. and a VL domain with at least 80% sequence identity to SEQ ID NO:2, comprising the amino acids: 6Q, 23C, 38Q, 44P, 59P, 61R, 62F, 64G, 66G, 82D, 86Y, 88C, 98F, 99G and 101G, and wherein the antigen-binding polypeptide comprises a substitution according to the invention, in particular an LCDR1 and / or LCDR2 as defined in (ii) of the first aspect of the invention.

[0324] In one embodiment, the antigen binding polypeptide is selected from the group consisting of SEQ ID NO:7 (VH H90Y); SEQ ID NO:9 (VH_T30N_S31R), SEQ ID NO:10 (VH_T30S_S31R_Y53R_E100aD), SEQ ID NO:11 (VH S31R), SEQ ID NO:12 (VH_T30S_Y53R), SEQ ID NO:14 (VH N54K H90Y), SEQ ID NO:15 (VH_T30N_S31N_Y53R), SEQ ID NO:16 (VH_T30N_S31R_V56I), SEQ ID NO:17 (VH_S31R_N54K_E100aD), SEQ ID NO:19 (VH_T30R), SEQ ID NO:20 (VH T30K), SEQ ID NO:21 (VH S31K), SEQ ID NO:22 (VH_Y53R), SEQ ID NO:23 (VH_Y53K), SEQ ID NO:24 (VH_N54R), SEQ ID NO:25 (VH_N54K), SEQ ID NO:29 (VH_Y53H), SEQ ID NO:30 (VH_S31H), SEQ ID NO:31 (VH S31R H90Y), SEQ ID NO:32 (VH Y53R H90Y), SEQ ID NO:33 (VH N54R and a VH comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 (VH_E61Q_H90Y), SEQ ID NO: 23 (VH_E61Q_H90Y), and SEQ ID NO: 34 (VH_E61Q_H90Y), or a VH variant comprising an amino acid sequence at least 85%, at least 90% or at least 95% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 7, 9, 10, 11, 12, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 29, 30, 31, 32, 33, and 34, respectively, wherein the VH variant retains each of the inventive substitutions compared to a VH having a sequence according to SEQ ID NO: 1 and preferably comprises HCDRs 1 to 3 of the sequence according to SEQ ID NO: 7, 9, 10, 11, 12, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 29, 30, 31, 32, 33, and 34, respectively. As used herein, "retaining each substitution" means that the substitutions of the invention as provided herein are maintained. Thus, in certain embodiments, an antigen-binding polypeptide that is % identical to a given SEQ ID NO retains, for example, a substitution of the invention at (i) one or more of the following positions in the heavy chain: 30, 31, 53, and 54, and / or (ii) one or more of the following positions in the light chain: 31 and 56, and / or at position 90 in the heavy chain.In a preferred embodiment, the antigen binding polypeptide comprises a VH comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 7, 9, 10, 11, 12, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 29, 30, 31, 32, 33, and 34. In a particular embodiment, the antigen binding polypeptide comprises a VH comprising the amino acid sequence of SEQ ID NO: 11 (VH S31R) or SEQ ID NO: 22 (VH Y53R). In a further preferred embodiment, the antigen binding polypeptide may also be a functional fragment of a VH as provided above, which is a functional fragment comprising a substitution of the invention.

[0325] In one embodiment, the antigen-binding polypeptide comprises a VL comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 8 (VL S31R S56R), SEQ ID NO: 13 (VL S31N S56R S93N), SEQ ID NO: 18 (VL S56R), SEQ ID NO: 26 (VL_S31R), SEQ ID NO: 27 (VL_S31K), and SEQ ID NO: 28 (VL_S56K), or a VL variant thereof comprising an amino acid sequence that is at least 85%, at least 90%, or at least 95% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 13, 18, 26, 27, and 28, respectively, wherein the VL variant retains each of the inventive substitutions compared to a VL having a sequence according to SEQ ID NO: 2, and preferably comprises LCDR1-3 of said sequences according to SEQ ID NOs: 8, 13, 18, 26, 27, and 28, respectively. As used herein, "retaining each of the substitutions" means that the inventive substitutions as provided herein are maintained. Thus, in certain embodiments, an antigen binding polypeptide that is % identical to a given SEQ ID NO: bears a substitution of the invention, for example, at (i) one or more of the following positions in the heavy chain: 30, 31, 53, and 54, and / or (ii) one or more of the following positions in the light chain: 31 and 56, and / or at position 90 in the heavy chain. In preferred embodiments, the antigen binding polypeptide comprises a VL comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 13, 18, 26, 27, and 28. In further preferred embodiments, the antigen binding polypeptide may be a functional fragment of a VL provided above, which is a functional fragment comprising a substitution of the invention.

[0326] Hereinafter, the specific combinations of VH and VL provided herein are described. It is understood that the VH and VL provided herein above may be combined with each other.

[0327] In one embodiment, the antigen-binding polypeptide comprises a VH and a VL comprising a sequence selected from the group consisting of: SEQ ID NO:7 and SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:2, SEQ ID NO:10 and SEQ ID NO:2, SEQ ID NO:11 and SEQ ID NO:2, SEQ ID NO:12 and SEQ ID NO:2, SEQ ID NO:11 and SEQ ID NO:13, SEQ ID NO:14 and SEQ ID NO:2, SEQ ID NO:15 and SEQ ID NO:2, SEQ ID NO:16 and SEQ ID NO:2, SEQ ID NO:17 and SEQ ID NO:2, SEQ ID NO:1 and SEQ ID NO:18, SEQ ID NO:11 and SEQ ID NO:18, SEQ ID NO:11 and SEQ ID NO:8, SEQ ID NO:12 and SEQ ID NO:18, SEQ ID NO:12 and SEQ ID NO:8, SEQ ID NO:14 and SEQ ID NO:18, SEQ ID NO:14 and SEQ ID NO:8, SEQ ID NO:19 and SEQ ID NO:2 , SEQ ID NO:20 and SEQ ID NO:2, SEQ ID NO:21 and SEQ ID NO:2, SEQ ID NO:22 and SEQ ID NO:2, SEQ ID NO:23 and SEQ ID NO:2, SEQ ID NO:24 and SEQ ID NO:2, SEQ ID NO:25 and SEQ ID NO:2, SEQ ID NO:1 and SEQ ID NO:26, SEQ ID NO:1 and SEQ ID NO:27, SEQ ID NO:1 and SEQ ID NO:28, SEQ ID NO:29 and SEQ ID NO:2, SEQ ID NO:30 and SEQ ID NO:2, SEQ ID NO:7 and SEQ ID NO:2, SEQ ID NO:31 and SEQ ID NO:2, SEQ ID NO:31 and SEQ ID NO:18, SEQ ID NO:32 and SEQ ID NO:2, SEQ ID NO:33 and SEQ ID NO:2, SEQ ID NO:32 and SEQ ID NO:18, SEQ ID NO:7 and SEQ ID NO:18.

[0328] In a further preferred embodiment, the antigen-binding polypeptide may also be a functional fragment of the VL and VH provided above, which functional fragment comprises a substitution of the invention.

[0329] Preferably, the antigen-binding polypeptide comprises a VH and VL according to SEQ ID NO:11 and SEQ ID NO:2, SEQ ID NO:22 and SEQ ID NO:2, SEQ ID NO:14 and SEQ ID NO:2, SEQ ID NO:31 and SEQ ID NO:2, SEQ ID NO:32 and SEQ ID NO:2, SEQ ID NO:32 and SEQ ID NO:18 (VH_Y53R_H90Y and VL_S56R); SEQ ID NO:14 and SEQ ID NO:18 (VH_N54K_H90Y and VL_S56R); SEQ ID NO:31 and SEQ ID NO:18 (VH_S31R_H90Y and VL_S56R); or SEQ ID NO:7 and SEQ ID NO:2 (VH_H90Y and BMA031(V36)_VL).

[0330] More preferably, the antigen-binding polypeptide comprises a VH and a VL according to SEQ ID NO:11 and SEQ ID NO:2, SEQ ID NO:22 and SEQ ID NO:2, SEQ ID NO:32 and SEQ ID NO:2, SEQ ID NO:14 and SEQ ID NO:2, or SEQ ID NO:31 and SEQ ID NO:2.

[0331] As disclosed herein above and below, the present invention preferably relates to an antigen-binding polypeptide, wherein the VH comprises the amino acid sequence of SEQ ID NO: 32 (VH Y53R H90Y) or a VH variant thereof comprising an amino acid sequence which is at least 85%, at least 90% or at least 95% identical to the amino acid sequence of SEQ ID NO: 32, wherein the VH variant retains the respective substitutions (Y53 and H90Y, or corresponding amino acid substitutions) compared to the VH having a sequence according to SEQ ID NO: 1, and wherein the VL comprises the VL of an antibody which binds to the α / β TCR / CD3 complex (as defined herein), in particular wherein the VL comprises the amino acid sequence of SEQ ID NO: 2.

[0332] In a further preferred embodiment, the antigen-binding polypeptide may be a functional fragment of VH and VL as defined above, which is a functional fragment comprising the substitution of the invention. In one embodiment, the antigen-binding polypeptide comprises further modifications, such as further substitutions of amino acids in the same category as the amino acids in the CDRs. Further modifications may be the substitution of a polar uncharged amino acid with another polar uncharged amino acid, the substitution of a negatively charged amino acid with another negatively charged amino acid, and / or the substitution of a hydrophobic amino acid with another hydrophobic amino acid. Further modifications may also be the substitution of a polar uncharged amino acid with another polar uncharged amino acid, the substitution of a negatively charged amino acid with another negatively charged amino acid, and the substitution of a hydrophobic amino acid with another hydrophobic amino acid.

[0333] In one embodiment, position 31 in the heavy chain and position 56 in the light chain are substituted with a positively charged amino acid, preferably position 31 in the heavy chain is substituted with R and position 56 in the light chain is substituted with R.

[0334] In one embodiment, position 31 in the heavy chain and position 56 in the light chain according to SEQ ID NO:1 are substituted with a positively charged amino acid and position 90 in the heavy chain is Y, preferably position 31 in the heavy chain is substituted with R, position 56 in the light chain is substituted with R and position 90 in the heavy chain is Y.

[0335] In one embodiment, position 31 in the heavy chain is substituted with a positively charged amino acid and position 90 in the heavy chain is Y, preferably, position 31 in the heavy chain is substituted with R and position 90 in the heavy chain is Y.

[0336] In one embodiment, position 53 in the heavy chain and position 56 in the light chain are substituted with a positively charged amino acid, preferably position 53 in the heavy chain is substituted with R and position 56 in the light chain is substituted with R.

[0337] In one embodiment, position 53 in the heavy chain and position 56 in the light chain are substituted with a positively charged amino acid and position 90 in the heavy chain is Y, preferably position 53 in the heavy chain is substituted with R, position 90 in the heavy chain is Y and position 56 in the light chain is substituted with R.

[0338] In one embodiment, position 54 in the heavy chain is substituted with a positively charged amino acid and position 90 in the heavy chain is Y, preferably, position 54 in the heavy chain is substituted with R and position 90 in the heavy chain is Y.

[0339] In one embodiment, position 90 in the heavy chain is Y and position 56 in the light chain is substituted with a positively charged amino acid, preferably position 90 in the heavy chain is Y and position 56 in the light chain is substituted with R.

[0340] In one embodiment, position 56 in the heavy chain is substituted with a positively charged amino acid and preferably position 56 in the light chain is substituted with R.

[0341] In one embodiment, position 54 in the heavy chain and position 56 in the light chain are substituted with a positively charged amino acid and position 90 in the heavy chain is substituted with a hydrophobic amino acid, preferably position 54 in the heavy chain is substituted with K, position 56 in the light chain is substituted with R and position 90 in the heavy chain is substituted with Y.

[0342] In one embodiment, position 54 in the heavy chain and positions 31 and 56 in the light chain are substituted with a positively charged amino acid and position 90 in the heavy chain is substituted with a hydrophobic amino acid, preferably position 54 in the heavy chain is substituted with K, positions 31 and 56 in the light chain are substituted with R, and position 90 in the heavy chain is substituted with Y.

[0343] In one embodiment, positions 31 and 53 in the heavy chain are substituted with a positively charged amino acid, preferably positions 31 and 53 in the heavy chain are substituted with R.

[0344] In one embodiment, position 53 in the heavy chain and positions 31 and 56 in the light chain are substituted with a positively charged amino acid, preferably position 53 in the heavy chain is substituted with R and positions 31 and 56 in the light chain are substituted with R.

[0345] In one embodiment, position 31 in the heavy chain is substituted with a positively charged amino acid, preferably position 31 in the heavy chain is substituted with R.

[0346] In one embodiment, position 31 in the heavy chain is substituted with a positively charged amino acid, preferably position 31 in the heavy chain is substituted with a K.

[0347] In one embodiment, position 30 in the heavy chain is substituted with a positively charged amino acid, preferably position 30 in the heavy chain is substituted with K.

[0348] In one embodiment, position 56 in the light chain is substituted with a positively charged amino acid, preferably position 56 in the light chain is substituted with R.

[0349] In one embodiment, position 56 in the light chain is substituted with a positively charged amino acid, preferably position 56 in the light chain is substituted with a K.

[0350] In one embodiment, position 54 in the heavy chain is substituted with a positively charged amino acid, preferably position 54 in the heavy chain is substituted with a K.

[0351] In one embodiment, position 54 in the heavy chain is substituted with a positively charged amino acid and position 90 in the heavy chain is substituted with a hydrophobic amino acid, preferably, position 54 in the heavy chain is substituted with K and position 90 in the heavy chain is substituted with Y.

[0352] In one embodiment, positions 31 and 54 in the heavy chain are substituted with positively charged amino acids, preferably, position 31 in the heavy chain is substituted with R and position 54 in the heavy chain is substituted with K.

[0353] In one embodiment, position 53 in the heavy chain is substituted with a positively charged amino acid, preferably position 53 in the heavy chain is substituted with R.

[0354] In one embodiment, position 53 in the heavy chain is substituted with a positively charged amino acid and position 90 is Y, preferably position 53 in the heavy chain is substituted with R and position 90 is Y.

[0355] In one embodiment, position 31 in the heavy chain is substituted with a positively charged amino acid, preferably position 31 in the heavy chain is substituted with R.

[0356] In one embodiment, position 31 in the heavy chain and positions 31 and 56 in the light chain are substituted with a positively charged amino acid, preferably position 31 in the heavy chain is substituted with R and positions 31 and 56 in the light chain are substituted with R.

[0357] In one embodiment, position 53 in the heavy chain is substituted with a positively charged amino acid, preferably position 53 in the heavy chain is substituted with R.

[0358] In one embodiment, positions 31 and 56 in the light chain are substituted with a positively charged amino acid and position 90 in the heavy chain is substituted with a hydrophobic amino acid, preferably positions 31 and 56 in the light chain are substituted with R and position 90 in the heavy chain is substituted with Y.

[0359] In one embodiment, VH and VL or Vα and Vβ are covalently or non-covalently linked. Preferably, VH and VL or Vα and Vβ are covalently linked by a disulfide bond.

[0360] In one embodiment, the antigen-binding polypeptide further comprises one or more additional antigen-binding sites. For example, if the antigen-binding polypeptide comprises a first and a second binding site and further comprises an additional binding site, the antigen-binding polypeptide may be a trispecific molecule, trivalent, etc. In one embodiment, the antigen-binding polypeptide may further comprise a transmembrane region. In one embodiment, the antigen-binding polypeptide may further comprise a transmembrane region, optionally including a cytoplasmic signaling region. In one embodiment, the antigen-binding polypeptide may further comprise a diagnostic agent. In one embodiment, the antigen-binding polypeptide may further comprise a therapeutic agent. In one embodiment, the antigen-binding polypeptide of the present invention may be administered simultaneously with, before, or after various drugs and treatments widely used in cancer treatment, such as chemotherapeutic agents, non-chemotherapeutic agents, antitumor agents, and / or radiation, preferably chemotherapeutic agents. In one embodiment, such therapeutic agents may be growth inhibitors, such as cytotoxic agents or radioisotopes.

[0361] In one embodiment, the antigen-binding polypeptides of the invention can be used in a bispecific format, in particular in a bispecific TCER® molecule. Surprisingly, it has been shown that bispecific molecules comprising an antigen-binding polypeptide comprising a first binding site as described above, substituted with at least one positively charged amino acid at each of the HCDR1 and / or HCDR2 and / or LCDR1 and / or LCDR2 positions, and further comprising a second binding site, e.g. comprising a TCR or a fragment thereof, exhibit improved effector function in a bispecific format. As demonstrated in the examples herein below, such bispecific molecules comprising a first and a second binding site as defined herein above exhibit increased efficacy in T-cell mediated killing of tumor cells (see Example 3 described below). Thus, it has been shown surprisingly that the antigen-binding polypeptides described according to the first aspect of the invention above are also functional and exhibit improvements in a bispecific format. It has also been surprisingly shown that the antigen-binding polypeptides according to the first aspect of the invention above exert increased potency in T-cell mediated tumor killing of peptide-HLA positive tumor cells, and furthermore, cytotoxicity against peptide-HLA negative tumor cell lines is barely detectable with the bispecific TCER® scaffold compared to the parent antigen-binding polypeptide comprising the VH of BMA031 (V36) in TCER® format. The potency of said bispecific TCER® molecules is assessed by measuring the released LDH and EC50 values ​​(functional EC50 as defined herein above). For example, the functional EC50 of the antigen-binding polypeptide against Hs695T cells and U2OS cells is reduced compared to the parent antigen-binding polypeptide comprising the VH and VL of BMA031 (V36) in TCER® format.

[0362] In one embodiment, the antigen-binding polypeptide comprises first and second polypeptide chains which form first and second antigen-binding sites, the first polypeptide chain having the formula: V1-L1-V2-L2-D1[I] and having a structure represented by During the ceremony, V1 is the first variable domain, V2 is a second variable domain, L1 and L2 are linkers, L2 is present or absent, D1 is a dimerization domain, present or absent; The second polypeptide chain has the formula: V3-L3-V4-L4-D2[II] and having a structure represented by During the ceremony, V3 is the third variable domain, V4 is the fourth variable domain, L3 and L4 are linkers, L4 is present or absent, D2 is a dimerization domain, present or absent; D1 and D2 specifically bind to each other, One of V1, V2, V3, V4 is V as defined in the context of the present invention. H and One of V1, V2, V3, V4 is V as defined in the context of the present invention. L and one of V1, V2, V3, V4 is a Vα or Vγ of the TCR; and One of V1, V2, V3, V4 is Vβ or Vδ of said TCR.

[0363] In one embodiment, V H and V L form the first binding site, and Vα and Vβ, or Vγ and Vδ, form the second binding site.

[0364] In one embodiment, V1 or V2 is V as defined in the context of the present invention. L and V3 or V4 is V as defined in the context of the present invention. H where V3 or V4 is the Va or Vy of the TCR, and V1 or V2 is the Vβ or Vδ of the TCR.

[0365] In one embodiment, V1 or V2 is V as defined in the context of the present invention. H and V3 or V4 is V as defined in the context of the present invention. L where V3 or V4 is Vβ or Vδ of the TCR, and V1 or V2 is Vα or Vγ of the TCR.

[0366] In one embodiment, V1 or V2 is V as defined in the context of the present invention. L and V3 or V4 is V as defined in the context of the present invention. H and V3 or V4 is a Vβ or Vδ of the TCR, and V1 or V2 is a Vα or Vγ of the TCR. In one embodiment, V1 or V2 is a Vα or Vγ of the TCR as defined in the context of the present invention. H and V3 or V4 is V as defined in the context of the present invention. L where V3 or V4 is the Va or Vy of the TCR, and V1 or V2 is the Vβ or Vδ of the TCR.

[0367] In one embodiment, the antigen-binding polypeptide comprises the following V1 to V4: V1 is V H and V2 is V β or V δ and V3 is V α or V γ and V4 is V L It is.

[0368] In one embodiment, the antigen-binding polypeptide comprises the following V1 to V4: V1 is V β or V δ and V2 is V H and V3 is V L and V4 is V α or V γ It is.

[0369] In one embodiment, the antigen-binding polypeptide comprises the following V1 to V4: V1 is V β or V δ and V2 is V L and V3 is V H and V4 is Vα or V γ It is.

[0370] In one embodiment, the antigen-binding polypeptide comprises the following V1 to V4: V1 is V β or V δ and V2 is V L and V3 is V α or V γ and V4 is V H It is.

[0371] In one embodiment, the antigen-binding polypeptide comprises the following V1 to V4: V1 is V H and V2 is V β or V δ and V3 is V L and V4 is V α or V γ It is.

[0372] In one embodiment, the antigen-binding polypeptide comprises the following V1 to V4: V1 is V β or V δ and V2 is V H and V3 is V α or V γ and V4 is V L It is.

[0373] In one embodiment, the antigen-binding polypeptide comprises the following V1 to V4: V1 is V L and V2 is V β or V δ and V3 is V H and V4 is V α or V γ It is.

[0374] In one embodiment, the antigen-binding polypeptide comprises the following V1 to V4: V1 is V β or V δ and V2 is V L and V3 is V α or V γ and V4 is V H It is.

[0375] In one embodiment, the antigen-binding polypeptide comprises the following V1 to V4: V1 is V H and V2 is V L and V3 is V α or V γ and V4 is V β or V δ It is.

[0376] In one embodiment, the antigen-binding polypeptide comprises the following V1 to V4: V1 is V L and V2 is V H and V3 is V α or V γ and V4 is V β or V δ It is.

[0377] In one embodiment, the antigen-binding polypeptide comprises the following V1 to V4: V1 is V H and V2 is V L and V3 is V β or V δ and V4 is V α or V γ It is.

[0378] In one embodiment, the antigen-binding polypeptide comprises the following V1 to V4: V1 is V L and V2 is V H and V3 is V β or V δ and V4 is V α or V γ It is.

[0379] With respect to Formulas I and II, V H and V L are located on different polypeptide chains, and V α or V γ , and V β or V δ Preferably, V1 is located on different polypeptide chains, and the dimerization domains D1 and D2 are heterodimerization domains. H and V2 is Vβ and V3 is V α and V4 is V L In one embodiment, D1 and D2 of the antigen-binding polypeptide are Fc domains, preferably a pair of Fc domains, preferably different and containing mutations that force heterodimerization, preferably "knobs-into-holes" mutations.

[0380] L1, L2, L3, L4, when present, can be 2-25, 2-20, or 3-18 amino acids in length. In some embodiments, linkers such as L1, L2, L3, L4 can be peptides up to 14, 13, 12, 11, 10, 9, 8, 7, 6, or 5 amino acids in length. In other embodiments, linkers such as L1, L2, L3, L4 can be 5-25, 5-15, 4-11...

Claims

1. An antigen-binding polypeptide comprising a heavy-chain variable domain (VH) and a light-chain variable domain (VL), wherein (1) the VH comprises (a) a heavy-chain complementarity-determining region 1 (HCDR1) comprising the amino acid sequence of SEQ ID NO: 52, (b) YINPYNDVTKY X １ X ２ KFX ３ HCDR2 containing the amino acid sequence of G (SEQ ID NO: 53), wherein X １ is A, X ２ is E and / or X ３ is Q; wherein the tyrosine (Y) at position 53 of HCDR2 is substituted with a positively charged amino acid, the second tyrosine (Y) from the N-terminus of SEQ ID NO: 53 is substituted with a positively charged amino acid, and the second tyrosine (Y) is at position 53 of HCDR2 according to Kabat numbering, HCDR2, (c) an HCDR3 comprising the amino acid sequence of SEQ ID NO: 64, and (d) heavy-chain framework regions (HFR) 1 to 4 ; and (2) the VL comprises (a) a light-chain complementarity-determining region 1 (LCDR1) comprising the amino acid sequence of SEQ ID NO: 54, (b) an LCDR2 comprising the amino acid sequence of SEQ ID NO: 55, (c) an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74, and (d) light-chain framework regions (LFR) 1 to 4 ; position 90 in HFR3 according to Kabat numbering is substituted with a tyrosine (Y) residue, and the antigen-binding polypeptide specifically binds to an α / β T cell receptor (TCR) / CD3 complex.

2. The antigen-binding polypeptide according to claim 1, wherein the positively charged amino acid in the heavy chain is at position 53 and is R, K or H.

3. The antigen-binding polypeptide according to claim 1, wherein VH and VL form a first binding site and the antigen-binding polypeptide comprises a second antigen-binding site.

4.

5. The antigen-binding polypeptide according to claim 1, wherein the antigen-binding polypeptide comprises the VH set forth in SEQ ID NO:

32.

6. The antigen-binding polypeptide according to claim 1, wherein the antigen-binding polypeptide comprises the VL set forth in SEQ ID NO:

2.

7. A nucleic acid or set of nucleic acids encoding the antigen-binding polypeptide according to claim 1, or a nucleic acid vector comprising said nucleic acid. (i) The α (V α ) and / or β (V β ) chain, or (ii) The γ (V γ ) and / or δ (V δ ) chain, or

8. A recombinant host cell comprising the antigen-binding polypeptide according to claim 1, or the nucleic acid or set of nucleic acids or vector according to claim 7, wherein the host cell is (i) a lymphocyte, preferably a T lymphocyte or T lymphocyte progenitor cell, such as a CD4-positive T cell or a CD8-positive T cell, or (ii) a cell for recombinant expression, such as a Chinese hamster ovary (CHO) cell or a yeast cell.

9. ​ ​ ​ ​ ​ ​ ​ ​ A pharmaceutical composition comprising the antigen polypeptide according to claim 1, the nucleic acid or set of nucleic acids or vector according to claim 7, or the host cell according to claim 8, and a pharmaceutically acceptable carrier, diluent, stabilizer, and / or excipient.

10. A pharmaceutical composition comprising the antigen-binding polypeptide according to claim 1 dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous medium.

11. A method for producing a pharmaceutical composition comprising the step of dissolving or dispersing the antigen-binding polypeptide according to claim 1 in a pharmaceutically acceptable carrier or aqueous medium.

12. A method for producing the antigen-binding polypeptide according to any one of claims 1 to 6, comprising: (i) providing a suitable host cell; (ii) providing a gene construct comprising a coding sequence encoding the antigen-binding polypeptide according to any one of claims 1 to 6; (iii) introducing the gene construct into the suitable host cell; and (iv) expressing the gene construct by the suitable host cell. A method comprising the above.

13. The antigen-binding polypeptide according to any one of claims 1 to 6, the nucleic acid or set of nucleic acids or vector according to claim 7, the host cell according to claim 8, or the pharmaceutical composition according to claim 9 or 10 for use in medicine.

14. The antigen-binding polypeptide according to any one of claims 1 to 6, the nucleic acid or vector according to claim 7, the host cell according to claim 8, or the pharmaceutical composition according to claim 9 or 10 for use in the diagnosis of proliferative diseases.

15. A method for improving or maintaining the binding of an antigen-binding polypeptide comprising a heavy chain variable domain (VH) and a light chain variable domain (VL), and / or for improving the stability of the antigen-binding polypeptide, comprising: (1) wherein VH comprises: (a) a heavy chain complementarity-determining region 1 (HCDR1) comprising the amino acid sequence of SEQ ID NO: 52 (SYVMH); (b) YINPYNDVTKYX １ X ２ KFX ３ An HCDR2 containing the amino acid sequence of G (SEQ ID NO: 53), wherein: X １ is A and X ２ is E and / or X ３ is Q; wherein the tyrosine (Y) at position 53 of HCDR2 is substituted with a positively charged amino acid, the second tyrosine (Y) from the N-terminus of SEQ ID NO: 53 is substituted with a positively charged amino acid, and the second tyrosine (Y) is at position 53 of HCDR2 according to Kabat numbering, HCDR2; (c) an HCDR3 comprising the amino acid sequence of SEQ ID NO: 64; and (d) heavy chain framework regions (HFR) 1 to 4. And (2) wherein VL comprises: (a) a light chain complementarity-determining region 1 (LCDR1) comprising the amino acid sequence of SEQ ID NO: 54 (SATSVSYMH); (b) an LCDR2 comprising the amino acid sequence of SEQ ID NO: 55 (DTSKLAS); (c) an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74; and (d) Light chain frameworks (LCR) 1-4 comprising position 90 in HFR3 according to Kabat numbering is substituted with a tyrosine (Y) residue, (1) the binding of the antigen-binding polypeptide to the α / β T cell receptor (TCR) / CD3 complex is increased compared to the parental antigen-binding polypeptide, (2) the binding of the antigen-binding polypeptide to the α / β T cell receptor (TCR) / CD3 complex is maintained or increased compared to the parental antigen-binding polypeptide, and the stability of the antigen-binding polypeptide is increased, or (3) the stability of the antigen-binding polypeptide is increased compared to the parental antigen-binding polypeptide, a method. **Claim 16** A method for detecting, determining or enriching T cells expressing the α / β TCR / CD3 complex, the method comprising the step of contacting the cells with the antigen-binding polypeptide according to any one of claims 1-6.

Images